0001628280-25-023833.txt : 20250508 0001628280-25-023833.hdr.sgml : 20250508 20250508162040 ACCESSION NUMBER: 0001628280-25-023833 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 25926530 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 10-Q 1 blfs-20250331.htm 10-Q blfs-20250331
000083436512-312025Q1falseP2YP2YP1Yhttp://fasb.org/us-gaap/2024#PrimeRateMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesblfs:reportable_segmentblfs:reporting_unitblfs:employeexbrli:pureblfs:lawsuit00008343652025-01-012025-03-3100008343652025-05-0100008343652025-03-3100008343652024-12-310000834365us-gaap:SeriesAPreferredStockMember2024-12-310000834365us-gaap:SeriesAPreferredStockMember2025-03-310000834365us-gaap:ProductMember2025-01-012025-03-310000834365us-gaap:ProductMember2024-01-012024-03-310000834365us-gaap:ServiceMember2025-01-012025-03-310000834365us-gaap:ServiceMember2024-01-012024-03-310000834365blfs:RentalRevenueMember2025-01-012025-03-310000834365blfs:RentalRevenueMember2024-01-012024-03-3100008343652024-01-012024-03-310000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-12-310000834365us-gaap:CommonStockMember2024-12-310000834365us-gaap:AdditionalPaidInCapitalMember2024-12-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000834365us-gaap:RetainedEarningsMember2024-12-310000834365us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310000834365us-gaap:CommonStockMember2025-01-012025-03-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310000834365us-gaap:RetainedEarningsMember2025-01-012025-03-310000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-03-310000834365us-gaap:CommonStockMember2025-03-310000834365us-gaap:AdditionalPaidInCapitalMember2025-03-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310000834365us-gaap:RetainedEarningsMember2025-03-310000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-12-310000834365us-gaap:CommonStockMember2023-12-310000834365us-gaap:AdditionalPaidInCapitalMember2023-12-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000834365us-gaap:RetainedEarningsMember2023-12-3100008343652023-12-310000834365us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000834365us-gaap:CommonStockMember2024-01-012024-03-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000834365us-gaap:RetainedEarningsMember2024-01-012024-03-310000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-03-310000834365us-gaap:CommonStockMember2024-03-310000834365us-gaap:AdditionalPaidInCapitalMember2024-03-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000834365us-gaap:RetainedEarningsMember2024-03-3100008343652024-03-310000834365blfs:GlobalCoolingMember2024-04-170000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-04-172024-04-170000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-04-170000834365us-gaap:EmployeeSeveranceMember2025-01-012025-03-310000834365blfs:StockCompensationExpenseMember2025-01-012025-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2025-03-310000834365blfs:SciSafeDivestitureMemberus-gaap:EmployeeSeveranceMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-11-122024-11-120000834365blfs:SciSafeDivestitureMemberblfs:EarnOutPaymentMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-11-122024-11-120000834365blfs:SciSafeDivestitureMemberblfs:StockCompensationExpenseMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-11-122024-11-120000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:SciSafeMember2024-11-122024-11-120000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:SciSafeMember2025-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:SciSafeMember2025-01-012025-03-310000834365blfs:CBSMemberblfs:StockCompensationExpenseMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-11-142024-11-140000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:CBSMember2024-11-142024-11-140000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:CBSMember2025-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:CBSMember2025-01-012025-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-01-012024-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:SciSafeMember2024-01-012024-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:CBSMember2024-01-012024-03-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-01-012024-03-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2025-03-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:FairValueMeasurementsRecurringMember2025-03-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:FairValueMeasurementsRecurringMember2024-12-310000834365us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310000834365us-gaap:CorporateDebtSecuritiesMember2025-03-310000834365us-gaap:OtherDebtSecuritiesMember2025-03-310000834365us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000834365us-gaap:CorporateDebtSecuritiesMember2024-12-310000834365us-gaap:OtherDebtSecuritiesMember2024-12-310000834365us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-03-310000834365us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310000834365us-gaap:SeriesEPreferredStockMemberblfs:PanTHERACryoSolutionsInc.Member2025-03-310000834365us-gaap:SeriesEPreferredStockMemberblfs:PanTHERACryoSolutionsInc.Member2024-12-310000834365blfs:PanTHERAheraCryosolutionsMemberus-gaap:SubsequentEventMemberblfs:PanTHERACryoSolutionsInc.Member2025-04-040000834365blfs:PanTHERAheraCryosolutionsMemberus-gaap:SubsequentEventMember2025-04-042025-04-040000834365blfs:RealEstateLeaseMembersrt:MinimumMember2025-03-310000834365blfs:RealEstateLeaseMembersrt:MaximumMember2025-03-310000834365us-gaap:LeaseholdImprovementsMember2025-03-310000834365us-gaap:LeaseholdImprovementsMember2024-12-310000834365blfs:FurnitureAndComputerEquipmentMember2025-03-310000834365blfs:FurnitureAndComputerEquipmentMember2024-12-310000834365us-gaap:ManufacturingFacilityMember2025-03-310000834365us-gaap:ManufacturingFacilityMember2024-12-310000834365us-gaap:ConstructionInProgressMember2025-03-310000834365us-gaap:ConstructionInProgressMember2024-12-310000834365us-gaap:CustomerRelationshipsMember2025-03-310000834365us-gaap:TradeNamesMember2025-03-310000834365us-gaap:TechnologyBasedIntangibleAssetsMember2025-03-310000834365us-gaap:NoncompeteAgreementsMember2025-03-310000834365us-gaap:CustomerRelationshipsMember2024-12-310000834365us-gaap:TradeNamesMember2024-12-310000834365us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310000834365us-gaap:NoncompeteAgreementsMember2024-12-310000834365blfs:The2023TermLoanMember2022-09-200000834365blfs:The2023TermLoanMember2022-09-202022-09-200000834365blfs:The2023TermLoanMemberblfs:VariableRateComponentTwoMember2022-09-202022-09-200000834365blfs:The2023TermLoanMember2025-03-310000834365blfs:SecondAmendmentTermLoanMember2024-04-170000834365blfs:SecondAmendmentTermLoanMember2024-11-110000834365blfs:TermLoanMember2024-12-310000834365blfs:TermLoanMember2025-03-310000834365blfs:FinancedInsurancePremiumMember2025-03-310000834365blfs:FinancedInsurancePremiumMember2024-12-310000834365blfs:TotalDebtMember2025-03-310000834365blfs:TotalDebtMember2024-12-310000834365blfs:ProductCellProcessingMember2025-01-012025-03-310000834365blfs:ProductCellProcessingMember2024-01-012024-03-310000834365blfs:ProductEvoAndThawMember2025-01-012025-03-310000834365blfs:ProductEvoAndThawMember2024-01-012024-03-310000834365blfs:ServiceEvoAndThawMember2025-01-012025-03-310000834365blfs:ServiceEvoAndThawMember2024-01-012024-03-310000834365blfs:RentalRevenueEvoAndThawMember2025-01-012025-03-310000834365blfs:RentalRevenueEvoAndThawMember2024-01-012024-03-310000834365us-gaap:EmployeeStockOptionMember2025-03-310000834365us-gaap:RestrictedStockMember2024-12-310000834365us-gaap:RestrictedStockMember2025-01-012025-03-310000834365us-gaap:RestrictedStockMember2025-03-310000834365us-gaap:PerformanceSharesMember2024-03-082024-03-080000834365us-gaap:PerformanceSharesMembersrt:MinimumMember2024-03-082024-03-080000834365us-gaap:PerformanceSharesMembersrt:MaximumMember2024-03-082024-03-080000834365us-gaap:PerformanceSharesMember2024-03-080000834365us-gaap:PerformanceSharesMember2024-10-012024-12-310000834365us-gaap:PerformanceSharesMember2025-01-012025-03-310000834365us-gaap:PerformanceSharesMember2025-03-310000834365blfs:MarketbasedRestrictedStockMember2024-12-310000834365blfs:MarketbasedRestrictedStockMember2025-01-012025-03-310000834365blfs:MarketbasedRestrictedStockMember2025-03-310000834365blfs:MarketbasedRestrictedStockMember2023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMembersrt:MinimumMember2023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMembersrt:MaximumMember2023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMember2024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMembersrt:MinimumMember2024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMembersrt:MaximumMember2024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMember2025-03-182025-03-180000834365blfs:MarketbasedRestrictedStockMembersrt:MinimumMember2025-03-182025-03-180000834365blfs:MarketbasedRestrictedStockMembersrt:MaximumMember2025-03-182025-03-180000834365blfs:MarketbasedRestrictedStockMember2023-01-012023-12-310000834365blfs:MarketbasedRestrictedStockMember2024-01-012024-12-310000834365blfs:MarketbasedRestrictedStockMember2024-01-012024-03-310000834365us-gaap:CostOfSalesMember2025-01-012025-03-310000834365us-gaap:CostOfSalesMember2024-01-012024-03-310000834365us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310000834365us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310000834365us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310000834365us-gaap:SellingAndMarketingExpenseMember2024-01-012024-03-310000834365us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310000834365us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310000834365blfs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-03-310000834365blfs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000834365blfs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365blfs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365blfs:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000834365blfs:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365blfs:CustomerDMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-03-310000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000834365country:US2025-03-310000834365blfs:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2025-01-012025-03-310000834365blfs:TwoSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2025-01-012025-03-310000834365blfs:ThreeSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2025-01-012025-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________________________________________________
FORM 10-Q
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from          to
Commission File Number 001-36362
____________________________________________________
BioLife Solutions, Inc.
(Exact name of registrant as specified in its charter)
Img 0.jpg
____________________________________________________
Delaware94-3076866
(State or other jurisdiction of
incorporation or organization)
(IRS Employer
Identification No.)
3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021
(Address of registrant’s principal executive offices, Zip Code)
(425) 402-1400
(Telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of exchange on which registered
Common stock, par value $0.001 per shareBLFS
The NASDAQ Stock Market, LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit said files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ
As of May 1, 2025, 47,561,171 shares of the registrant’s common stock were outstanding.
1
BIOLIFE SOLUTIONS, INC.
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2025
TABLE OF CONTENTS
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Balance Sheets
March 31,December 31,
(In thousands, except per share and share data)20252024
Assets
Current assets:
Cash and cash equivalents$66,945 $95,386 
Available-for-sale securities, current portion21,635 9,198 
Accounts receivable, trade, net of allowance for credit losses of $117 and $153 as of March 31, 2025 and December 31, 2024, respectively
9,167 9,168 
Inventories27,566 29,013 
Prepaid expenses and other current assets5,816 5,996 
Total current assets131,129 148,761 
Assets held for rent, net5,690 6,103 
Property and equipment, net6,605 6,084 
Operating lease right-of-use assets, net10,128 10,674 
Long-term deposits and other assets378 379 
Available-for-sale securities, long-term19,055 4,628 
Equity investments995 995 
Intangible assets, net8,857 9,559 
Goodwill212,304 212,304 
Total assets$395,141 $399,487 
Liabilities and Shareholders’ Equity
  
Current liabilities:  
Accounts payable$3,297 $3,573 
Accrued expenses and other current liabilities8,213 12,451 
Sales taxes payable3,929 4,256 
Lease liabilities, operating, current portion1,835 1,511 
Debt, current portion10,449 10,943 
Total current liabilities27,723 32,734 
Lease liabilities, operating, long-term12,165 12,723 
Debt, long-term2,499 4,997 
Deferred tax liabilities130 124 
Total liabilities42,517 50,578 
Commitments and contingencies (Note 11)
Shareholders’ equity:  
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024
- - 
Common stock, $0.001 par value; 150,000,000 shares authorized, 47,548,431 and 46,906,765 shares issued and outstanding, respectively, as of March 31, 2025 and December 31, 2024
48 47 
Additional paid-in capital688,092 683,939 
Accumulated other comprehensive loss, net of taxes33 24 
Accumulated deficit(335,549)(335,101)
Total shareholders’ equity352,624 348,909 
Total liabilities and shareholders’ equity$395,141 $399,487 
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
3
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Operations
Three Months Ended
March 31,
(In thousands, except per share and share data)20252024
 
Product revenue$22,299 $16,743 
Service revenue60 25 
Rental revenue1,582 1,665 
Total product, rental, and service revenue23,941 18,433 
Costs and operating expenses:
Cost of product revenue (exclusive of intangible assets amortization)7,109 5,136 
Cost of service revenue (exclusive of intangible assets amortization)10 - 
Cost of rental revenue (exclusive of intangible assets amortization)1,036 1,056 
General and administrative11,501 10,397 
Sales and marketing2,597 2,376 
Research and development2,204 2,075 
Intangible asset amortization702 688 
Total operating expenses25,159 21,728 
Operating loss(1,218)(3,295)
 
Other income:
Interest income (expense), net681 (140)
Other income103 253 
Total other income, net784 113 
 
Loss before income tax expense(434)(3,182)
Income tax expense(14)(17)
Net loss from continuing operations(448)(3,199)
 
Discontinued operations:
Loss from discontinued operations before income tax expense- (6,908)
Income tax expense- (114)
Loss from discontinued operations- (7,022)
Net loss$(448)$(10,221)
Loss from continuing operations, attributable to common shareholders:
Basic and Diluted$(448)$(3,199)
Loss from discontinued operations, attributable to common shareholders:
Basic and Diluted$- $(7,022)
Loss per share from continuing operations, attributable to common shareholders:
Basic and Diluted$(0.01)$(0.07)
Loss per share from discontinued operations, attributable to common shareholders:
Basic and Diluted$- $(0.15)
Net loss attributable to common shareholders:
Basic and Diluted$(448)$(10,221)
Net loss per share attributable to common shareholders:
Basic and Diluted$(0.01)$(0.22)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic and Diluted47,134,72045,432,426
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
4
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Comprehensive Loss
Three Months Ended
March 31,
(In thousands)20252024
Net loss$(448)$(10,221)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax- (203)
Unrealized gain (loss) on available-for-sale securities, net of tax9 (18)
Comprehensive loss$(439)$(10,442)
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
5
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Shareholders’ Equity

Three Months Ended March 31, 2025
(In thousands, except share data)Series A
Preferred
Stock
Shares		Series A
Preferred
Stock
Amount		Common
Stock
Shares		Common
Stock
Amount		Additional
Paid-in
Capital		Accumulated
Other
Comprehensive
Income
Accumulated Deficit
Total Shareholders’ Equity
Balance, December 31, 2024-$- 46,906,765$47 $683,939 $24 $(335,101)$348,909 
Stock-based compensation-- -- 4,153 - - 4,153 
Stock issued – on vested RSUs-- 641,6661 - - - 1 
Unrealized loss on available-for-sale securities-- -- - 9 - 9 
Net loss-- -- - - (448)(448)
Balance, March 31, 2025-$- 47,548,431$48 $688,092 $33 $(335,549)$352,624 

 Three Months Ended March 31, 2024
(In thousands, except share data)Series A
Preferred
Stock
Shares		 Series A
Preferred
Stock
Amount		 Common
Stock
Shares		 Common
Stock
Amount		 
Additional Paid-in Capital
 
Accumulated
Other
Comprehensive
Loss
 Accumulated
Deficit		 
Total Shareholders’ Equity
Balance, December 31, 2023- $-  45,167,225$45 $652,880 $(345) $(314,917) $337,663 
Stock-based compensation- -  - -  6,183  -  -  6,183 
Stock issued – on vested RSAs--  522,358 1  -  -  -  1 
Foreign currency translation--  - -  -  (203) -  (203)
Unrealized gain on available-for-sale securities-- -- - (18)- (18)
Net loss- -  - -  -  -  (10,221) (10,221)
Balance, March 31, 2024- $-  45,689,583 $46  $659,063  $(566) $(325,138) $333,405 
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
6
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
7
Three Months Ended
March 31,
(In thousands)20252024
Cash flows from operating activities  
Net loss$(448)$(10,221)
Adjustments to reconcile net loss to net cash used in operating activities  
Depreciation682 1,364 
Amortization of intangible assets702 914 
Stock-based compensation4,153 6,183 
Non-cash lease expense (benefit)312 (83)
Deferred income tax expense6 5 
Accretion of available-for-sale investments(105)(182)
Gain on disposal of property and equipment, net- (14)
Loss on disposal of assets held for rent, net187 198 
 
Change in operating assets and liabilities, net of effects of acquisitions 
Accounts receivable, trade, net1 65 
Inventories1,447 42 
Prepaid expenses and other assets181 2,392 
Accounts payable(828)(1,956)
Accrued expenses and other current liabilities(4,252)(2,825)
Sales taxes payable(327)20 
Other16 (377)
Net cash provided by (used in) operating activities1,727 (4,475)
  
Cash flows from investing activities  
Purchases of available-for-sale securities(30,324)(6,374)
Proceeds from sale of available-for-sale securities573 973 
Maturities of available-for-sale securities3,000 6,000 
Purchases of assets held for rent(250)(464)
Purchases of property and equipment(175)(356)
Net cash used in investing activities(27,176)(221)
  
Cash flows from financing activities  
Payments on equipment loans- (241)
Payments on term loans(2,500)- 
Payments on financed insurance premium(502)(727)
Other10 16 
Net cash used in financing activities(2,992)(952)
  
Net decrease in cash, cash equivalents, and restricted cash(28,441)(5,648)
Cash, cash equivalents, and restricted cash – beginning of period95,386 35,438 
Effects of currency translation on cash, cash equivalents, and restricted cash- (65)
Cash, cash equivalents, and restricted cash – end of period$66,945 $29,725 
Non-cash investing and financing activities  
Purchase of property and equipment not yet paid$552 $26 
Unrealized gains on currency translation$- $(6)
Unrealized gains (losses) on available-for-sale securities$(9)$18 
Cash interest paid$265 $445 
8
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
9
BioLife Solutions, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
1.    Organization and significant accounting policies
Business
BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products include proprietary biopreservation media, automated thawing devices, and cloud-connected shipping containers. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in CGT that can be filled manually or with high throughput systems, CryoCase™ cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement, dated April 17, 2024 (the “Global Cooling Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Global Cooling Purchase Agreement, the Global Cooling business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “SciSafe Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“SciSafe Buyer”), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (“SciSafe Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock (the “SciSafe Shares”) of SciSafe to SciSafe Buyer. Upon the execution of the SciSafe Purchase Agreement, the SciSafe business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On November 14, 2024, the Company entered into a Stock Purchase Agreement (the “CBS Purchase Agreement”), by and among the Company, Standex International Corporation, a Delaware corporation (“CBS Buyer”), and Arctic Solutions, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (doing business as Custom Biogenic Systems, or “CBS”), for the sale by the Company of all of the issued and outstanding shares of common stock (the “CBS Shares”) of CBS to CBS Buyer (the “CBS Divestiture”). Upon the execution of the CBS Purchase Agreement, the CBS business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On April 4, 2025, pursuant to a Stock Purchase Agreement (the “PanTHERA Purchase Agreement”), by and among the Company, Casdin Partners Master Fund L.P. and each other person listed on Schedule A thereto (the “PanTHERA Sellers”), Alberta LTD., an Alberta corporation and a wholly owned subsidiary of the Company (“PanTHERA Buyer Sub”), PanTHERA CryoSolutions Inc., an Alberta corporation (“PanTHERA”) and Dr. Jason Acker, solely in his capacity as Sellers’ Representative, the Company acquired all of the issued and outstanding shares of common stock of PanTHERA from the Sellers (the “PanTHERA Transaction”). The acquisition of PanTHERA was considered a subsequent event to the financial results presented as of March 31, 2025. For additional information on the acquisition of PanTHERA see Note 19: Subsequent events.
The Company is presenting Global Cooling, SciSafe, and CBS within this Quarterly Report on Form 10-Q (this “Form 10-Q”) as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed
10
Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented in this Form 10-Q reflect only the continuing operations of the Company unless otherwise noted. See Note 2: Discontinued operations within this Form 10-Q for further details regarding the divestitures described above.
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s valuation of market-based stock awards, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.
The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation and consolidation
The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2025 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2025 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”) and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 2: Discontinued operations for additional details about the divestitures.
Foreign currency exchange
The Company's sales are primarily denominated in the U.S. dollar. Accordingly, our sales are not generally impacted by foreign currency exchange rates. For any transactions denominated in a foreign currency, which were immaterial during the three months ended March 31, 2025 and 2024, the Company remeasures foreign currency transactions into U.S. dollars on its Unaudited Condensed Consolidated Financial Statements in the Other income line item.
11
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional information on the Company's segment considerations, see Note 17: Segment, customer, and geographic information.
Significant accounting policies
There have been no significant changes to the accounting policies during the three months ended March 31, 2025, as compared to the significant accounting policies described in our Annual Report.
Liquidity and capital resources

On March 31, 2025 and December 31, 2024, we had $107.6 million and $109.2 million in cash, cash equivalents, and available-for-sale securities, respectively. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Form 10-Q.
Risks and uncertainties
The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.
For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q.
Recent accounting pronouncements
Recently issued accounting pronouncements not yet adopted
In November 2024, the Financial Accounting Standards Board ("FASB") issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures - Clarifying the Effective Date to clarify the effective date for non-calendar year-end entities. The amendments in this ASU will be effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the effects adoption of this guidance will have on the Consolidated Financial Statements.
2.     Discontinued operations
In 2024, the Company, management, and our board of Directors (the "Board"), made the decision to sell Global Cooling and CBS (the "Freezer Business"), allowing the Company to optimize its product portfolio by focusing on its recurring higher margin revenue streams. Additionally, in November of 2024, the Company, management, and the Board determined the sale of SciSafe would further optimize the Company's product portfolio toward its proprietary high margin cell processing and other bioproduction products. Accordingly, the results of these businesses are reported in the “Loss from
12
discontinued operations” line in the Condensed Consolidated Statements of Operations. These changes have been applied to all periods presented.
Divestiture of Global Cooling, Inc.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings pursuant to the Global Cooling Purchase Agreement. The Company analyzed the quantitative and qualitative factors relevant to the sale of Global Cooling and determined that the conditions for discontinued operations presentation were met during the second quarter of 2024.
As a condition of the Global Cooling Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$- 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Less: Global Cooling carrying basis as of April 17, 20241,650 
Less: Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balances of loans under Global Cooling as of the date of the Global Cooling Divestiture.
In connection with the Company’s entry into the Global Cooling Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing approximately 11% of its full-time employees as of the date of the RIF). The Board approved the RIF on March 29, 2024, and all affected employees of Global Cooling were informed by April 18, 2024, following the execution of the Global Cooling Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees- 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 
As outlined in the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies. Prior to the Global Cooling Divestiture, a lawsuit was filed by a previous customer related to Global Cooling's commercial freezer products seeking payment of up to $4.0 million for losses the customer claims to have incurred. As of the year ended December 31, 2024, the Company recorded a loss contingency under the discontinued
13
operations of Global Cooing related to this product liability claim as outlined in the Global Cooling Purchase Agreement. During the fourth quarter of 2024, it became probable this loss would be settled within the next fiscal year. The product liability claim is subject to insurance recovery, which management believes is probable as enforceable under the Company's insurance policy, covering the entirety of the loss contingency aside from the Company's insurance deductibles. The Company estimates the legal expenses to be incurred will be immaterial. There were no changes in the status of this claim during the three months ended March 31, 2025
In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement ("Global Cooling TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of the Global Cooling Divestiture. The Global Cooling TSA has since expired pursuant to its terms on the stated expiration date. The Company has no other significant continuing involvement with Global Cooling.
Divestiture of SciSafe, Inc.
On November 12, 2024, the Company entered into the SciSafe Purchase Agreement, and SciSafe, for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock of SciSafe to SciSafe Buyer ("SciSafe Divestiture"). The Company analyzed the quantitative and qualitative factors relevant to the sale of SciSafe and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.
In connection with the closing of the SciSafe Divestiture, the Company incurred $0.4 million in severance costs, paid the former stockholders of SciSafe $3.3 million in cash to waive all rights with respect to certain potential earn-out payments, and recognized $4.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with SciSafe upon the closing of this transaction.
The Company recognized a gain on disposal of SciSafe, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$71,291 
Cash proceeds from escrow483 
Costs to sell(1)
(506)
Total proceeds71,268 
Less: SciSafe carrying basis as of November 12, 202442,507 
Less: Release of SciSafe currency translation adjustment622 
Net gain on disposal$28,139 
(1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million.
In accordance with ASC 350, upon the disposal of SciSafe, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to SciSafe was based on the relative fair value of SciSafe to the fair value of the Company as SciSafe was fully integrated into the Company's one reportable segment. The fair value of SciSafe was determined based on the enterprise value per the SciSafe Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $11.3 million of goodwill was to be allocated to SciSafe upon its disposal. The allocated goodwill was included in the carrying basis of SciSafe presented in the above table.
In addition, upon the closing of the SciSafe Divestiture, the Company and SciSafe entered into a transition services agreement ("SciSafe TSA"), pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the closing of the transaction. The SciSafe Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the closing of the SciSafe Divestiture.
14
In connection with the disposal of SciSafe, the Company remains liable and responsible for the full performance and observance of all of the provisions, covenants, and conditions in one of SciSafe's operating leases. In the case of a breach or violation of any provision of the lease by the SciSafe Buyer, the Company is deemed to be in default of the lease provisions. Simultaneously, the Company received indemnification pursuant any obligation owed by the Company under this operating lease. This indicates the Company undertakes the obligation to stand ready to perform over the term of the guarantee in the event of the specified triggering events noted above, or conditions, such as breach or default, occur. However, the non-contingent aspect of the guarantee enables the Company to recover any losses from the SciSafe Buyer. As of March 31, 2025, the fair value of this guarantee is not material. The outstanding minimum lease payments equal approximately $2.5 million and the lease terminates in 2031.
The Company has no other significant continuing involvement with SciSafe upon the expiration of its SciSafe and other related covenants.
Divestiture of Custom Biogenics
On November 14, 2024, the Company entered into the CBS Purchase Agreement, for the sale by the Company of all of the issued and outstanding shares of common stock of CBS. The Company analyzed the quantitative and qualitative factors relevant to the CBS Divestiture and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.
The Company recognized $2.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with CBS upon the closing of the CBS Divestiture.
The Company recognized a loss on disposal of CBS, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$2,785 
Cash proceeds from escrow615 
Net price adjustment(1)
179 
Costs to sell(2)
(148)
Total proceeds3,431 
Less: CBS carrying basis as of November 14, 20246,796 
Net loss on disposal$(3,365)
(1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the CBS Divestiture.
(2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million.
In accordance with ASC 350, upon the disposal of CBS, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to CBS was based on the relative fair value of CBS to the fair value of the Company as CBS was fully integrated into the Company's one reportable segment. The fair value of CBS was determined based on the enterprise value per the CBS Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $1.1 million of goodwill was to be allocated to CBS upon its disposal. The allocated goodwill was included in the carrying basis of CBS presented in the above table.
In addition, upon the closing of the CBS Divestiture, the Company and CBS entered into a transition service agreement (the "CBS TSA"), pursuant to which the Company will provide certain transition services to CBS following the closing of the CBS Divestiture. The CBS Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with CBS, soliciting its employees or interfering with its business relationships for two years after the closing of the CBS Divestiture. The Company has no other significant continuing involvement with CBS upon the expiration of its CBS TSA and related covenants.
15
Summarized financial data of discontinued operations
The tables below summarize financial data of discontinued operations for the three months ended March 31, 2024. Interest expenses directly associated with the debt of a disposed entity is reported in discontinued operations below.
The table below summarizes the key components of loss from discontinued operations as follows:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Revenue$4,948 $5,135 $3,210 $13,293 
Cost of revenue6,600 3,725 2,648 12,973 
Gross profit(1,652)1,410 562 320 
Operating expenses(4,314)(1,663)(1,175)(7,152)
Other income (expense), net(33)(18)(25)(76)
Loss before income taxes(5,999)(271)(638)(6,908)
Income tax expense(10)(100)(4)(114)
Loss from discontinued operations, net of income taxes$(6,009)$(371)$(642)$(7,022)
Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Depreciation$— $667 $— $667 
Amortization$— $227 $— $227 
Stock-based compensation$947 $706 $402 $2,055 
Interest expense, net$38 $2 $26 $66 
Capital expenditures$26 $255 $— $281 
All divested entities had no remaining balances as of March 31, 2025 or December 31, 2024.
3.    Fair value measurement
In accordance with the FASB ASC Topic 820, Fair Value Measurements and Disclosures, (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.
16
Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
There were no remeasurements to fair value during the three months ended March 31, 2025 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, based on the three-tier fair value hierarchy:
(In thousands)
As of March 31, 2025Level 1Level 2 Total
Assets:
Cash equivalents:
Money market accounts$61,852 $-  $61,852 
Available-for-sale securities:    
U.S. government securities8,297 -  8,297 
Corporate debt securities2,796 21,496  24,292 
Other debt securities- 8,101  8,101 
Total$72,945 $29,597  $102,542 
As of December 31, 2024
Assets:
Cash equivalents:
Money market accounts$89,119 $-  $89,119 
Available-for-sale securities:
U.S. government securities1,494 -  1,494 
Corporate debt securities398 8,602  9,000 
Other debt securities- 3,332  3,332 
Total$91,011 $11,934  $102,945 
There have been no transfers of assets or liabilities between the fair value measurement levels. We had no financial assets that utilize Level 3 inputs of measurement as of March 31, 2025 and December 31, 2024.
17
4.    Investments
Available-for-sale securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
March 31, 2025
Amortized
Cost		 Gross unrealized Estimated
Fair Value
(In thousands) GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$6,509 $3 $- $6,512 
Corporate debt securities11,638 13 (1)11,650 
Other debt securities3,472 2 (1)3,473 
Total short-term21,619 18 (2)21,635 
     
Available-for-sale securities, long-term    
U.S. government securities1,779 7 - 1,786 
Corporate debt securities12,631 14 (4)12,641 
Other debt securities4,628 3 (3)4,628 
Total long-term19,038 24 (7)19,055 
Total marketable securities$40,657 $42 $(9)$40,690 
December 31, 2024
Amortized
Cost		Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$1,493 $1 $- $1,494 
Corporate debt securities5,775 14 (1)5,788 
Other debt securities1,912 4 - 1,916 
Total short-term9,180 19 (1)9,198 
Available-for-sale securities, long-term
Corporate debt securities3,210 4 (2)3,212 
Other debt securities1,412 5 (1)1,416 
Total long-term4,622 9 (3)4,628 
Total marketable securities$13,802 $28 $(4)$13,826 
March 31, 2025
(In thousands)Amortized
Cost		Estimated
Fair Value
Due in one year or less$21,619 $21,636 
Due after one year through five years19,038 19,054 
Total$40,657 $40,690 
18
The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:
March 31, 2025
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$4,913 $(4)$4,913 $(4)
Other debt securities5,082 (2)5,082 (2)
Total$9,995 $(6)$9,995 $(6)
December 31, 2024
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$2,091 $(3)$2,091 $(3)
Other debt securities1,030 (1)1,030 (1)
Total$3,121 $(4)$3,121 $(4)
As of March 31, 2025 and December 31, 2024, all available-for-sale securities investments presented above with unrealized losses have been in an unrealized loss position for less than 12 months.
As of March 31, 2025, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded.
Equity investments
The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The Company has adopted the measurement alternative whereby equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series E Preferred Stock in PanTHERA carried at $1.0 million as of March 31, 2025 and December 31, 2024.
On April 4, 2025, the Company purchased the remaining 90% of PanTHERA common shares it did not own as of March 31, 2025 for an $10.0 million in cash and 213,361 shares of the Company's Common stock and other contingent consideration. For additional details on the transaction, see Note 19: Subsequent events.
5.    Inventories
Inventories consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Raw materials$9,846 $11,768 
Work in progress4,489 4,082 
Finished goods13,231 13,163 
Total inventories$27,566 $29,013 
6.    Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of two to eleven years and have remaining lease terms of two to six years. The Company excludes options that are not reasonably certain to be exercised from our lease terms,
19
ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases.
We did not have any financing lease arrangements as of March 31, 2025 and December 31, 2024.
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Weighted average discount rate - operating leases6.4 %6.4 %
Weighted average remaining lease term in years - operating leases5.96.1
The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended
March 31,
(In thousands)20252024
Operating lease costs$625 $385 
Short-term lease costs31 17 
Total operating lease costs656 402 
 
Variable lease costs298 239 
Total lease costs$954 $641 
Maturities of our lease liabilities as of March 31, 2025 are as follows:
(In thousands)Operating
Leases
2025 (9 months remaining)$1,900 
20263,029 
20272,583 
20282,642 
20292,724 
Thereafter3,946 
Total lease payments16,824 
Less: interest(2,824)
Total present value of lease liabilities$14,000 
20
7.     Assets held for rent
Assets held for rent consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Shippers placed in service$8,994 $9,505 
Accumulated depreciation(6,350)(6,499)
Net2,644 3,006 
Shippers and related components in production3,046 3,097 
Total$5,690 $6,103 
Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.5 million and $0.6 million in depreciation expense related to assets held for rent during the three months ended March 31, 2025 and March 31, 2024, respectively.
8.    Property and equipment
Property and equipment consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Property and equipment  
Leasehold improvements$3,587 $3,527 
Furniture and computer equipment306 306 
Manufacturing and other equipment4,116 4,073 
Construction in-progress3,094 2,478 
Subtotal11,103 10,384 
Less: Accumulated depreciation(4,498)(4,300)
Property and equipment, net$6,605 $6,084 
Depreciation expense for property and equipment was $0.2 million and $0.2 million for the three months ended March 31, 2025 and March 31, 2024, respectively.
9.    Goodwill and intangible assets
Goodwill
Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350.
Intangible assets
Intangible assets, net consisted of the following as of March 31, 2025 and December 31, 2024:
21
(In thousands, except weighted average useful life)March 31, 2025
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,512)$4 0.3
Tradenames4,114 (1,901)2,213 5.6
Technology - acquired18,672 (12,032)6,640 2.9
Non-compete agreements90 (90)- 0.0
Total intangible assets$25,392 $(16,535)$8,857 3.1
(In thousands, except weighted average useful life)December 31, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,508) $8  0.6
Tradenames4,114 (1,799) 2,315  5.9
Technology - acquired18,672 (11,436) 7,236  3.1
Non-compete agreements90 (90) -  0.0
Total intangible assets$25,392 $(15,833) $9,559  3.3
Amortization expense for definite-lived intangible assets was $0.7 million and $0.7 million for the three months ended March 31, 2025 and March 31, 2024, respectively. As of March 31, 2025, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2025 (9 months remaining)$2,105 
20262,692 
20271,938 
2028828 
2029530 
Thereafter764 
Total$8,857 

10.    Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Accrued expenses$4,341  $7,116 
Accrued compensation3,755  5,232 
Deferred revenue, current117  103 
Total accrued expenses and other current liabilities$8,213  $12,451 
22
11.    Commitments and contingencies
Employment agreements
We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason.
Litigation
From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, as our industry is characterized by frequent claims and litigation, including claims regarding intellectual property. Management does not believe any of the current claims are material to the Company’s business. Future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company carries certain insurance policies that may cover the aforementioned costs. The probability of claims that could result in a loss are evaluated and disclosed, as needed, individually and on a gross basis. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company other than those listed below.
Pending litigation item
One lawsuit has been filed by a previous customer seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. Pursuant to the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies and if this previous customer was successful on such claim, then the Company would be responsible for indemnifying Global Cooling for any losses. This lawsuit does not currently have probable outcomes determined and we continue to defend vigorously against the claims made. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential loss incurred to be covered by insurance.
Indemnification
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of March 31, 2025 and December 31, 2024.
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of March 31, 2025, our total short-term obligations were $10.0 million.
Non-income related taxes
Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2024, the Company determined that a sales tax liability related to the periods of 2019 through 2024 was probable and determined an estimated liability. The estimated liability was approximately $3.9 million and $4.3 million as of March 31, 2025 and December 31, 2024, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period.
23
12.    Long-term debt
Term Loan
On September 20, 2022, the Company and certain of its subsidiaries entered into the Loan and Security Agreement, by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), Global Cooling, and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton”), as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Second Amendment”), that certain Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024 (the “Third Amendment”), and that certain Consent and Fourth Amendment to Loan and Security Agreement, dated April 4, 2025 (the "Fourth Amendment", and the foregoing collectively, the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of March 31, 2025, the implied interest rate of the Term Loan is 11.1% and the implied value of the Term Loan is $13.4 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of March 31, 2025, the Company is in compliance with the covenants set forth in the Loan Agreement.
On April 17, 2024, the Company entered into the Second Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton (the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton, collectively, the “Second Amendment Borrower”). Pursuant to the Second Amendment and subject to the conditions set forth therein, Bank consented to the Global Cooling Divestiture and released its security interests in the assets of Global Cooling and the shares of common stock of Global Cooling arising under the Loan Agreement. In addition, effective as of the closing of the Global Cooling Divestiture, the Second Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Second Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Second Amendment also contains customary representations and warranties of Second Amendment Borrower and provides for a release of Bank by Second Amendment Borrower for any claims existing or arising through the date of the Second Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
On November 11, 2024, the Company entered into the Third Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent and Sexton (the Company, SAVSU, Arctic, SciSafe Parent and Sexton, collectively, the “Third Amendment Borrower”). Pursuant to the Third Amendment and subject to the conditions set forth therein, Bank consented to the SciSafe Divestiture as required pursuant to the Loan Agreement. In addition, effective as of the closing of the SciSafe Divestiture, the Third Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Third Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date for any reason. The Third Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Third Amendment Borrower and provides for a release of Bank by Third Amendment Borrower for any claims existing or arising through the date of the Third Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
24
On April 4, 2025, the Company entered into the Fourth Amendment by and among Bank, the Company, SAVSU and Sexton. For additional information on the Fourth Amendment, see Note 19: Subsequent events.
Long-term debt consisted of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)Maturity DateInterest Rate20252024
Term Loan(1)
Jun-267.0 %$12,500 $15,000 
Insurance premium financingVarious8.3 %473 975 
Total debt, excluding unamortized debt issuance costs12,973 15,975 
Less: unamortized debt issuance costs(25)(35)
Total debt12,948 15,940 
Less: current portion of debt(10,449)(10,943)
Total long-term debt$2,499 $4,997 
(1) As of March 31, 2025, the Term Loan was secured by substantially all assets of BioLife, SAVSU, and Sexton, other than intellectual property.
As of March 31, 2025, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2025 (9 months remaining)$7,951 
20264,997 
2027- 
2028- 
2029- 
Thereafter- 
Total debt$12,948 
13.    Revenue
To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of both March 31, 2025 and December 31, 2024, our deferred revenue balance totaled $0.1 million. During the three months ended March 31, 2025, the Company recognized approximately $18 thousand of revenue that was included in the deferred revenue balance at the beginning of the year.
The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, hPL media, evo ModPaks, and ThawSTAR products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control
25
of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations.
Service revenues are generated from various customer service agreements to provide warranty and other engineering services. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three months ended March 31, 2025.
The Company generates revenue from the leasing of our evo cold chain systems to customers pursuant to rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under rental arrangements for durations of one year or less, with each unit having the option to continue its rental arrangement on a month-to-month basis until returned to the Company beyond the initial rental period. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term.
Total bioproduction tools and services revenue for the three months ended March 31, 2025 and 2024 were composed of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024
Product revenue
Cell processing$21,574 $16,186 
evo and Thaw725 557 
Service revenue
evo and Thaw60 25 
Rental revenue
evo and Thaw1,582 1,665 
Total revenue$23,941 $18,433 
There was no estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period of March 31, 2025. The Company elected not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers.

26
14.    Stock-based compensation
Service-based vesting stock options
The following is a summary of service-based vesting stock option activity for the three months ended March 31, 2025, and the status of service-based vesting stock options outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period127,000 $2.19 
Exercised— — 
Outstanding as of March 31, 2025127,000 $2.19 
Stock options exercisable as of March 31, 2025127,000 $2.19 
As of March 31, 2025, there was $2.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2025. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three months ended March 31, 2025. There were no exercises of service vesting-based awards during the three months ended March 31, 2025. There were no service-based vesting options granted during the three months ended March 31, 2025. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of March 31, 2025 is 1.2 years. There were no unrecognized compensation costs for service-based vesting stock options as of March 31, 2025.
Restricted stock
Service-based vesting restricted stock
The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2025, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period1,295,640 $16.00 
Granted290,333 25.33 
Vested(171,379)19.47 
Forfeited(15,151)14.17 
Non-vested as of March 31, 20251,399,443 $17.53 
The aggregate fair value of the service-based vesting awards granted was $7.4 million during the three months ended March 31, 2025. The aggregate fair value of the service-based vesting awards that vested was $4.5 million during the three months ended March 31, 2025.
We recognized stock compensation expense related to service-based vesting awards of $2.7 million during the three months ended March 31, 2025. As of March 31, 2025, there was $22.5 million in unrecognized compensation costs related
27
to service-based vesting awards. The weighted average remaining recognition period over which these service-based vesting awards will be expensed is approximately 2.8 years.
Performance-based restricted stock
On March 8, 2024, the Company granted a performance-based restricted stock award for 109,512 shares to an executive. The shares granted contain performance conditions based on Company metrics related to future performance. The shares will vest as to between 0% and 200% of the number of restricted shares granted to the recipient based on performance conditions during the period beginning on January 1, 2024 through December 31, 2025. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025.
During the fourth quarter of the year ended December 31, 2024, it was determined the probability of attainment of the performance condition increased to greater than 100% of shares granted. In accordance with ASC 718, we recognized a cumulative catch up in stock compensation expense of $0.4 million to reflect the increased probability the performance-based award would vest in excess of the shares originally granted. The fair value of this award is being expensed on a straight-line basis in accordance with the estimated quantity of shares expected to vest over the requisite service period ending on December 31, 2025.
During the three months ended March 31, 2025, the Company's Board approved a modification to the metrics underlying the performance-based award to give effect to the adjusted operating results of the Company following the divestitures that occurred during the year ended December 31, 2024. The modification increased the probability that the performance-based award would vest in excess of the shares originally granted to its maximum amount of 200%. In accordance with ASC 718, this modification resulted in an incremental compensation cost of $1.6 million, which will be recognized over the remainder of the service period of the award.
We recognized stock compensation expense of $0.4 million related to performance-based restricted stock awards for the three months ended March 31, 2025. As of March 31, 2025, there was $2.7 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 0.8 years. Non-cash compensation costs are expensed over the period for which performance was measured.

There were no performance-based restricted stock awards granted or vested during the three months ended March 31, 2025.
Market-based restricted stock
The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2025 and the status of market-based restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period495,686 $25.69 
Granted451,801 32.91 
Vested(470,287)25.19 
Non-vested as of March 31, 2025477,200 $33.02 





28
The following is a summary of key inputs to our market-based restricted stock awards as of March 31, 2025:
Fair Value Assumptions
Grant DateTarget SharesVesting RangeMarket Condition PeriodFV of Award
(in millions)		VolatilityRisk Free RateDividend RateAttainment %Vested Shares
2023 TSR(1)
1/3/2023268,738
0% - 200%
1/1/2023 - 12/31/2024$6.8 78 %4.4 %— %175 %470,287
2024 TSR(2)
3/8/2024239,464
0% - 200%
1/1/2024 - 12/31/2025$6.3 80 %4.6 %— %N/AN/A
2025 TSR3/18/2025250,252
0% - 200%
1/1/2025 - 12/31/2026$9.8 60 %4.1 %— %N/AN/A
(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.
(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.
Each of the market-based restricted stock awards outlined above were granted to its executives. The restricted stock awards granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards vest at a range determined by the Compensation Committee of the Board of Directors in comparison to the TSR of a group of the Company's peers. The fair value of these awards are determined using a Monte Carlo simulation with various assumptions. These assumptions include historical volatility, dividend yield, and a risk-free interest rate. The historical volatility is based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the measurement date with a maturity consistent with the 2-year term associated with the market condition of these awards. The fair value of these awards are expensed on a straight-line basis over the grant date to the vesting date.
When the TSR period for each award has elapsed, the Company determines the TSR attainment percentage to award each recipient based on the targeted amount of shares granted.
We recognized stock compensation expense of $1.0 million and $1.1 million related to market-based restricted stock awards for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, there were $12.0 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. The weighted average remaining recognition period over which these market-based awards will be expensed is approximately 1.5 years.
The aggregate fair value of the market-based awards granted was $6.3 million for both the three months ended March 31, 2025 and 2024. The aggregate fair value of the market-based awards that vested was $11.5 million and $5.1 million for the three months ended March 31, 2025 and 2024, respectively.
29
Total stock compensation expense
Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three months ended March 31, 2025 and 2024, as follows:
 Three Months Ended
March 31,
(In thousands)20252024
Cost of revenue$292 $308 
General and administrative costs2,967 2,833 
Sales and marketing costs388 424 
Research and development costs506 563 
Total$4,153 $4,128 
15.    Income taxes
The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. Income tax expense of $14.0 thousand for the three months ended March 31, 2025 resulted in an effective income tax rate of negative 3.2%. Included in the $14.0 thousand of tax expense was discrete tax benefit of $0.5 million related to stock compensation, which was offset by a change in the valuation allowance.
The Company’s projected effective income tax rate for the year ending December 31, 2025 excluding the impact, if any, of discrete items is negative 5.3%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits.
Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates all available positive and negative evidence to determine if it is more likely than not that its deferred tax assets are realizable. As of March 31, 2025, the Company continues to provide a full valuation allowance against its deferred tax assets as the realization of such assets is not considered to be more likely than not at this time. If the Company's conclusion about the realizability of its deferred tax assets and therefore the appropriateness of the valuation allowance changes in a future period, the Company could record a substantial tax benefit in its Condensed Consolidated Statements of Operations when that occurs.
16.    Net loss from continuing operations per common share
Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.
30
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
March 31,
(In thousands, except share and earnings per share data)20252024
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(448)$(3,199)
Denominator:
Weighted-average common shares issued and outstanding47,134,72045,432,426
Basic and diluted loss from continuing operations per common share$(0.01)$(0.07)
Anti-dilutive shares1,232,8361,070,693

17. Segment, customer, and geographic information
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, Mr. Roderick de Greef, who is the CODM, reviews the Company’s operations on a consolidated basis for purposes of allocating resources and evaluating financial performance. As a single reportable segment entity, the Company’s segment performance measure is consolidated net (loss) income from continuing operations.
Significant segment expenses are presented in the Company’s Condensed Consolidated Statements of Operations. Additional significant segment expenses that are not separately presented in the Company’s Condensed Consolidated Statements of Operations include Shared-based compensation and Depreciation expense. These are presented in the Condensed Consolidated Statement of Cash Flows, and Note 14: Stock-based compensation, Note 7: Assets held for rent, and Note 8: Property and equipment.
Other expense items not individually significant in net loss from continuing operations are changes in inventory values due to changes in its carrying basis, costs associated with the Company’s acquisitions or divestitures in the period these take place, and gain or loss on disposal of fixed assets. The information provided to the Company’s CODM for purposes of making decisions and assessing segment performance excludes asset information.
Concentrations of risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
 Accounts ReceivableRevenue
 March 31,December 31,Three Months Ended March 31,
 2025202420252024
Customer A18 % * **
Customer B*18 %18 %19 %
Customer C*21 %11 %*
Customer D13 %***
*less than 10%
31
The following is a summary of revenue by major product family representing over 10% of the Company's total revenue:
Three Months Ended
March 31,
Product revenue concentration20252024
CryoStor77 %73 %
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
March 31,
Revenue by customers’ geographic locations
20252024
United States81 %81 %
Europe, Middle East, Africa (EMEA)14 %14 %
Other5 %5 %
Total revenue100 %100 %
All of the Company's long-lived assets, totaling $22.4 million as of March 31, 2025, are located within the United States. Though the Company's evo shippers under rental arrangements may be outside of the United States, all are shipped back to our United States warehouse upon completion of the applicable rental arrangement.
In the three months ended March 31, 2025 and 2024, no suppliers accounted for more than 10% of purchases.
As of March 31, 2025, three different suppliers accounted for 17%, 16%, and 11% of accounts payable. As of December 31, 2024, no suppliers accounted for more than 10% of accounts payable.
18.    Employee benefit plan
The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.2 million in contributions to this plan for both the three months ended March 31, 2025 and 2024.
19.    Subsequent events
The Company has evaluated events subsequent to March 31, 2025 through the date of this filing to assess the need for potential recognition or disclosure.
Stock Purchase Agreement for PanTHERA Acquisition
On April 4, 2025, the Company entered into the PanTHERA Purchase Agreement for the purchase by the Company of all of the issued and outstanding shares of common stock of PanTHERA from the Sellers for an aggregate purchase price of $22.7 million, net of cash acquired, which included $10.0 million in cash, subject to any adjustments pursuant to the purchase price adjustment provision in the PanTHERA Purchase Agreement, 213,361 shares of our common stock, and an additional $7.2 million in earnout payments over the next three years contingent on the achievement of certain scientific and revenue milestones (the “PanTHERA Transaction”). Following the execution of the PanTHERA Purchase Agreement, the PanTHERA Transaction was consummated on April 4, 2025 (the “Closing Date”). The PanTHERA Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto.
The Company acquired PanTHERA's portfolio of molecules and other assets including certain technology under development. Management is in the process of determining the purchase price allocation and accounting treatment. The
32
preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax incurred thus far were $0.2 million.
Consent and Fourth Amendment to Loan and Security Agreement with Silicon Valley Bank
On April 4, 2025, the Company entered into a Consent and Fourth Amendment to Loan and Security Agreement (the “Fourth Amendment”), by and among Bank, the Company, SAVSU, SciSafe Parent, and Sexton. Pursuant to the Fourth Amendment and subject to the conditions set forth therein, Bank consented to the PanTHERA Transaction and the SciSafe Dissolution as required pursuant to the Loan Agreement. The Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of the Company, SAVSU, SciSafe Parent, and Sexton and provides for a release of Bank by the Company, SAVSU, SciSafe Parent, and Sexton for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
33
Item 2. Management’s discussion and analysis of financial condition and results of operations
Forward looking statements
Certain statements contained in this Quarterly Report on Form 10-Q are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission (the “SEC”), all of which are available at www.sec.gov, including our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the "Annual Report"). Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Overview
Management’s discussion and analysis provides additional insight into the Company and is provided as a supplement to, and should be read in conjunction with, our Annual Report.
We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
We currently operate as one bioproduction products and services business which supports several steps in the biologic material manufacturing and delivery process. We have a diversified portfolio of tools and services that focuses on biopreservation, cell processing, and thawing of biologic materials. We have in-house expertise in cryobiology and the broader CGT workflow, and continue to evaluate opportunities to maximize the value of our product platforms for our extensive customer base through organic growth innovations, partnerships, and acquisitions.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”) to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”), pursuant to a Stock Purchase Agreement (the “Global Cooling Purchase Agreement”), dated April 17, 2024, by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Global Cooling Purchase Agreement, the Global Cooling business is presented in the accompanying condensed financial statements as a discontinued operation for all periods presented. See Item I, Note 2: Discontinued operations, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further details regarding the Global Cooling Divestiture.
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “SciSafe Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“SciSafe Buyer”), SciSafe, Inc., a Delaware corporation and an indirect wholly owned subsidiary of the Company (“SciSafe Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock of SciSafe to SciSafe Buyer. Upon the execution of the SciSafe Purchase Agreement, the SciSafe business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented. The Company dissolved SciSafe Seller on November 12, 2024 (the “SciSafe Dissolution”). See Item I, Note 2: Discontinued operations, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further details regarding the SciSafe Divestiture.
On November 14, 2024, the Company entered into a Stock Purchase Agreement (the “CBS Purchase Agreement”), by and among the Company, Standex International Corporation, a Delaware corporation (“CBS Buyer”), and Arctic Solutions, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (doing business as Custom Biogenic Systems,
34
or “CBS”), for the sale by the Company of all of the issued and outstanding shares of common stock (the “CBS Shares”) of CBS to CBS Buyer (the “CBS Divestiture”). Upon the execution of the CBS Purchase Agreement, the CBS business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented. See Item I, Note 2: Discontinued operations, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q for further details regarding the CBS Divestiture.
On April 4, 2025, pursuant to a Stock Purchase Agreement (the “PanTHERA Purchase Agreement”), by and among the Company, Casdin Partners Master Fund L.P. and each other person listed on Schedule A thereto (the “PanTHERA Sellers”), Alberta LTD., an Alberta corporation and a wholly owned subsidiary of the Company (“PanTHERA Buyer Sub”), PanTHERA CryoSolutions Inc., an Alberta corporation (“PanTHERA”) and Dr. Jason Acker, solely in his capacity as Sellers’ Representative, the Company acquired all of the issued and outstanding shares of common stock of PanTHERA from the Sellers (the “PanTHERA Transaction”). The acquisition of PanTHERA was considered a subsequent event to the financial results presented as of March 31, 2025. For additional information on the acquisition of PanTHERA see Note 19: Subsequent events.
Our products
Our bioproduction products and services are comprised of two revenue lines that contain four main offerings:
•Cell processing
◦Biopreservation media
◦Human platelet lysate media (“hPL”), cryogenic vials, and automated cell-processing fill machines
•Evo and ThawSTAR devices
◦Cloud connected “smart” shipping containers
◦Automated thawing devices
Critical accounting policies and estimates
A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a description of our critical accounting policies that affect our more significant judgments and estimates used in the preparation of our Unaudited Condensed Consolidated Financial Statements, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations and our significant accounting policies in Note 1 to the Consolidated Financial Statements included in our Annual Report and Part I, Note 1 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Results of operations
The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the related footnotes thereto.
35
Revenues
Total revenue for the three months ended March 31, 2025 and 2024 consisted of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024$ Change% Change
Product revenue
Cell processing$21,574 $16,186 $5,388 33 %
evo and Thaw725 557 $168 30 %
Service revenue
evo and Thaw60 25 $35 140 %
Rental revenue
evo and Thaw1,582 1,665 $(83)(5)%
Total revenue$23,941 $18,433 $5,508 30 %
Product revenue
Product revenue was $22.3 million for the three months ended March 31, 2025, representing an increase of $5.6 million, or 33%, compared with the same period in 2024. The increase in product revenues for the three months ended March 31, 2025 is largely driven by an increase in customer demand for our cell processing products compared to the same period in the prior year.
Product revenue: Cell processing
Product revenue from our cell processing products increased by $5.4 million, or 33%, during the three months ended March 31, 2025, compared with the same period in 2024. The increase in revenue from cell processing products is driven by an overall market improvement compared to the prior year when our customers reduced safety stock levels. During the three months ended March 31, 2024, our revenues were impacted by our customers' reduction in purchases. This trend of reduced safety stock abated after our second quarter of 2024. Our largest customers additionally increased demand of purchases during the three months ended March 31, 2025 when compared to the same period in 2024.
Product revenue: evo and Thaw
Product revenue from our evo and Thaw products increased by $0.2 million, or 30%, during the three months ended March 31, 2025, compared with the same period in 2024. The increase in the three months ended March 31, 2025 is primarily due to new customer acquisitions when compared to the same period in 2024.
Service revenue
Service revenues, which are primarily generated from various customer service agreements to provide warranty and other engineering services, were an immaterial portion of our total revenues earned during the three months ended March 31, 2025 and 2024.
Rental revenue
Rental revenue was $1.6 million for the three months ended March 31, 2025, representing a decrease of $0.1 million, or 5%, compared with the same period in 2024. The decrease is primarily driven by the timing of returned units requiring repairs, decreasing the quantity of units under rental agreements compared to the same period in the prior year.
36
Costs and operating expenses
Total costs and operating expenses for three months ended March 31, 2025 and 2024 were composed of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024$ Change% Change
Cost of product, rental, and service revenue$8,155 $6,192 $1,963 32 %
General and administrative11,501 10,397 $1,104 11 %
Sales and marketing2,597 2,376 $221 9 %
Research and development2,204 2,075 $129 6 %
Intangible asset amortization702 688 $14 2 %
Total operating expenses$25,159 $21,728 $3,431 16 %
Cost of product, rental, and service revenue
Cost of product, rental, and service revenue increased $2.0 million, or 32%, for the three months ended March 31, 2025, compared to the same period in 2024. The increase during the three months ended March 31, 2025 is due primarily to increases in sales across multiple product lines compared to the same period in the prior year.
Cost of revenue inclusive of intangible amortization related to acquired technology was 37% as a percentage of revenue for both the three months ended March 31, 2025 and 2024. Although cost of revenue inclusive of intangible amortization was consistent between the three months ended March 31, 2025 and 2024, costs of materials, labor, and overhead were higher in the current period than in the prior year period due to increased sales of our biopreservation media product line, all offset by lower depreciation, intangible amortization, and warranty expenses.
General and administrative expenses
General and administrative (“G&A”) expenses consist primarily of personnel-related expenses, stock-based compensation, professional fees, such as accounting and consulting fees, and corporate insurance.
G&A expenses for the three months ended March 31, 2025 increased $1.1 million, or 11%, compared to the same period in 2024. The increase for the three months ended March 31, 2025 is primarily driven by an increase in professional fees incurred with third-party service providers in the process of acquiring PanTHERA, which finalized on April 4, 2025 and is further discussed in Item I, Note 19: Subsequent events to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q. There were additional increases in salary and severance expenses compared to the same period in the prior year.
Sales and marketing expenses
Sales and marketing expenses (“S&M”) consist primarily of personnel-related costs, stock-based compensation, consulting, advertising, and travel expense.
S&M expense for the three months ended March 31, 2025 increased $0.2 million, or 9%, compared with the same period in 2024. The increase is primarily due to an increase in marketing materials expenses and salaries compared to the same period in the prior year.
Research and development expenses
Research and development (“R&D”) expenses consist primarily of personnel-related costs, consulting, research supplies, and milestone expenses related to third-party research agreements.
R&D expenses for the three months ended March 31, 2025 increased $0.1 million, or 6%, compared with the same period in 2024. The increase is primarily due to an increase in bonus expenses compared to the prior year, offset by lower research milestone payments in relation to our PanTHERA equity investment.
37
Intangible asset amortization expense
Intangible asset amortization expense consists of charges related to the amortization of intangible assets associated with the acquisitions of Astero, SAVSU, and Sexton in which we acquired definite-lived intangible assets.
Other income
Total other income for the three months ended March 31, 2025 and 2024 was composed of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024$ Change% Change
Interest income (expense), net$681 $(140)$821 586 %
Other income103 253 $(150)(59)%
Total other income, net$784 $113 $671 594 %
Interest income (expense), net
Interest expense, net incurred during the three months ended March 31, 2025 related primarily to the Term Loan (as defined in Note 12: Long-term debt, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q) obtained in September 2022 and indirect tax liabilities. We also earn interest on cash held in our money market account and available-for-sale securities. The increase in our interest income, net during the three months ended March 31, 2025 can be attributed to the increases in interest income from our available-for-sale securities compared to the same period in 2024.
Liquidity and capital resources
On March 31, 2025 and December 31, 2024, we had $107.6 million and $109.2 million in cash, cash equivalents, and available-for-sale securities, respectively, in our continuing operations.
On April 17, 2024, we consummated the Global Cooling Divestiture. In connection with the closing of this transaction, we provided $6.7 million in cash funding to effectuate this transaction and paid $0.6 million to the brokers, attorneys, and other external parties. In addition, we recognized $6.1 million in cash expenditures from operations during the third quarter of 2024 to meet certain post-closing requirements, costs to sell Global Cooling, the assumption of certain liabilities and debt, and severance expenses related to the Reduction in Force ("RIF") implemented on the business of Global Cooling, which reduced our workforce by 47 employees. We are also required to indemnify Global Cooling for preexisting legal contingencies. Prior to the Global Cooling Divestiture, a lawsuit was filed by a previous customer related to Global Cooling's commercial freezer products seeking payment of up to $4.0 million for losses the customer claims to have incurred. The product liability claim is subject to insurance recovery, which management believes is probable as enforceable under our insurance policy, covering the entirety of the loss contingency aside from our insurance deductibles. We estimate the legal expenses to be incurred will be immaterial. For additional information on the details of this transaction, the RIF and its related costs, see Item I, Note 2: Discontinued operations within the Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
On November 12, 2024, we consummated the SciSafe Divestiture. In connection with the closing of this transaction, we received net proceeds of $71.3 million. We also incurred additional expenses related to this transaction, including $0.5 million to the brokers, attorneys, and other external parties for legal and other transaction services, and incurred $0.4 million in severance costs. We also paid the former stockholders of SciSafe approximately $3.3 million in cash to waive all rights with respect to certain potential earn-out payments and recognized $4.0 million in stock compensation expense in connection with the acceleration of unvested shares for all of our former employees that remained with SciSafe upon the closing of this transaction. For additional information on the SciSafe divestiture, see Item I, Note 2: Discontinued operations within the Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
On November 14, 2024, we consummated the CBS Divestiture. In connection with the closing of this transaction, we received net proceeds of $3.4 million. We also incurred additional expenses related to this transaction, including $0.1 million to the brokers, attorneys, and other external parties for legal and other transaction services. We also recognized $2.0 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees that
38
remained with CBS upon the closing of this transaction. For additional information on the CBS Divestiture, see Item I, Note 2: Discontinued operations within the Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
On April 4, 2025, we consummated the acquisition of PanTHERA. The aggregate purchase price of the acquisition was $22.7 million, which included $10.0 million in cash, 213,361 shares of our common stock, and an additional $7.2 million of our common stock over the next three years contingent on the achievement of certain scientific and revenue milestones. For additional information on the acquisition of PanTHERA, see Item I, Note 19: Subsequent events within the Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q and for the foreseeable future. However, the Company may choose to raise additional capital through a debt or equity financing for strategic purposes. Additional capital, if required, may not be available on reasonable terms, if at all.
Cash flows
Three Months Ended
March 31,
(In thousands)20252024$ Change
Operating activities$1,727 $(4,475)$6,202 
Investing activities(27,176)(221)$(26,955)
Financing activities(2,992)$(952)$(2,040)
Net decrease in cash and cash equivalents$(28,441)$(5,648)$(22,793)
Net cash provided by (used in) operating activities
Net cash provided by operating activities was $1.7 million during the three months ended March 31, 2025 compared to $4.5 million used in operating activities during the three months ended March 31, 2024. The increase in cash provided by operating activities was primarily due to a decrease in operating losses driven by stronger revenues compared to the prior year in addition to the timing of collection and disbursement of working capital related items in inventories, prepaid expenses, and accrued expenses.
Net cash used in investing activities
Net cash used in investing activities totaled $27.2 million during the three months ended March 31, 2025 compared to $0.2 million used in investing activities for the three months ended March 31, 2024. The increase in cash used in investing activities was primarily driven by the $24.0 million in additional purchases of our investments in available-for-sale marketable securities compared to the same period in the prior year. We additionally had $3.0 million less in maturities of available-for-sale securities compared to the prior year.
Net cash used in financing activities
Net cash used in financing activities totaled $3.0 million during the three months ended March 31, 2025, compared to $1.0 million used in financing activities during the three months ended March 31, 2024. The increase in cash used in financing activities was primarily the result of a $2.5 million increase in payments on the Term Loan compared to the same period in the prior year.
Contractual obligations
Our material cash requirements include contractual and other obligations which we previously disclosed within the financial statements and Management Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report. Other than the contractual obligation listed below, there have been no significant changes to these obligations in the three months ended March 31, 2025.
39
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of March 31, 2025, our total short-term obligations were $10.0 million.
Item 3. Quantitative and qualitative disclosures about market risk
Interest rate risk
Our exposure to market risk for changes in interest rates relates primarily to our long-term debt. Our long-term debt primarily bears interest at a fixed rate, with a variable component subject to an interest rate ceiling. Fluctuations in interest rates therefore do not materially impact our consolidated financial statements from long-term debt. For additional information, see Note 12, Long-term debt to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Item 4. Controls and procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2025.
Changes in Internal Control Over Financial Reporting
As previously reported, we identified a material weakness in our internal control over financial reporting ("ICFR") as of December 31, 2024, with regard to ineffective internal controls to verify that key inputs for the Company's stock-based awards were entered correctly into the equity system early in 2024. This weakness was attributed to an outdated internal policy with unclear guidance regarding the appropriate inputs. During the quarter ended March 31, 2025, our management made significant changes to our ICFR to remediate the material weakness, as follows:
•Updated the Stock-Based Compensation Policy to include clearer guidance and considerations on how to identify the appropriate inputs; and
•Trained Accounting team members on the updated policy and execution.
Other than the changes noted above, there were no other changes in our ICFR that occurred during the quarter ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, our ICFR.
Limitations on Effectiveness of Control
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.
40
PART II: Other information
Item 1. LEGAL PROCEEDINGS
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Item 1A. RISK FACTORS
During the three months ended March 31, 2025, there were no material changes to the risk factors described in Part I, Item 1A of our Annual Report.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. MINE SAFETY DISCLOSURES
None.
Item 5. OTHER INFORMATION
None.


41
Item 6. Exhibits
Exhibit No.Description
31.1
31.2
32.1#
32.2#
101.INS**XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH**Inline XBRL Taxonomy Extension Schema Document
101.CAL**Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
#The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Company specifically incorporates the foregoing information into those documents by reference.
**In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report on Form 10-Q for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.
42
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOLIFE SOLUTIONS, INC.
Date: May 8, 2025
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer
(Duly authorized officer and principal
financial and accounting officer)
43
 EX-31.1 2 exhibit311-q12025.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) or RULE 13d-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
I, Roderick de Greef, certify that:
1.I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 8, 2025
/s/ Roderick de Greef
Roderick de Greef
Chief Executive Officer and Chairman of the Board

 EX-31.2 3 exhibit312-q12025.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) or RULE 13d-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
I, Troy Wichterman, certify that:
1.I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 8, 2025
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer

 EX-32.1 4 exhibit321-q12025.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roderick de Greef, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 8, 2025
/s/ Roderick de Greef
Roderick de Greef
Chief Executive Officer and Chairman of the Board

 EX-32.2 5 exhibit322-q12025.htm EX-32.2 Document

EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Troy Wichterman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 8, 2025
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer

 EX-101.SCH 6 blfs-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Unaudited Condensed Consolidated Statements of Operations - Alternative Calculation link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Unaudited Condensed Consolidated Statements of Operations - Alternative Calculation link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Discontinued operations link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Assets held for rent link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Property and equipment link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Goodwill and intangible assets link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Long-term debt link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Net loss from continuing operations per common share link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Segment, customer, and geographic information link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Employee benefit plan link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Organization and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Discontinued operations (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Assets held for rent (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Property and equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Goodwill and intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Long-term debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Net loss from continuing operations per common share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Segment, customer, and geographic information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Organization and significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Discontinued operations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Discontinued operations - Schedule of Gain on Disposal (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Fair value measurement (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Investments - Schedule of Available-for-Sale Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Leases - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Assets held for rent - Schedule of Assets Held for Rent (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Assets held for rent - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Property and equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Property and equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Goodwill and intangible assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Long-term debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Long-term debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Long-term debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Long-term debt - Schedule of Maturities of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Stock-based compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Stock-based compensation - Schedule of Stock Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Segment, customer, and geographic information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Employee benefit plan (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 blfs-20250331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 blfs-20250331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 blfs-20250331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Thereafter Lessee Operating Lease Liability Payments Due After Year Four Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Selling price: $1 Disposal Group, Including Discontinued Operation, Selling Price Disposal Group, Including Discontinued Operation, Selling Price Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Total marketable securities, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Lease Expense Lease, Cost [Table Text Block] Cover [Abstract] Cover [Abstract] Expected reduction of workforce Restructuring and Related Cost, Expected Number of Positions Eliminated Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Assets held for rent Assets Held For Rent [Text Block] The entire disclosure for assets held for rent. Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities Less: SciSafe carrying basis as of November 12, 2024 Disposal Group, Including Discontinued Operation, Carrying Basis Disposal Group, Including Discontinued Operation, Carrying Basis Accrued compensation Deferred Compensation Liability, Current Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Vesting period (year) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Competition covenant period Competition Covenant Period Competition Covenant Period Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Weighted-average common shares issued, basic (in shares) Weighted Average Number of Shares Issued, Basic Disposal Group Name [Domain] Disposal Group Name [Domain] Equity investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Accounts receivable, trade, net Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Stock issued - on vested RSAs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair value measurement Fair Value Disclosures [Text Block] Unrealized gain (loss) on available-for-sale securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Loss on disposal of assets held for rent, net Gain (Loss) On Disposition Of Assets, Held For Rent Amount of gain (loss) on sale or disposal of assets held for rent. Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Leases Lessee, Operating Leases [Text Block] Loss from continuing operations, attributable to common shareholders: Net Income (Loss) Available to Common Stockholders, Continuing Operations [Abstract] Net Income (Loss) Available to Common Stockholders, Continuing Operations Common stock, outstanding (in shares) Beginning balance, common stock, outstanding (in shares) Ending balance, common stock, outstanding (in shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Lease liabilities, operating, long-term Operating Lease, Liability, Noncurrent Number of pending litigation claims Loss Contingency, Pending Claims, Number Segment reporting Segment Reporting, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Deferred revenue, current Contract with Customer, Liability, Current United States UNITED STATES Gross unrealized Losses, current portion Debt Securities, Available-for-Sale, Unrealized Loss, Current Current portion of amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Net Shippers Placed In Service, Net The carrying value of shippers placed in service, net of accumulated depreciation. Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Gross Carrying Value Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Expected reduction of workforce (percent) Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent Less: Release of SciSafe currency translation adjustment Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses) Total Shippers Placed In Service And Fixed Assets Held For Rent, Net Represents shippers placed in service and fixed assets held for rent, net Money market accounts Money Market Funds [Member] Supplier [Domain] Supplier [Domain] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Sales taxes payable Taxes Payable, Current Net loss per share attributable to common shareholders: Earnings Per Share Reconciliation [Abstract] Equity Components [Axis] Equity Components [Axis] Amortization of intangible assets Amortization Of Intangible Assets, Consolidated Basis Amortization Of Intangible Assets, Consolidated Basis Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Available-for-sale securities Estimated Fair Value, Total marketable securities Total Debt Securities, Available-for-Sale Restructuring Type [Axis] Restructuring Type [Axis] Tradenames Trade Names [Member] Discontinued operation, selling costs paid by divested entity Disposal Group, Including Discontinued Operation, Selling Costs Paid By Divested Entity Disposal Group, Including Discontinued Operation, Selling Costs Paid By Divested Entity Employee benefit plan Defined Contribution Plan [Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] Total operating expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stock issued – on vested RSUs Stock Issued During Period, Value, Restricted Stock Unit, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Unit, Net of Forfeitures Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value of exercisable service vesting-based stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Computations of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Two Supplier Two Supplier [Member] Two Supplier Disposal Group Classification [Axis] Disposal Group Classification [Axis] Non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Net loss on disposal Net gain on disposal Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Non-cash lease expense (benefit) Non-cash lease expense Amount of noncash lease expense. Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Period of transition services Discontinued Operation, Period of Continuing Involvement after Disposal Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Europe, Middle East, Africa (EMEA) EMEA [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost [Abstract] Sales and marketing costs Selling and Marketing Expense [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Accrued expenses Accrued Liabilities, Current Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Loss contingency accrual Loss Contingency Accrual Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Depreciation Disposal Group, Including Discontinued Operation, Depreciation Disposal Group, Including Discontinued Operation, Depreciation Debt instrument, variable interest rate, type [extensible enumeration] Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Measurement date with a maturity period (year) Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Period Represents expected volatility rate period for share based payment award by share based payment. Total fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Cash, cash equivalents, and restricted cash – beginning of period Cash, cash equivalents, and restricted cash – end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accretion of available-for-sale investments Accretion (Amortization) of Discounts and Premiums, Investments Unrecognized compensation costs for service vesting-based stock options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill Goodwill Less: Global Cooling carrying basis as of April 17, 2024 Disposal Group, Including Discontinued Operation, Carrying Basis Excluding Assumed Liabilities Disposal Group, Including Discontinued Operation, Carrying Basis Excluding Assumed Liabilities Inventories Inventory Disclosure [Text Block] Net loss from continuing operations Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Options Share-Based Payment Arrangement, Option [Member] Short-term lease costs Short-Term Lease, Cost Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Property and equipment, depreciation expense Depreciation Fair Value Disclosures [Abstract] Other liabilities Assumed liabilities: Accounts payable Disposal Group, Including Discontinued Operation, Assumed Liabilities, Accounts Payable Disposal Group, Including Discontinued Operation, Assumed Liabilities, Accounts Payable 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Other Proceeds from (Payments for) Other Financing Activities Attainment (percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Attainment Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Attainment Rate Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, outstanding (in shares) Beginning balance, preferred stock, outstanding (in shares) Ending balance, preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Award Type [Axis] Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption Schedule Of Share-Based Payment Award, Market-Based Awards Valuation Assumption [Table Text Block] Schedule Of Share-Based Payment Award, Market-Based Awards Valuation Assumption Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Work in progress Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Long-lived assets Long-Lived Assets Unrealized losses, less than 12 months Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Stock options exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of reporting units Number of Reporting Units Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Without Discrete Items Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Without Discrete Items, Percent Schedule of Available-for-Sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign currency exchange Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Total proceeds Disposal Group, Including Discontinued Operation, Positive (Negative) Selling Price Disposal Group, Including Discontinued Operation, Positive (Negative) Selling Price Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Lease liabilities, operating, current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk, percent Concentration Risk, Percentage Total unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Event [Line Items] Subsequent Event [Line Items] Subtotal Property, Plant and Equipment, Gross Total shareholder return attainment (percent) Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Awards Percent of shares that may be issued in accordance with the plan as a proportion of outstanding awards. Stock option exercises (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development costs Research and Development Expense [Member] Wtd. Avg. Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, authorized (in shares) Common Stock, Shares Authorized Basis of presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Restructuring costs Restructuring Costs MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] 2025 (9 months remaining) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Shares granted percentage Share-Based Payment Arrangement, Shares Granted Percentage Share-Based Payment Arrangement, Shares Granted Percentage Accounts Payable Accounts Payable [Member] Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Furniture and computer equipment Furniture and Computer Equipment [Member] Represents the furniture and computer equipment. Debt instrument, maximum borrowing capacity Debt Instrument, Maximum Borrowing Capacity Represents maximum borrowing capacity. Proceeds from term loans Proceeds from Issuance of Debt Operating lease, renewal term Lessee, Operating Lease, Renewal Term Revenue Disposal Group, Including Discontinued Operation, Revenue Deferred income tax expense Deferred Income Tax Expense (Benefit) Property and equipment Property, Plant and Equipment Disclosure [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Accounts payable Accounts Payable Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable, trade, net of allowance for credit losses of $117 and $153 as of March 31, 2025 and December 31, 2024, respectively Accounts Receivable, after Allowance for Credit Loss, Current Cost of revenue Cost of Sales [Member] Service based-vesting options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross evo and Thaw Product, Evo And Thaw [Member] Gross unrealized Gains, current portion Debt Securities, Available-for-Sale, Unrealized Gain, Current The unrealized gain of debt securities available-for-sale classified as current. Product revenue Product [Member] Segment Reporting Information [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Other Increase (Decrease) in Other Operating Liabilities Total debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Sales and excise tax payable Sales and Excise Tax Payable Business combination, acquisition related costs Business Combination, Acquisition Related Costs 2029 Long-Term Debt, Maturity, Year Four Prepaid expenses and other assets Increase (Decrease) In Prepaid Expense, Other Current Assets, And Long-term Deposits Amount of increase (decrease) in prepaid expenses, other current assets and long-term deposits during the period. All Executive Categories All Executive Categories [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual life (year) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Dividend yield (percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Defined contribution plan, employer matching contribution, percent of employees' gross pay Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Rental revenue Rental Revenue [Member] Represents information pertaining to rental revenue. Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Real Estate Lease Real Estate Lease [Member] Leases related to real estate. Vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Total Debt Securities, Available-for-Sale, Amortized Cost Schedule of Amortization Expense for Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Available-for-sale securities, long-term Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent Risk-free interest rate (percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Purchases of assets held for rent Payments To Acquire Assets, Held For Rent The cash outflow for payments to acquire assets held for rent. Subsequent Event [Table] Subsequent Event [Table] Debt instrument, additional maximum at discretion of lender Debt Instrument, Additional Maximum At Discretion of Lender Amount of additional maximum borrowing at the discretion of the lender. Maximum Maximum [Member] Accumulated depreciation Shippers Placed In Service Accumulated Depreciation The cumulative amount of depreciation, related to related to shippers placed in service and fixed assets held for rent. Estimated Fair Value Debt Securities, Available-for-Sale [Abstract] Intangible asset amortization Amortization of Intangible Assets Deferred revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net Carrying Value Finite-Lived Intangible Assets, Net Less: CBS carrying basis as of November 14, 2024 Disposal Group, Including Discontinued Operation, Carrying Basis, Including Assumed Liabilities Disposal Group, Including Discontinued Operation, Carrying Basis, Including Assumed Liabilities Accounts payable Accounts Payable, Current Leasehold improvements Leasehold Improvements [Member] Schedule of Assets Held for Rent Schedule Of Assets Held For Rent [Table Text Block] Tabular disclosure of assets held for rent. Gross profit Disposal Group Including Discontinued Operation, Gross Profit Disposal Group Including Discontinued Operation, Gross Profit Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease costs Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] PanTHERA Cryosolutions Investment PanTHERA Cryosolutions Investment [Member] Information pertaining to PanTHERA Cryosolutions investment. Negative selling price Disposal Group, Including Discontinued Operation, Negative Selling Price Disposal Group, Including Discontinued Operation, Negative Selling Price Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Thereafter Long-Term Debt, Maturity, After Year Four Represents amount of long-term debt maturity that takes place after year four. Schedule of Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Variable lease costs Variable Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Supplier Concentration Risk Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Weighted Average Useful Life (in years) Finite-Lived Intangible Asset, Useful Life Disposal group, including discontinued operation, goodwill Disposal Group, Including Discontinued Operation, Goodwill Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Additional Paid-in Capital Additional Paid-in Capital [Member] Transition services period Transition Services Period Transition Services Period Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Options to borrow Debt Instrument, Additional Maximum Amount Within Nine Months After Closing The maximum amount of additional borrowing capacity within 9 months of closing. Amortized Cost, current portion Due in one year or less Debt Securities, Available-for-Sale, Amortized Cost, Current Termination fee, amount Debt Instrument, Non-Refundable Termination Fee, Amount Debt Instrument, Non-Refundable Termination Fee, Amount Customer relationships Customer Relationships [Member] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Cash required on closing date, funded by entity Cash to Global Cooling funded by Company Disposal Group, Including Discontinued Operation, Charges Related To Cash Funded By Entity Disposal Group, Including Discontinued Operation, Charges Related To Cash Funded By Entity Long-term debt Long-Term Debt [Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Series A Preferred Stock Series A Preferred Stock [Member] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Loss from discontinued operations Loss from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from sale of available-for-sale securities Proceeds from Sale of Debt Securities, Available-for-Sale Cash, cash equivalents, and available-for-sale securities Cash, Cash Equivalents, and Short-Term Investments Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Issued, Diluted Weighted Average Number of Shares Issued, Diluted Retirement Benefits [Abstract] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] The 2023 Term Loan The 2023 Term Loan [Member] Represents the 2023 term loan 3. Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Unrealized gains on currency translation Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Severance Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Loss per share from continuing operations, attributable to common shareholders: Earnings Per Share, Continuing Operations, Attributable to Common Shareholders [Abstract] Earnings Per Share, Continuing Operations, Attributable to Common Shareholders Earn-Out Payment Earn-Out Payment [Member] Earn-Out Payment Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Sales and marketing Selling and Marketing Expense Aggregate fair value of the service vesting-based awards that vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Payments on term loans Repayments of Secured Debt Income tax expense Income tax expense (benefit) Income Tax Expense (Benefit) Other income: Nonoperating Income (Expense) [Abstract] Interest rate Interest Rate Debt Instrument, Interest Rate, Stated Percentage Aggregate fair value of the market-based awards that vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Available-for-sale securities, current portion Due in one year or less Debt Securities, Available-for-Sale, Current Cash required on closing date Disposal Group, Including Discontinued Operation, Cash Required On Closing Date Disposal Group, Including Discontinued Operation, Cash Required On Closing Date Period for recognition (year) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Diluted Net Income (Loss) Available to Common Stockholders, Diluted Total other income, net Nonoperating Income (Expense) Service revenue Service [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross unrealized Gains, long term Debt Securities, Available-for-Sale, Unrealized Gain, Noncurrent The amount of unrealized gain of debt securities available-for-sale classified as noncurrent. Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Insurance premium financing Financed Insurance Premium [Member] Represents financed insurance premium. Number of reportable segments Number of Reportable Segments Total liabilities and shareholders’ equity Liabilities and Equity Subsequent events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] CBS CBS [Member] CBS Capital expenditures Disposal Group, Including Discontinued Operation, Capital Expenditures Cost Disposal Group, Including Discontinued Operation, Capital Expenditures Cost Total employment related divestiture expenditures Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income (expense), net Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Manufacturing and other equipment Manufacturing Facility [Member] Schedule of Service Vesting-Based and Market Based Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Diluted Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Stock issued – on vested RSAs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Operating and Finance Lease Terms and Discount Rates Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block] Tabular disclosure represents the operating and finance lease term and discount rate of leases. Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Interest expense, net Disposal Group, Including Discontinued Operation, Interest Expense Earnout payments Business Combination, Consideration Transferred, Liabilities Incurred Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Inventories Total inventories Inventory, Net U.S. government securities US Government Agencies Debt Securities [Member] Basic (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Preferred stock, designated (in shares) Preferred stock, shares designated (in shares) The number of nonredeemable preferred shares designated. Costs and operating expenses: Operating Expenses [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Aggregate principal amount Business Combination, Consideration Transferred Global Cooling Global Cooling [Member] Global Cooling Grant date fair value (in dollars per share) Outstanding as of beginning of period (in dollars per share) Outstanding as of end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] evo and Thaw Service, Evo And Thaw [Member] Related to storage and storage services. Series E Preferred Stock Series E Preferred Stock [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Total operating lease costs Operating Lease Costs And Short-term Lease Costs Represents the amount of operating lease costs along with short-term lease costs. Due after one year through five years Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Three Supplier Three Supplier [Member] Three Supplier Outstanding as of beginning of period (in dollars per share) Outstanding as of end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Market-based Restricted Stock Market-based Restricted Stock [Member] Represents information related to market-based restricted stock. Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding as of beginning of period (in shares) Outstanding as of end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Effective income tax rate reconciliation, at federal statutory income tax rate, percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Property, Plant and Equipment [Abstract] Total debt, excluding unamortized debt issuance costs Long-Term Debt, Gross Exercise Price Award Exercise Price Lease Contractual Term [Axis] Lease Contractual Term [Axis] Purchases of property and equipment Payments for (Proceeds from) Property, Plant, And Equipment Payments for (Proceeds from) Property, Plant, And Equipment Net loss from continuing operations per common share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Shippers placed in service Shippers Placed In Service The gross value of shippers placed in service. Subsequent Event Subsequent Event [Member] Leases Lessee, Finance Leases [Text Block] Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Goodwill and intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Basic (in dollars per share) Basic loss from continuing operations per common share (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Cash proceeds from escrow Disposal Group, Including Discontinued Operation, Cash Proceeds From Escrow Disposal Group, Including Discontinued Operation, Cash Proceeds From Escrow Shareholders’ equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other debt securities Other Debt Obligations [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Customer C Customer C [Member] Represents information about major customer C. 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Aggregate fair value of the service vesting-based awards granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Fair value of non-vested equity-based payment instruments, excluding stock (or unit) options, vested. Organization and significant accounting policies Basis of Presentation and Significant Accounting Policies [Text Block] Shippers and related components in production Shippers And Related Components In Production The carrying value of shippers and related components in production. PEO PEO [Member] Debt instrument, additional maximum amount upon certain milestone achievements Debt Instrument, Additional Maximum Amount Upon Certain Milestone Achievements Amount of additional maximum capacity upon achievement of certain milestones. Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other income Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Total marketable securities, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term SciSafe Holdings, Inc SciSafe Divestiture [Member] Represents information related to SciSafe Holdings, Inc. Basic Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic 2025 (9 months remaining) Long-Term Debt, Maturity, Remainder of Fiscal Year Schedule of Concentrations of Credit Risk and Business Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Schedule of Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Gross unrealized Losses, long term Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent The non-current portion of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Diluted (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Local Phone Number Local Phone Number Intangible assets, gross Intangible Assets, Gross (Excluding Goodwill) Supplier [Axis] Supplier [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Deferred tax liabilities Deferred Income Tax Liabilities, Net Historical volatility (percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Debt instrument, balloon payment due Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Payments on financed insurance premium Repayments Of Financed Insurance Premium Repayments Of Financed Insurance Premium PEO Total Compensation Amount PEO Total Compensation Amount Business acquisition, equity interest issued or issuable, number of shares Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt instrument, interest rate, maximum stated percentage for each tranche borrowed Debt Instrument, Interest Rate, Maximum Stated Percentage for Each Tranche Borrowed Represents maximum stated interest rate for each tranche borrowed. Common Stock Common Stock [Member] Measure: Measure [Axis] Non-compete agreements Noncompete Agreements [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company evo and Thaw Rental Revenue, Evo And Thaw [Member] Related to storage and storage services rental revenue. Segment Reporting [Abstract] Assumed liabilities: Debt Disposal Group, Including Discontinued Operation, Assumed Liabilities, Debt Disposal Group, Including Discontinued Operation, Assumed Liabilities, Debt Entity Central Index Key Entity Central Index Key Aggregate fair value of the market-based awards granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period, Aggregate Fair Value Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options. General and administrative costs General and Administrative Expense [Member] Cell processing Product, Cell Processing [Member] Related to cell processing product. Target Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Shares Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Cost of revenue Disposal Group, Including Discontinued Operation, Costs of Goods Sold Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] RIF employee costs Other Restructuring Costs Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Cash proceeds received from Buyer Disposal Group, Including Discontinued Operation, Cash Proceeds From Buyer Disposal Group, Including Discontinued Operation, Cash Proceeds From Buyer Discontinued operations, outstanding minimum lease payments for the lease terminations Discontinued Operations, Outstanding Minimum Lease Payments For the Lease Terminations Discontinued Operations, Outstanding Minimum Lease Payments For the Lease Terminations Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segment, customer, and geographic information Segment Reporting Disclosure [Text Block] Debt, current portion Less: current portion of debt Long-Term Debt, Current Maturities Repayment of indebtedness Disposal Group, Including Discontinued Operation, Debt Repayment Cost Disposal Group, Including Discontinued Operation, Debt Repayment Cost Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted Stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Maturities of available-for-sale securities Maturities Of Available-For-Sale Securities The amount of cash inflow from proceeds from maturity of marketable securities. Total long-term debt Total Debt [Member] Related to total debgt. Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Costs to sell Global Cooling Costs to sell Disposal Group, Including Discontinued Operation, Selling Costs Disposal Group, Including Discontinued Operation, Selling Costs Revenue by customers' geographic locations Geographic Concentration Risk [Member] City Area Code City Area Code Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Current liabilities: Liabilities, Current [Abstract] Loss from discontinued operations before income tax expense Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Change in operating assets and liabilities, net of effects of acquisitions Increase (Decrease) in Operating Assets [Abstract] Cash interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Assets held for rent, depreciation expense Assets Held For Rent, Depreciation The amount of depreciation expenses recognized for assets held for rent. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Preferred Stock Preferred Stock [Member] Sales taxes payable Increase (Decrease) in Accrued Taxes Payable Assets held for rent, net Assets Held For Rent, Net Amount of assets held for rent classified as noncurrent. Stock options exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2028 Long-Term Debt, Maturity, Year Three Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Debt, long-term Total long-term debt Long-Term Debt, Excluding Current Maturities Wtd. Avg. Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair value of non-marketable equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income taxes Income Tax Disclosure [Text Block] Investments Investment [Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Net loss attributable to common shareholders: Earnings Per Share [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Schedule of Product Revenue Concentration Revenue from External Customers by Products and Services [Table Text Block] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Schedule of Debt Schedule of Debt [Table Text Block] General and administrative General and Administrative Expense CryoStor CryoStor Products [Member] Information pertaining to CryoStor products. 2027 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Other Geographic, Other [Member] Represents other geographic location. Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Total present value of lease liabilities Operating Lease, Liability Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] Amendment Flag Amendment Flag Reported Value Measurement Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Payments to acquire businesses, gross Payments to Acquire Businesses, Gross Gain on disposal of property and equipment, net Gain (Loss) on Disposition of Property Plant Equipment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation Depreciation, Depletion and Amortization Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] One Supplier One Supplier [Member] Information pertaining to one supplier. Less: unamortized debt issuance costs Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Loss from discontinued operations, attributable to common shareholders: Net Income (Loss) Available to Common Stockholders, Discontinued Operations [Abstract] Net Income (Loss) Available to Common Stockholders, Discontinued Operations Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Common stock shares issued Stock Issued During Period, Value, New Issues Technology - acquired Technology-Based Intangible Assets [Member] Less: Release of Global Cooling currency translation adjustment Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Currency Translation Adjustment Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Currency Translation Adjustment Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Consolidation Consolidation, Policy [Policy Text Block] SciSafe SciSafe [Member] Information pertaining to SciSafe. Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.001 par value; 150,000,000 shares authorized, 47,548,431 and 46,906,765 shares issued and outstanding, respectively, as of March 31, 2025 and December 31, 2024 Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Amortization Disposal Group, Including Discontinued Operation, Amortization Disposal Group, Including Discontinued Operation, Amortization Loss per share from discontinued operations, attributable to common shareholders: Earnings Per Share, Discontinued Operations, Attributable to Common Shareholders [Abstract] Earnings Per Share, Discontinued Operations, Attributable to Common Shareholders Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Amortized Cost, long term Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Effects of currency translation on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Second Amendment Term Loan Second Amendment Term Loan [Member] Second Amendment Term Loan Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 Preferred Stock, Value, Issued Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Accrued expenses Accrued Liabilities Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Long-term deposits and other assets Deposits Assets, Noncurrent Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Selling price per share (in dollars per share) Disposal Group, Including Discontinued Operation, Selling Price, Per Share Disposal Group, Including Discontinued Operation, Selling Price, Per Share Purchase of property and equipment not yet paid Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average shares used to compute loss per share attributable to common shareholders: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Incremental cost Share-Based Payment Arrangement, Plan Modification, Incremental Cost 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of goods and services sold (exclusive of intangible assets amortization) Cost of Goods and Services Sold Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Thereafter Finite-lived Intangible Asset, Expected Amortization, After Year Four Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Net price adjustment Disposal Group, Including Discontinued Operation, Net Price Adjustment Disposal Group, Including Discontinued Operation, Net Price Adjustment Operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 11) Commitments and Contingencies Term Loan Term Loan [Member] Term Loan Stock issued – on vested RSUs (in shares) Stock Issued During Period, Shares, Restricted Stock Unit, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Unit, Net of Forfeitures Termination Date Trading Arrangement Termination Date Fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value Customer A Customer A [Member] Information about customer A. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] 2026 Long-Term Debt, Maturity, Year One Stock-based compensation Share-Based Payment Arrangement [Text Block] PanTHERA CryoSolutions, Inc. PanTHERA CryoSolutions, Inc. [Member] PanTHERA CryoSolutions, Inc. Schedule of Revenue by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Service Vesting-Based Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Intrinsic value of service vesting-based awards exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock based compensation expense Total Share-Based Payment Arrangement, Expense Discontinued operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Total product, rental, and service revenue Revenue from Contract with Customer, Including Assessed Tax Customer D Customer D [Member] Customer D Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Defined contribution plan, employer discretionary contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Discontinued operation, gross selling costs Disposal Group, Including Discontinued Operation, Gross Selling Costs Disposal Group, Including Discontinued Operation, Gross Selling Costs Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Stock-based compensation Disposal Group, Including Discontinued Operation, Stock-Based Compensation Disposal Group, Including Discontinued Operation, Stock-Based Compensation Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Product revenue concentration Product Concentration Risk [Member] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Former Global Cooling employees Severance Costs Operating lease, term of contract Lessee, Operating Lease, Term of Contract Assets Assets, Fair Value Disclosure Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name 2025 (9 months remaining) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term in years - operating leases Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Outstanding as of beginning of period (in shares) Outstanding as of end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Basic Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Discontinued operations: Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Diluted (in dollars per share) Diluted loss from continuing operations per common share (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Deferred revenue, revenue recognized Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable Accounts Receivable [Member] Maximum borrowing capacity Debt Instrument, Maximum Borrowing Capacity At Closing Represents maximum borrowing capacity at closing. Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Stock Compensation Stock Compensation Expense [Member] Stock Compensation Expense Short-term purchase obligations Purchase Obligation Earnout payment period Earnout Payment Period Earnout Payment Period Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss, net of taxes Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Customer B Customer B [Member] Represents information about major customer B. Basic (in shares) Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Unrealized gains (losses) on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in-progress Construction in Progress [Member] Revenue Revenue Benchmark [Member] Other income (expense), net Disposal Group, Including Discontinued Operation, Other Income (Expense) Disposal Group, Including Discontinued Operation, Other Income (Expense) Schedule of Bioproduction Tools and Service Revenues Revenues By Product Line [Table Text Block] Tabular disclosure of revenues by product line. Payments on equipment loans Repayments of Other Long-Term Debt Entity Filer Category Entity Filer Category Schedule of Accrued Expenses and Other Current Liabilities Other Current Liabilities [Table Text Block] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchases of available-for-sale securities Payments to Acquire Debt Securities, Available-for-Sale Diluted Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted Company Selected Measure Name Company Selected Measure Name Prime Rate [Member] EX-101.PRE 10 blfs-20250331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 blfs-20250331_g1.jpg GRAPHIC begin 644 blfs-20250331_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" !4 D@# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]41C-(V*4 M'DTQFP?;O[5/J+T%W>V*21MJDYPN.MRKU)^E?!WQU_P""@FK^*H[C2_ J'1].?,?]H2#]_(.AVYX7\LU[N79/C,SD ME2A:/=['DXS,Z&!CS3E<^ROBI^TAX%^$,8&NZK&UT>EG:?O)3]1GC\:9\*?V ME/ GQ<4KHFJ+'>#K9W>(Y?RS@_@37X^:IJE[K%[+>7]U+>74QR\TSEF/XFF: M9JEYH]XEU97,MGI^!\3_K17=;F2]P_=N. M0,.!D>M//M7YO? K_@H%K/A-;72?'"-JVG@A%OD'[]?8X^]_.OO/X?\ Q0\. M?%#1TU+P[JT%_#CYUC<;D/HPZ@_6OSC,LFQ>5S:K1NNY]K@MJM]AU+24C,%ZGMFF4.HIJG/?-+0 M%)3=_J<?X2*5F.<9Y^G\Z )**BW-@D\XY^7H:59"WT]J )**9\Q& M<#O@TU;I&R%=6/^RM #J*** "BBB@ HHHH **** M "BBB@ HHHH ***:QZ23ZGY[^./B%XA^(FL2:EK^IS:A<2'/S,=J_[H["N= MQP6 ([#CDU]D_%__ ()Z:[I-Y]K\!7*ZM832<6MPZK+$#WW,1D?CFO2_@9_P M3YTCPVUIJ_CIX]8U!0&&GQD^2AZ_-_>/YBOU7_6+*\+AE4I._P#=['YW')4A'MG&2?PIWQ>_9J\;_!B[_P") MQIWG:>?NW]J#)"?QQD'\*_8#3='L]'T^*TL;6.RM81M2*% JJ/I1JFE6VK6, MMI=V\=Y;2@J\4RAU8'L0:^-7&6)^LZ MG@5T/@GX@^(?AWJL.H:!J$]A-$_QT_X)]:-XG:XU7P--'I& MIMEWL)&/D2'T4=%)_ 5YE\(O^">NM:I>->^/KA-)L8&Q]CAE5GD /]Y3@+CW MSTK[./$65XK"-U):]4]_D?-2R7'86LE!?,]=_9;_ &S+[XH7\'ASQ#H=P=5X M O[&/,+>[@_=_,U].1#@A@IP:ZA? MNBN1^+G_ "3'Q5_V#I__ $ U\Z?6+<_#N\_:M^+:7DRKXZU4 .P"K+@8STJ+ M_AK#XM/-6QV_?=?TKRR^XOIB,C#MS^-?JU^PK^S+\-/B-^S;XY62XF7);$[J/T%!5C\^1^UA\7-VT^.]6S_ -=>*ZCPC^WE\:?"$R2Q M>+9]0BCQFWO?WB'GOT[9K]6Y/V)_@Q)&4/@;3]C#LI%?!O\ P4+_ &-_#'P3 MTO3/&/@Z%K'3KJZ^S7&GEB45BK,"O_?/ZT"/JS]C?]N[3?VAG_X1[7;6/2?% MT:Y"QOF*Z7'WESC!]N:K_P#!3'XA^)/AS\%=(U+PUJMQH][)K$4+36S;7V&. M4E?H2!^5?EE^S[XFOO"/QH\':I8R2+/'J4!RIZKO&5X]>E?MS\;O#/PW\9>" M[&#XG3:=%HRS1RI_:=TMNAFVG;R2.<%N/K0!^3_[/'[2WQ0\0_&SP1I]_P", M]4NK.ZU>UAFADF^5D,R@@^H(X_&OVUW5\H>"_A#^ROIOBS2;OP]=>&#K<=TD MED(-71W,RL"NU=_)W 8'>OJS>O//2@1+16-XD\8Z'X.L6O-'_!,WA?7+O1 MGNI[E93;/MW;1'C/YFOF7]B7]H7XC>-/VE/!VD:WXNU'4-.N)I1+;S295@(9 M#R/J!7N7_!8'_D6?A]_U\7?_ *#%7R3_ ,$_O^3L/ O_ %WF_P#1$E!=C[T_ MX*>?$CQ+\-?AWX5O/#6LW.CSSW\B326[[2RA 0*^,OV5?VD/B9XE_:#\#:1J MGC'5+S3[B_$".N[C%?FE^V%_P4?UW1O%VI>$OAR\-E#I[&*XU60;G9Q]X(!TQZYK[Q M^)?Q8\)>#])U73]6\4:3I6K-8RO%;W-['%(QV';A6()/2OP#\47?VWQ)JUT9 M?/W7N/ZT%)'J/_#5'QAUO5TF?QMK,DA<%E20D')] *_?#GPM.;".5SA?MFZW4_C( * /<**J:?JMGJMK%=65U#>6THRDT$@=&'L1P:M YH$ M!;D"OD_]M3]MNR_9SL8]#T:&/4?&-VF^..0_NX$Z;V]3GMQ7U<^CUN1A =6CMBLC?*D88?+].?UH [/P];_M/_M:,^I66H:FVF2D MGSFD-O:=<87J<5TTW_!/?]HS2;?[?;Z_92W.-WEPZI*9?I@IC]:_5'PMH&F^ M%?#^F:9H\,,&EVL*Q0K" %VA< \<'/K6S@[O;\:"C\:[?X]?M%_LB^)8+3Q- M)>/:!\-:ZD#+!,H[(V>#CO\ I7Z9?LP_M,^'_P!I3P.FK:7FTU.W_=WVGR," MT+^Q[J>H/O6G^T7\&=&^-GPLUK0M5LXKF80-+:S,OSQ2J,J5(Y&<8X]:_,S] M@&Z\6?![]I:'2[O2-433-0DFT^[+6L@AW L%;.,8#8Y]!0!^P:R[F(QVS3MU M1#/F9/3''M5;5]:T_P /V,M[J=];Z?9QC<\]U*L:*//BS5_!/[.&NZMH=_-INHQ2QA+B!L,,AJ^@EF1UR'!& M,]?6OF3_ (*,.'_97\18.?WL?\FH$>1_\$M?BGXM^)=IXV;Q1KUYK;6TD7DF MZ?=L!':OOC=7YN_\$??^/'Q__OP?RK[FU_X[?#_PMK4ND:MXOTC3]3C(5[6X MNT20$@$#:3GH10,[ZBF0S)<0I)&ZR1L-RLIR"/6G,P4$G]*!!2$Y&*X;Q)\< MO 7A'6GTC6?%>EZ9J:[\G6-)"06 !)] :!GQE^TM_P40U[X'_&34_!EGX7M=0M;7RU%Q)/#'&L'VV/>6V@8QGK0!YY_P4 M2\7>)/!?[/5YJ'A:_NM.U,7<"B:SSOV^8N>@],UQ7_!,GQ_XO\?>"/%%QXMU M.^U*>&]587OLY"E!P,BOJWQYXA\*^']!-[XMN]-M]'W*#)J3)Y621M^]P><5 M3^&_BOP/XFL[J7P7>:3=VR.!,VE&,J&]]E =#M:*8TRKU/Z5YS\1OVBOAS\* M24\2^+=-TZ<,HD=VVJTMK,B M_B2H _&O;_"_C30?&>GK?:%K%GJ]HW(ELIUE ^NTG% &U2;J1I%5O:N$ M;X[?#Y?$3Z"?&&CC6$E\DV?VQ/,WYQMVYSG/:@#O-U&ZN,^('QB\&?"VS^T^ M*/$=AI"8R$GF D(]0G4CZ"O+;3]OCX'7EZMM'XUA#L*V,T"%W4;J\V^('[1GPV^%\ MCQ>)/%^F6%RGWK43B29?K&N6'Y5Q&G_MX? _4KR.VA\;P"1S@&2WE11]6*@" M@=CZ"KRGX^?&K_A4&DV)MK :CJM^SK!$[[$541G=V.#T56.,M]H&LV.L6K?\M+.=90/KM)Q7+_&#X/:5\9-(M;>ZGFLKRRE\VVO(?O1M M@@@@\,K*2"#P0:!')_L[?M%#XRRW=E=6*VE]# MW%+"^Z.>%F90>@P0R.,>P MYYHK;^"O[/\ I7P=N-1O8;F34-3OPJ23,BQI'&N<1QHN%49+'@#)8T4 '[3G M'P,\8CJ?L;']17XX12^2V]'*.IW;ER",>]?LC^T[_P D+\8?]>3?S%?C4WWC M7[!P73C+"5(O^;]$?F'%+?UB"\C]!/\ @GC\5/$_BZYUO0M8U26_TZQ@#VZS M_,R<@<-Z?6OMYV' R17YZ?\ !,O_ )&[Q5GG_1%_]"%?H=M^4<<5\3Q-&,,R MFJ<>5:;'UF0SE5P,95-=S"\3>,M(\&V?VG6+Z*S@[-(V*;X7\9:3XTLFNM'O MX;R%3C=$V:^=?VOO"^M:A?:9J%O;3W>G0HR,D(R%;(ZCWX_*E_8_\+:WI^HZ MKJ%U;2VFFR1>6J2# 9PP.X#\#5/*,*\IEC?:_O.Q\]'B'&+/(Y;[!^S_ )CZ MC15W'GD5\Q_M<>-]:T&ZTS3=.O&M;2XC=Y?*X+8(&/UKZ=7'<8[5\B?MI<>) M- '_ $PD_FM3PU&,\RIQFKFW&U:I1R>I.,K2O;0^=/,+,2Q)+?\ BU/AKU^R@?J:_.W^*OT4^!O_ "2GPU_U[#^9K[?C6/+@Z,'LI:?.__P"/Z?')WMCC/>OT0_9$_;[^'WP0^!NB>$M M9G^SQ93YY6?C\&K\[[]L7TV.N]L<9[U]:? '_@G;XC^/GPRTSQGIWB/3K"SO MFE5(+@2!QL=D;.%/4J?SH*9]>W'_ 5:^%2PLT>G:O+(.B&,#-?%O[97[:5S M^TU<6.D:3IDFE>';.7S(X7DWRS28(W$8&!@GBO6F_P""1/C%59D\8:.6 X7$ MO_Q%?-?[0?[)OCS]FV\MY=>MEGTV5]EOJMD=T9;KCL0< ]<4 >Y_L)_L4^)/ M%7C[1_&WBK39--\+:?*EU;B9"K7;J0R[1_=S_6OHS_@K(HB^ >AA?^@Y#CCM MY4N!7S%^QU^WIXG^&_BS2_#?C'59]7\'W4B6RRWE?37_!6" MXCNOV>] FB97CDUJ!D8'.1Y4O/ZT ?G-^S&Q_P"&@/A_\VO%DEUK^ MJW&KW=Y)Y<5I S>6I)X2- >1^M>M^%_^"DR!TBO+@QR8 MQQ\N"1Q[UW?_ 2U^$>G^-OBYJ?B/4XH[E?#]OO@209VS,0 P_ M7ZY9XSC) M'- 7/Y\_'OPU\=?L_P#BR*SURTOO#VJ+\T4T3E/,QW1N_:OOO]@/]N>^\8:I M9_#[X@7J3ZA(N--U*4[&<@?ZN3_:[#\*]V_X*#?"?3_B)^SMKU_- CZGH:"^ MM9L?.,':5S[[OTK\7/#>N7/A?Q%INK6CL+NPN8KF)O="&'\J W/TM_X+ _\ M(L?#[_KXN_\ T&*ODK_@G]_R=AX%_P"N\W_HB2OH_P#X*:>(?^$L^#/P=U=_ MG:[265_J8X!<]?/F_]$24!8^S_ /@KH!_PJWP;NZ?V ME+U_W%[5\&_L[VY_M)=V5(+?*V,FXEDGG MV$;%!. !Z U^9MW;OI]Y/!*-LEN[1N?X5(/(%?T8^-?^1-U[_KQN/_1;5_.W MXH_Y&35_^ON7_P!#- XGNGPK_8<^*OQ1\)Z9XKT#3[.;2;DAXI);O8P (R2- MOI7M'[7G[:6MZ?H^E_"OP9?'3K?2=/M[#5]2M7^>29(U61(S_=!!7Z@U]+?L M\^+)/ __ 3Q_MN+B>TTJ8QMZ,P"C]6K\@=0OIM4U"\O)Y&ENKAVEFM+J)H95,,6"C @C_6>AH!,^*_V2 M_P!LCQ-\!O&5I;ZA?S7_ (1N)%%YI]PY\3")+^ZOM!G;J+N$&,?\#R/Y5Z%\3/V+_A)\5)9KG5/"UK;7TI^:\L%$ M,C$]R5'-?.7C?_@D=X6O/-D\,>*;O3I#]R"\0R1C\>3^E [GV)X(^.?@+XE1 M*?#GBK3M3WC(2&8;OH1781:/IZ2I.EE;K+G<)%B7(/KG%?C!\8/V#OBS\ ?, MUZQB_MK3[0Y_M#1W.^(#H=IPP_ 5['^Q%^WUXAM_%^E^!?B%J,NJ:9>2+;6N MI7)/G0R'A$-?%VF^ _"VI:_J\RP:=I\+32R,<< 5^07COXK M?$S]OCXR+X>\-R75KH4DK?9+.,E8;>$'_638ZG'X$GH*^Q?^"I?CJXT#X#6& MDV'C5J0J3Q^)4 M&@9;\!_\$GO EAI$/_"4ZSJFI:FRYF:TD6.,-[ JU>;_ ![_ ."7<_A'1;GQ M%\,M:NKBYLE,QT^Z.9W Y.R1=O3TV\^M?IT*BD4,I!&03C_&@D_-/_@G[^V7 MK*^)H_AAX_NY+AW=H-/O;OB2*0$CR7]>?E'?D5](?\%%#_QBSXD&01YL>#WZ M-7YY?MQ>%8_@S^UI?WVC+]G1KBWUBWQQB7"2$_\ ?>:^[_VTO$'_ E7[#;Z MN?O7=O;2GZE6S^M VK'C?_!'[_CQ^(';YX/_ $&OF_\ ;L(_X:^\0'!53/_T$5I=Z"3\5O^"@BC_AK[51C[Q@SC)Q MSZYK]&?CM^R_8_M1_"OPEI&H:K-HRV'EW2M"H?K\Y_\ @H'_ ,GA M:I_O6_\ ,U^Q?@O_ )%'1?\ KUC_ /0104C\(_VD/@O;_ _XQ:EX-M;]K^&T M,:BXD3#$,BMTS[U]Z_#_ /X)9Z%H]_H7B)/&-V[PM#=^4T Y(PV,YKY3_P"" MA/\ R=EXB_W[?_T6E?LYX4_Y%G2O^O6/_P!!% 'RA_P5 7R_V8;O@G%];@'T MS(G:O/O^"1:C_A77BTYP1?*"QZ'Y:]#_ ."I'_)L-Y_U_P!M_P"C4KS?_@DC M+Y/PQ\:R=-EX&_),T#Z'1?\ !0G]LF[^$5B/ OA*=4\2WR9NKM>6M(_8?WFX MQ[9KP3]G#_@GOXA^/E@GC;XD:S>V&G7W[Z&$G-S= _Q%FSM!^AKQZ\DD_:#_ M &V@FH'?%J?B!P4/01([,!_WRN/QK]M]-L(=,T^VLH(Q%;V\:Q1(.RJ, ?D* M";'Q5X@_X)1_#2\TEETS5M:LK\)A)I9D=<^Z[!D?C7QSXDTGXJ_\$\_BM9-! MJPY^9"N>&QGOTK]IU&U0 ,"OE7_ (*1?#JV\;_LVZQ?O&OV MW1)([R"0CE?G56_\=)H!'L?P/^+VE_'+X9:=XLTH[5NHRLT&?]5* -RG\Q^! M%?C)\;?$U[X-_:T\6ZYIR++J-EXBN)H(F3(\P.P QGGKT]J^L_\ @D;X\NIF M\<>$996>RC2*]MU/0.VY7_1%KYL\4:7!KG[=VH6=TN^VF\6N2OTF)H*V/I7X M6?L#>*?VAMOCSXP^);V.75,W<%A V9%5N5SGA5]%Q^-=5\1/^"3OA";P],DL4I .%("J03ZY_"OON"W6U@6&)0D<:!$4=@!Q4W;% KGXJ M?LK_ !=\6_LO_M$6GA;59Y4T^341I6I:>[$Q!V?R@ZYZ88AOPK]#_P!OCXYZ ME\%_@3+?:#-Y.JZM(+6"X!QY:D#

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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2025
May 01, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 001-36362  
Entity Registrant Name BioLife Solutions, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 94-3076866  
Entity Address, Address Line One 3303 Monte Villa Parkway, Suite 310  
Entity Address, City or Town Bothell  
Entity Address, State or Province WA  
Entity Address, Postal Zip Code 98021  
City Area Code 425  
Local Phone Number 402-1400  
Title of 12(b) Security Common stock, par value $0.001 per share  
Trading Symbol BLFS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,561,171
Entity Central Index Key 0000834365  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 66,945 $ 95,386
Available-for-sale securities, current portion 21,635 9,198
Accounts receivable, trade, net of allowance for credit losses of $117 and $153 as of March 31, 2025 and December 31, 2024, respectively 9,167 9,168
Inventories 27,566 29,013
Prepaid expenses and other current assets 5,816 5,996
Total current assets 131,129 148,761
Assets held for rent, net 5,690 6,103
Property and equipment, net 6,605 6,084
Operating lease right-of-use assets, net 10,128 10,674
Long-term deposits and other assets 378 379
Available-for-sale securities, long-term 19,055 4,628
Equity investments 995 995
Intangible assets, net 8,857 9,559
Goodwill 212,304 212,304
Total assets 395,141 399,487
Current liabilities:    
Accounts payable 3,297 3,573
Accrued expenses and other current liabilities 8,213 12,451
Sales taxes payable 3,929 4,256
Lease liabilities, operating, current portion 1,835 1,511
Debt, current portion 10,449 10,943
Total current liabilities 27,723 32,734
Lease liabilities, operating, long-term 12,165 12,723
Debt, long-term 2,499 4,997
Deferred tax liabilities 130 124
Total liabilities 42,517 50,578
Commitments and contingencies (Note 11)
Shareholders’ equity:    
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 0 0
Common stock, $0.001 par value; 150,000,000 shares authorized, 47,548,431 and 46,906,765 shares issued and outstanding, respectively, as of March 31, 2025 and December 31, 2024 48 47
Additional paid-in capital 688,092 683,939
Accumulated other comprehensive loss, net of taxes 33 24
Accumulated deficit (335,549) (335,101)
Total shareholders’ equity 352,624 348,909
Total liabilities and shareholders’ equity $ 395,141 $ 399,487
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Allowance for doubtful accounts $ 117 $ 153
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 1,000,000 1,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 47,548,431 46,906,765
Common stock, outstanding (in shares) 47,548,431 46,906,765
Series A Preferred Stock    
Preferred stock, designated (in shares) 4,250 4,250
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total product, rental, and service revenue $ 23,941,000 $ 18,433,000
Costs and operating expenses:    
General and administrative 11,501,000 10,397,000
Sales and marketing 2,597,000 2,376,000
Research and development 2,204,000 2,075,000
Intangible asset amortization 702,000 688,000
Total operating expenses 25,159,000 21,728,000
Operating loss (1,218,000) (3,295,000)
Other income:    
Interest income (expense), net 681,000 (140,000)
Other income 103,000 253,000
Total other income, net 784,000 113,000
Loss before income tax expense (434,000) (3,182,000)
Income tax expense (14,000.0) (17,000)
Net loss from continuing operations (448,000) (3,199,000)
Discontinued operations:    
Loss from discontinued operations before income tax expense 0 (6,908,000)
Income tax expense 0 (114,000)
Loss from discontinued operations 0 (7,022,000)
Net loss (448,000) (10,221,000)
Loss from continuing operations, attributable to common shareholders:    
Basic (448,000) (3,199,000)
Diluted (448,000) (3,199,000)
Loss from discontinued operations, attributable to common shareholders:    
Basic 0 (7,022,000)
Diluted $ 0 $ (7,022,000)
Loss per share from continuing operations, attributable to common shareholders:    
Basic (in dollars per share) $ (0.01) $ (0.07)
Diluted (in dollars per share) (0.01) (0.07)
Loss per share from discontinued operations, attributable to common shareholders:    
Basic (in dollars per share) 0 (0.15)
Diluted (in dollars per share) $ 0 $ (0.15)
Net loss attributable to common shareholders:    
Basic $ (448,000) $ (10,221,000)
Diluted $ (448,000) $ (10,221,000)
Net loss per share attributable to common shareholders:    
Basic (in dollars per share) $ (0.01) $ (0.22)
Diluted (in dollars per share) $ (0.01) $ (0.22)
Weighted average shares used to compute loss per share attributable to common shareholders:    
Basic (in shares) 47,134,720 45,432,426
Diluted (in shares) 47,134,720 45,432,426
Product revenue    
Total product, rental, and service revenue $ 22,299,000 $ 16,743,000
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization) 7,109,000 5,136,000
Service revenue    
Total product, rental, and service revenue 60,000 25,000
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization) 10,000 0
Rental revenue    
Total product, rental, and service revenue 1,582,000 1,665,000
Costs and operating expenses:    
Cost of goods and services sold (exclusive of intangible assets amortization) $ 1,036,000 $ 1,056,000
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Statement of Comprehensive Income [Abstract]    
Net loss $ (448) $ (10,221)
Other comprehensive income (loss):    
Foreign currency translation adjustment, net of tax 0 (203)
Unrealized gain (loss) on available-for-sale securities, net of tax 9 (18)
Comprehensive loss $ (439) $ (10,442)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Series A Preferred Stock
Preferred Stock
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2023     0        
Beginning balance at Dec. 31, 2023 $ 337,663   $ 0 $ 45 $ 652,880 $ (345) $ (314,917)
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2023       45,167,225      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 6,183       6,183    
Stock issued - on vested RSAs (in shares)       522,358      
Stock issued – on vested RSAs 1     $ 1      
Foreign currency translation (203)         (203)  
Unrealized loss on available-for-sale securities (18)         (18)  
Net loss (10,221)           (10,221)
Ending balance, preferred stock, outstanding (in shares) at Mar. 31, 2024     0        
Ending balance at Mar. 31, 2024 333,405   $ 0 $ 46 659,063 (566) (325,138)
Ending balance, common stock, outstanding (in shares) at Mar. 31, 2024       45,689,583      
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2024   0 0        
Beginning balance at Dec. 31, 2024 $ 348,909   $ 0 $ 47 683,939 24 (335,101)
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2024 46,906,765     46,906,765      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation $ 4,153       4,153    
Stock option exercises (in shares) 0            
Stock issued – on vested RSUs (in shares)       641,666      
Stock issued – on vested RSUs $ 1     $ 1      
Unrealized loss on available-for-sale securities 9         9  
Net loss (448)           (448)
Ending balance, preferred stock, outstanding (in shares) at Mar. 31, 2025   0 0        
Ending balance at Mar. 31, 2025 $ 352,624   $ 0 $ 48 $ 688,092 $ 33 $ (335,549)
Ending balance, common stock, outstanding (in shares) at Mar. 31, 2025 47,548,431     47,548,431      
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities    
Net loss $ (448) $ (10,221)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation 682 1,364
Amortization of intangible assets 702 914
Stock-based compensation 4,153 6,183
Non-cash lease expense (benefit) 312 (83)
Deferred income tax expense 6 5
Accretion of available-for-sale investments (105) (182)
Gain on disposal of property and equipment, net 0 (14)
Loss on disposal of assets held for rent, net 187 198
Change in operating assets and liabilities, net of effects of acquisitions    
Accounts receivable, trade, net 1 65
Inventories 1,447 42
Prepaid expenses and other assets 181 2,392
Accounts payable (828) (1,956)
Accrued expenses and other current liabilities (4,252) (2,825)
Sales taxes payable (327) 20
Other 16 (377)
Net cash provided by (used in) operating activities 1,727 (4,475)
Cash flows from investing activities    
Purchases of available-for-sale securities (30,324) (6,374)
Proceeds from sale of available-for-sale securities 573 973
Maturities of available-for-sale securities 3,000 6,000
Purchases of assets held for rent (250) (464)
Purchases of property and equipment (175) (356)
Net cash used in investing activities (27,176) (221)
Cash flows from financing activities    
Payments on equipment loans 0 (241)
Payments on term loans (2,500) 0
Payments on financed insurance premium (502) (727)
Other 10 16
Net cash used in financing activities (2,992) (952)
Net decrease in cash, cash equivalents, and restricted cash (28,441) (5,648)
Cash, cash equivalents, and restricted cash – beginning of period 95,386 35,438
Effects of currency translation on cash, cash equivalents, and restricted cash 0 (65)
Cash, cash equivalents, and restricted cash – end of period 66,945 29,725
Non-cash investing and financing activities    
Purchase of property and equipment not yet paid 552 26
Unrealized gains on currency translation 0 (6)
Unrealized gains (losses) on available-for-sale securities (9) 18
Cash interest paid $ 265 $ 445
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Organization and significant accounting policies
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and significant accounting policies Organization and significant accounting policies
Business
BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products include proprietary biopreservation media, automated thawing devices, and cloud-connected shipping containers. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in CGT that can be filled manually or with high throughput systems, CryoCase™ cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement, dated April 17, 2024 (the “Global Cooling Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Global Cooling Purchase Agreement, the Global Cooling business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “SciSafe Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“SciSafe Buyer”), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (“SciSafe Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock (the “SciSafe Shares”) of SciSafe to SciSafe Buyer. Upon the execution of the SciSafe Purchase Agreement, the SciSafe business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On November 14, 2024, the Company entered into a Stock Purchase Agreement (the “CBS Purchase Agreement”), by and among the Company, Standex International Corporation, a Delaware corporation (“CBS Buyer”), and Arctic Solutions, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (doing business as Custom Biogenic Systems, or “CBS”), for the sale by the Company of all of the issued and outstanding shares of common stock (the “CBS Shares”) of CBS to CBS Buyer (the “CBS Divestiture”). Upon the execution of the CBS Purchase Agreement, the CBS business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.
On April 4, 2025, pursuant to a Stock Purchase Agreement (the “PanTHERA Purchase Agreement”), by and among the Company, Casdin Partners Master Fund L.P. and each other person listed on Schedule A thereto (the “PanTHERA Sellers”), Alberta LTD., an Alberta corporation and a wholly owned subsidiary of the Company (“PanTHERA Buyer Sub”), PanTHERA CryoSolutions Inc., an Alberta corporation (“PanTHERA”) and Dr. Jason Acker, solely in his capacity as Sellers’ Representative, the Company acquired all of the issued and outstanding shares of common stock of PanTHERA from the Sellers (the “PanTHERA Transaction”). The acquisition of PanTHERA was considered a subsequent event to the financial results presented as of March 31, 2025. For additional information on the acquisition of PanTHERA see Note 19: Subsequent events.
The Company is presenting Global Cooling, SciSafe, and CBS within this Quarterly Report on Form 10-Q (this “Form 10-Q”) as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed
Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented in this Form 10-Q reflect only the continuing operations of the Company unless otherwise noted. See Note 2: Discontinued operations within this Form 10-Q for further details regarding the divestitures described above.
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s valuation of market-based stock awards, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.
The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation and consolidation
The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2025 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2025 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”) and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 2: Discontinued operations for additional details about the divestitures.
Foreign currency exchange
The Company's sales are primarily denominated in the U.S. dollar. Accordingly, our sales are not generally impacted by foreign currency exchange rates. For any transactions denominated in a foreign currency, which were immaterial during the three months ended March 31, 2025 and 2024, the Company remeasures foreign currency transactions into U.S. dollars on its Unaudited Condensed Consolidated Financial Statements in the Other income line item.
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional information on the Company's segment considerations, see Note 17: Segment, customer, and geographic information.
Significant accounting policies
There have been no significant changes to the accounting policies during the three months ended March 31, 2025, as compared to the significant accounting policies described in our Annual Report.
Liquidity and capital resources

On March 31, 2025 and December 31, 2024, we had $107.6 million and $109.2 million in cash, cash equivalents, and available-for-sale securities, respectively. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Form 10-Q.
Risks and uncertainties
The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.
For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q.
Recent accounting pronouncements
Recently issued accounting pronouncements not yet adopted
In November 2024, the Financial Accounting Standards Board ("FASB") issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures - Clarifying the Effective Date to clarify the effective date for non-calendar year-end entities. The amendments in this ASU will be effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the effects adoption of this guidance will have on the Consolidated Financial Statements.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued operations Discontinued operations
In 2024, the Company, management, and our board of Directors (the "Board"), made the decision to sell Global Cooling and CBS (the "Freezer Business"), allowing the Company to optimize its product portfolio by focusing on its recurring higher margin revenue streams. Additionally, in November of 2024, the Company, management, and the Board determined the sale of SciSafe would further optimize the Company's product portfolio toward its proprietary high margin cell processing and other bioproduction products. Accordingly, the results of these businesses are reported in the “Loss from
discontinued operations” line in the Condensed Consolidated Statements of Operations. These changes have been applied to all periods presented.
Divestiture of Global Cooling, Inc.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings pursuant to the Global Cooling Purchase Agreement. The Company analyzed the quantitative and qualitative factors relevant to the sale of Global Cooling and determined that the conditions for discontinued operations presentation were met during the second quarter of 2024.
As a condition of the Global Cooling Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$- 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Less: Global Cooling carrying basis as of April 17, 20241,650 
Less: Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balances of loans under Global Cooling as of the date of the Global Cooling Divestiture.
In connection with the Company’s entry into the Global Cooling Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing approximately 11% of its full-time employees as of the date of the RIF). The Board approved the RIF on March 29, 2024, and all affected employees of Global Cooling were informed by April 18, 2024, following the execution of the Global Cooling Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees- 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 
As outlined in the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies. Prior to the Global Cooling Divestiture, a lawsuit was filed by a previous customer related to Global Cooling's commercial freezer products seeking payment of up to $4.0 million for losses the customer claims to have incurred. As of the year ended December 31, 2024, the Company recorded a loss contingency under the discontinued
operations of Global Cooing related to this product liability claim as outlined in the Global Cooling Purchase Agreement. During the fourth quarter of 2024, it became probable this loss would be settled within the next fiscal year. The product liability claim is subject to insurance recovery, which management believes is probable as enforceable under the Company's insurance policy, covering the entirety of the loss contingency aside from the Company's insurance deductibles. The Company estimates the legal expenses to be incurred will be immaterial. There were no changes in the status of this claim during the three months ended March 31, 2025
In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement ("Global Cooling TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of the Global Cooling Divestiture. The Global Cooling TSA has since expired pursuant to its terms on the stated expiration date. The Company has no other significant continuing involvement with Global Cooling.
Divestiture of SciSafe, Inc.
On November 12, 2024, the Company entered into the SciSafe Purchase Agreement, and SciSafe, for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock of SciSafe to SciSafe Buyer ("SciSafe Divestiture"). The Company analyzed the quantitative and qualitative factors relevant to the sale of SciSafe and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.
In connection with the closing of the SciSafe Divestiture, the Company incurred $0.4 million in severance costs, paid the former stockholders of SciSafe $3.3 million in cash to waive all rights with respect to certain potential earn-out payments, and recognized $4.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with SciSafe upon the closing of this transaction.
The Company recognized a gain on disposal of SciSafe, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$71,291 
Cash proceeds from escrow483 
Costs to sell(1)
(506)
Total proceeds71,268 
Less: SciSafe carrying basis as of November 12, 202442,507 
Less: Release of SciSafe currency translation adjustment622 
Net gain on disposal$28,139 
(1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million.
In accordance with ASC 350, upon the disposal of SciSafe, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to SciSafe was based on the relative fair value of SciSafe to the fair value of the Company as SciSafe was fully integrated into the Company's one reportable segment. The fair value of SciSafe was determined based on the enterprise value per the SciSafe Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $11.3 million of goodwill was to be allocated to SciSafe upon its disposal. The allocated goodwill was included in the carrying basis of SciSafe presented in the above table.
In addition, upon the closing of the SciSafe Divestiture, the Company and SciSafe entered into a transition services agreement ("SciSafe TSA"), pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the closing of the transaction. The SciSafe Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the closing of the SciSafe Divestiture.
In connection with the disposal of SciSafe, the Company remains liable and responsible for the full performance and observance of all of the provisions, covenants, and conditions in one of SciSafe's operating leases. In the case of a breach or violation of any provision of the lease by the SciSafe Buyer, the Company is deemed to be in default of the lease provisions. Simultaneously, the Company received indemnification pursuant any obligation owed by the Company under this operating lease. This indicates the Company undertakes the obligation to stand ready to perform over the term of the guarantee in the event of the specified triggering events noted above, or conditions, such as breach or default, occur. However, the non-contingent aspect of the guarantee enables the Company to recover any losses from the SciSafe Buyer. As of March 31, 2025, the fair value of this guarantee is not material. The outstanding minimum lease payments equal approximately $2.5 million and the lease terminates in 2031.
The Company has no other significant continuing involvement with SciSafe upon the expiration of its SciSafe and other related covenants.
Divestiture of Custom Biogenics
On November 14, 2024, the Company entered into the CBS Purchase Agreement, for the sale by the Company of all of the issued and outstanding shares of common stock of CBS. The Company analyzed the quantitative and qualitative factors relevant to the CBS Divestiture and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.
The Company recognized $2.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with CBS upon the closing of the CBS Divestiture.
The Company recognized a loss on disposal of CBS, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$2,785 
Cash proceeds from escrow615 
Net price adjustment(1)
179 
Costs to sell(2)
(148)
Total proceeds3,431 
Less: CBS carrying basis as of November 14, 20246,796 
Net loss on disposal$(3,365)
(1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the CBS Divestiture.
(2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million.
In accordance with ASC 350, upon the disposal of CBS, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to CBS was based on the relative fair value of CBS to the fair value of the Company as CBS was fully integrated into the Company's one reportable segment. The fair value of CBS was determined based on the enterprise value per the CBS Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $1.1 million of goodwill was to be allocated to CBS upon its disposal. The allocated goodwill was included in the carrying basis of CBS presented in the above table.
In addition, upon the closing of the CBS Divestiture, the Company and CBS entered into a transition service agreement (the "CBS TSA"), pursuant to which the Company will provide certain transition services to CBS following the closing of the CBS Divestiture. The CBS Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with CBS, soliciting its employees or interfering with its business relationships for two years after the closing of the CBS Divestiture. The Company has no other significant continuing involvement with CBS upon the expiration of its CBS TSA and related covenants.
Summarized financial data of discontinued operations
The tables below summarize financial data of discontinued operations for the three months ended March 31, 2024. Interest expenses directly associated with the debt of a disposed entity is reported in discontinued operations below.
The table below summarizes the key components of loss from discontinued operations as follows:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Revenue$4,948 $5,135 $3,210 $13,293 
Cost of revenue6,600 3,725 2,648 12,973 
Gross profit(1,652)1,410 562 320 
Operating expenses(4,314)(1,663)(1,175)(7,152)
Other income (expense), net(33)(18)(25)(76)
Loss before income taxes(5,999)(271)(638)(6,908)
Income tax expense(10)(100)(4)(114)
Loss from discontinued operations, net of income taxes$(6,009)$(371)$(642)$(7,022)
Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Depreciation$— $667 $— $667 
Amortization$— $227 $— $227 
Stock-based compensation$947 $706 $402 $2,055 
Interest expense, net$38 $2 $26 $66 
Capital expenditures$26 $255 $— $281 
All divested entities had no remaining balances as of March 31, 2025 or December 31, 2024.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Fair value measurement
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
In accordance with the FASB ASC Topic 820, Fair Value Measurements and Disclosures, (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
There were no remeasurements to fair value during the three months ended March 31, 2025 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, based on the three-tier fair value hierarchy:
(In thousands)
As of March 31, 2025Level 1Level 2 Total
Assets:
Cash equivalents:
Money market accounts$61,852 $-  $61,852 
Available-for-sale securities:    
U.S. government securities8,297 -  8,297 
Corporate debt securities2,796 21,496  24,292 
Other debt securities- 8,101  8,101 
Total$72,945 $29,597  $102,542 
As of December 31, 2024
Assets:
Cash equivalents:
Money market accounts$89,119 $-  $89,119 
Available-for-sale securities:
U.S. government securities1,494 -  1,494 
Corporate debt securities398 8,602  9,000 
Other debt securities- 3,332  3,332 
Total$91,011 $11,934  $102,945 
There have been no transfers of assets or liabilities between the fair value measurement levels. We had no financial assets that utilize Level 3 inputs of measurement as of March 31, 2025 and December 31, 2024.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Investments
 3 Months Ended
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for-sale securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
March 31, 2025
Amortized
Cost		 Gross unrealized Estimated
Fair Value
(In thousands) GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$6,509 $3 $- $6,512 
Corporate debt securities11,638 13 (1)11,650 
Other debt securities3,472 2 (1)3,473 
Total short-term21,619 18 (2)21,635 
     
Available-for-sale securities, long-term    
U.S. government securities1,779 7 - 1,786 
Corporate debt securities12,631 14 (4)12,641 
Other debt securities4,628 3 (3)4,628 
Total long-term19,038 24 (7)19,055 
Total marketable securities$40,657 $42 $(9)$40,690 
December 31, 2024
Amortized
Cost		Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$1,493 $1 $- $1,494 
Corporate debt securities5,775 14 (1)5,788 
Other debt securities1,912 4 - 1,916 
Total short-term9,180 19 (1)9,198 
Available-for-sale securities, long-term
Corporate debt securities3,210 4 (2)3,212 
Other debt securities1,412 5 (1)1,416 
Total long-term4,622 9 (3)4,628 
Total marketable securities$13,802 $28 $(4)$13,826 
March 31, 2025
(In thousands)Amortized
Cost		Estimated
Fair Value
Due in one year or less$21,619 $21,636 
Due after one year through five years19,038 19,054 
Total$40,657 $40,690 
The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:
March 31, 2025
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$4,913 $(4)$4,913 $(4)
Other debt securities5,082 (2)5,082 (2)
Total$9,995 $(6)$9,995 $(6)
December 31, 2024
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$2,091 $(3)$2,091 $(3)
Other debt securities1,030 (1)1,030 (1)
Total$3,121 $(4)$3,121 $(4)
As of March 31, 2025 and December 31, 2024, all available-for-sale securities investments presented above with unrealized losses have been in an unrealized loss position for less than 12 months.
As of March 31, 2025, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded.
Equity investments
The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The Company has adopted the measurement alternative whereby equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series E Preferred Stock in PanTHERA carried at $1.0 million as of March 31, 2025 and December 31, 2024.
On April 4, 2025, the Company purchased the remaining 90% of PanTHERA common shares it did not own as of March 31, 2025 for an $10.0 million in cash and 213,361 shares of the Company's Common stock and other contingent consideration. For additional details on the transaction, see Note 19: Subsequent events.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories
 3 Months Ended
Mar. 31, 2025
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Raw materials$9,846 $11,768 
Work in progress4,489 4,082 
Finished goods13,231 13,163 
Total inventories$27,566 $29,013 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Leases
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Leases Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of two to eleven years and have remaining lease terms of two to six years. The Company excludes options that are not reasonably certain to be exercised from our lease terms,
ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases.
We did not have any financing lease arrangements as of March 31, 2025 and December 31, 2024.
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Weighted average discount rate - operating leases6.4 %6.4 %
Weighted average remaining lease term in years - operating leases5.96.1
The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended
March 31,
(In thousands)20252024
Operating lease costs$625 $385 
Short-term lease costs31 17 
Total operating lease costs656 402 
 
Variable lease costs298 239 
Total lease costs$954 $641 
Maturities of our lease liabilities as of March 31, 2025 are as follows:
(In thousands)Operating
Leases
2025 (9 months remaining)$1,900 
20263,029 
20272,583 
20282,642 
20292,724 
Thereafter3,946 
Total lease payments16,824 
Less: interest(2,824)
Total present value of lease liabilities$14,000 
Leases Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of two to eleven years and have remaining lease terms of two to six years. The Company excludes options that are not reasonably certain to be exercised from our lease terms,
ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases.
We did not have any financing lease arrangements as of March 31, 2025 and December 31, 2024.
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Weighted average discount rate - operating leases6.4 %6.4 %
Weighted average remaining lease term in years - operating leases5.96.1
The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended
March 31,
(In thousands)20252024
Operating lease costs$625 $385 
Short-term lease costs31 17 
Total operating lease costs656 402 
 
Variable lease costs298 239 
Total lease costs$954 $641 
Maturities of our lease liabilities as of March 31, 2025 are as follows:
(In thousands)Operating
Leases
2025 (9 months remaining)$1,900 
20263,029 
20272,583 
20282,642 
20292,724 
Thereafter3,946 
Total lease payments16,824 
Less: interest(2,824)
Total present value of lease liabilities$14,000 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Assets held for rent
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Assets held for rent Assets held for rent
Assets held for rent consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Shippers placed in service$8,994 $9,505 
Accumulated depreciation(6,350)(6,499)
Net2,644 3,006 
Shippers and related components in production3,046 3,097 
Total$5,690 $6,103 
Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.5 million and $0.6 million in depreciation expense related to assets held for rent during the three months ended March 31, 2025 and March 31, 2024, respectively
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Property and equipment
 3 Months Ended
Mar. 31, 2025
Property, Plant and Equipment [Abstract]  
Property and equipment Property and equipment
Property and equipment consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Property and equipment  
Leasehold improvements$3,587 $3,527 
Furniture and computer equipment306 306 
Manufacturing and other equipment4,116 4,073 
Construction in-progress3,094 2,478 
Subtotal11,103 10,384 
Less: Accumulated depreciation(4,498)(4,300)
Property and equipment, net$6,605 $6,084 
Depreciation expense for property and equipment was $0.2 million and $0.2 million for the three months ended March 31, 2025 and March 31, 2024, respectively.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Goodwill and intangible assets
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets Goodwill and intangible assets
Goodwill
Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350.
Intangible assets
Intangible assets, net consisted of the following as of March 31, 2025 and December 31, 2024:
(In thousands, except weighted average useful life)March 31, 2025
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,512)$4 0.3
Tradenames4,114 (1,901)2,213 5.6
Technology - acquired18,672 (12,032)6,640 2.9
Non-compete agreements90 (90)- 0.0
Total intangible assets$25,392 $(16,535)$8,857 3.1
(In thousands, except weighted average useful life)December 31, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,508) $8  0.6
Tradenames4,114 (1,799) 2,315  5.9
Technology - acquired18,672 (11,436) 7,236  3.1
Non-compete agreements90 (90) -  0.0
Total intangible assets$25,392 $(15,833) $9,559  3.3
Amortization expense for definite-lived intangible assets was $0.7 million and $0.7 million for the three months ended March 31, 2025 and March 31, 2024, respectively. As of March 31, 2025, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2025 (9 months remaining)$2,105 
20262,692 
20271,938 
2028828 
2029530 
Thereafter764 
Total$8,857 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued expenses and other current liabilities
 3 Months Ended
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Accrued expenses and other current liabilities Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Accrued expenses$4,341  $7,116 
Accrued compensation3,755  5,232 
Deferred revenue, current117  103 
Total accrued expenses and other current liabilities$8,213  $12,451 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and contingencies
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Employment agreements
We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason.
Litigation
From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, as our industry is characterized by frequent claims and litigation, including claims regarding intellectual property. Management does not believe any of the current claims are material to the Company’s business. Future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company carries certain insurance policies that may cover the aforementioned costs. The probability of claims that could result in a loss are evaluated and disclosed, as needed, individually and on a gross basis. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company other than those listed below.
Pending litigation item
One lawsuit has been filed by a previous customer seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. Pursuant to the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies and if this previous customer was successful on such claim, then the Company would be responsible for indemnifying Global Cooling for any losses. This lawsuit does not currently have probable outcomes determined and we continue to defend vigorously against the claims made. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential loss incurred to be covered by insurance.
Indemnification
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of March 31, 2025 and December 31, 2024.
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of March 31, 2025, our total short-term obligations were $10.0 million.
Non-income related taxes
Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2024, the Company determined that a sales tax liability related to the periods of 2019 through 2024 was probable and determined an estimated liability. The estimated liability was approximately $3.9 million and $4.3 million as of March 31, 2025 and December 31, 2024, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term debt
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Long-term debt Long-term debt
Term Loan
On September 20, 2022, the Company and certain of its subsidiaries entered into the Loan and Security Agreement, by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), Global Cooling, and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton”), as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Second Amendment”), that certain Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024 (the “Third Amendment”), and that certain Consent and Fourth Amendment to Loan and Security Agreement, dated April 4, 2025 (the "Fourth Amendment", and the foregoing collectively, the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of March 31, 2025, the implied interest rate of the Term Loan is 11.1% and the implied value of the Term Loan is $13.4 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of March 31, 2025, the Company is in compliance with the covenants set forth in the Loan Agreement.
On April 17, 2024, the Company entered into the Second Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton (the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton, collectively, the “Second Amendment Borrower”). Pursuant to the Second Amendment and subject to the conditions set forth therein, Bank consented to the Global Cooling Divestiture and released its security interests in the assets of Global Cooling and the shares of common stock of Global Cooling arising under the Loan Agreement. In addition, effective as of the closing of the Global Cooling Divestiture, the Second Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Second Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Second Amendment also contains customary representations and warranties of Second Amendment Borrower and provides for a release of Bank by Second Amendment Borrower for any claims existing or arising through the date of the Second Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
On November 11, 2024, the Company entered into the Third Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent and Sexton (the Company, SAVSU, Arctic, SciSafe Parent and Sexton, collectively, the “Third Amendment Borrower”). Pursuant to the Third Amendment and subject to the conditions set forth therein, Bank consented to the SciSafe Divestiture as required pursuant to the Loan Agreement. In addition, effective as of the closing of the SciSafe Divestiture, the Third Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Third Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date for any reason. The Third Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Third Amendment Borrower and provides for a release of Bank by Third Amendment Borrower for any claims existing or arising through the date of the Third Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
On April 4, 2025, the Company entered into the Fourth Amendment by and among Bank, the Company, SAVSU and Sexton. For additional information on the Fourth Amendment, see Note 19: Subsequent events.
Long-term debt consisted of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)Maturity DateInterest Rate20252024
Term Loan(1)
Jun-267.0 %$12,500 $15,000 
Insurance premium financingVarious8.3 %473 975 
Total debt, excluding unamortized debt issuance costs12,973 15,975 
Less: unamortized debt issuance costs(25)(35)
Total debt12,948 15,940 
Less: current portion of debt(10,449)(10,943)
Total long-term debt$2,499 $4,997 
(1) As of March 31, 2025, the Term Loan was secured by substantially all assets of BioLife, SAVSU, and Sexton, other than intellectual property.
As of March 31, 2025, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2025 (9 months remaining)$7,951 
20264,997 
2027- 
2028- 
2029- 
Thereafter- 
Total debt$12,948 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of both March 31, 2025 and December 31, 2024, our deferred revenue balance totaled $0.1 million. During the three months ended March 31, 2025, the Company recognized approximately $18 thousand of revenue that was included in the deferred revenue balance at the beginning of the year.
The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, hPL media, evo ModPaks, and ThawSTAR products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control
of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations.
Service revenues are generated from various customer service agreements to provide warranty and other engineering services. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three months ended March 31, 2025.
The Company generates revenue from the leasing of our evo cold chain systems to customers pursuant to rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under rental arrangements for durations of one year or less, with each unit having the option to continue its rental arrangement on a month-to-month basis until returned to the Company beyond the initial rental period. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term.
Total bioproduction tools and services revenue for the three months ended March 31, 2025 and 2024 were composed of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024
Product revenue
Cell processing$21,574 $16,186 
evo and Thaw725 557 
Service revenue
evo and Thaw60 25 
Rental revenue
evo and Thaw1,582 1,665 
Total revenue$23,941 $18,433 
There was no estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period of March 31, 2025. The Company elected not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
Service-based vesting stock options
The following is a summary of service-based vesting stock option activity for the three months ended March 31, 2025, and the status of service-based vesting stock options outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period127,000 $2.19 
Exercised— — 
Outstanding as of March 31, 2025127,000 $2.19 
Stock options exercisable as of March 31, 2025127,000 $2.19 
As of March 31, 2025, there was $2.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2025. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three months ended March 31, 2025. There were no exercises of service vesting-based awards during the three months ended March 31, 2025. There were no service-based vesting options granted during the three months ended March 31, 2025. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of March 31, 2025 is 1.2 years. There were no unrecognized compensation costs for service-based vesting stock options as of March 31, 2025.
Restricted stock
Service-based vesting restricted stock
The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2025, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period1,295,640 $16.00 
Granted290,333 25.33 
Vested(171,379)19.47 
Forfeited(15,151)14.17 
Non-vested as of March 31, 20251,399,443 $17.53 
The aggregate fair value of the service-based vesting awards granted was $7.4 million during the three months ended March 31, 2025. The aggregate fair value of the service-based vesting awards that vested was $4.5 million during the three months ended March 31, 2025.
We recognized stock compensation expense related to service-based vesting awards of $2.7 million during the three months ended March 31, 2025. As of March 31, 2025, there was $22.5 million in unrecognized compensation costs related
to service-based vesting awards. The weighted average remaining recognition period over which these service-based vesting awards will be expensed is approximately 2.8 years.
Performance-based restricted stock
On March 8, 2024, the Company granted a performance-based restricted stock award for 109,512 shares to an executive. The shares granted contain performance conditions based on Company metrics related to future performance. The shares will vest as to between 0% and 200% of the number of restricted shares granted to the recipient based on performance conditions during the period beginning on January 1, 2024 through December 31, 2025. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025.
During the fourth quarter of the year ended December 31, 2024, it was determined the probability of attainment of the performance condition increased to greater than 100% of shares granted. In accordance with ASC 718, we recognized a cumulative catch up in stock compensation expense of $0.4 million to reflect the increased probability the performance-based award would vest in excess of the shares originally granted. The fair value of this award is being expensed on a straight-line basis in accordance with the estimated quantity of shares expected to vest over the requisite service period ending on December 31, 2025.
During the three months ended March 31, 2025, the Company's Board approved a modification to the metrics underlying the performance-based award to give effect to the adjusted operating results of the Company following the divestitures that occurred during the year ended December 31, 2024. The modification increased the probability that the performance-based award would vest in excess of the shares originally granted to its maximum amount of 200%. In accordance with ASC 718, this modification resulted in an incremental compensation cost of $1.6 million, which will be recognized over the remainder of the service period of the award.
We recognized stock compensation expense of $0.4 million related to performance-based restricted stock awards for the three months ended March 31, 2025. As of March 31, 2025, there was $2.7 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 0.8 years. Non-cash compensation costs are expensed over the period for which performance was measured.

There were no performance-based restricted stock awards granted or vested during the three months ended March 31, 2025.
Market-based restricted stock
The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2025 and the status of market-based restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period495,686 $25.69 
Granted451,801 32.91 
Vested(470,287)25.19 
Non-vested as of March 31, 2025477,200 $33.02 
The following is a summary of key inputs to our market-based restricted stock awards as of March 31, 2025:
Fair Value Assumptions
Grant DateTarget SharesVesting RangeMarket Condition PeriodFV of Award
(in millions)		VolatilityRisk Free RateDividend RateAttainment %Vested Shares
2023 TSR(1)
1/3/2023268,738
0% - 200%
1/1/2023 - 12/31/2024$6.8 78 %4.4 %— %175 %470,287
2024 TSR(2)
3/8/2024239,464
0% - 200%
1/1/2024 - 12/31/2025$6.3 80 %4.6 %— %N/AN/A
2025 TSR3/18/2025250,252
0% - 200%
1/1/2025 - 12/31/2026$9.8 60 %4.1 %— %N/AN/A
(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.
(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.
Each of the market-based restricted stock awards outlined above were granted to its executives. The restricted stock awards granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards vest at a range determined by the Compensation Committee of the Board of Directors in comparison to the TSR of a group of the Company's peers. The fair value of these awards are determined using a Monte Carlo simulation with various assumptions. These assumptions include historical volatility, dividend yield, and a risk-free interest rate. The historical volatility is based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the measurement date with a maturity consistent with the 2-year term associated with the market condition of these awards. The fair value of these awards are expensed on a straight-line basis over the grant date to the vesting date.
When the TSR period for each award has elapsed, the Company determines the TSR attainment percentage to award each recipient based on the targeted amount of shares granted.
We recognized stock compensation expense of $1.0 million and $1.1 million related to market-based restricted stock awards for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, there were $12.0 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. The weighted average remaining recognition period over which these market-based awards will be expensed is approximately 1.5 years.
The aggregate fair value of the market-based awards granted was $6.3 million for both the three months ended March 31, 2025 and 2024. The aggregate fair value of the market-based awards that vested was $11.5 million and $5.1 million for the three months ended March 31, 2025 and 2024, respectively.
Total stock compensation expense
Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three months ended March 31, 2025 and 2024, as follows:
 Three Months Ended
March 31,
(In thousands)20252024
Cost of revenue$292 $308 
General and administrative costs2,967 2,833 
Sales and marketing costs388 424 
Research and development costs506 563 
Total$4,153 $4,128 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Income taxes
 3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. Income tax expense of $14.0 thousand for the three months ended March 31, 2025 resulted in an effective income tax rate of negative 3.2%. Included in the $14.0 thousand of tax expense was discrete tax benefit of $0.5 million related to stock compensation, which was offset by a change in the valuation allowance.
The Company’s projected effective income tax rate for the year ending December 31, 2025 excluding the impact, if any, of discrete items is negative 5.3%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits.
Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates all available positive and negative evidence to determine if it is more likely than not that its deferred tax assets are realizable. As of March 31, 2025, the Company continues to provide a full valuation allowance against its deferred tax assets as the realization of such assets is not considered to be more likely than not at this time. If the Company's conclusion about the realizability of its deferred tax assets and therefore the appropriateness of the valuation allowance changes in a future period, the Company could record a substantial tax benefit in its Condensed Consolidated Statements of Operations when that occurs.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Net loss from continuing operations per common share
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Net loss from continuing operations per common share Net loss from continuing operations per common share
Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
March 31,
(In thousands, except share and earnings per share data)20252024
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(448)$(3,199)
Denominator:
Weighted-average common shares issued and outstanding47,134,72045,432,426
Basic and diluted loss from continuing operations per common share$(0.01)$(0.07)
Anti-dilutive shares1,232,8361,070,693
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment, customer, and geographic information Segment, customer, and geographic information
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, Mr. Roderick de Greef, who is the CODM, reviews the Company’s operations on a consolidated basis for purposes of allocating resources and evaluating financial performance. As a single reportable segment entity, the Company’s segment performance measure is consolidated net (loss) income from continuing operations.
Significant segment expenses are presented in the Company’s Condensed Consolidated Statements of Operations. Additional significant segment expenses that are not separately presented in the Company’s Condensed Consolidated Statements of Operations include Shared-based compensation and Depreciation expense. These are presented in the Condensed Consolidated Statement of Cash Flows, and Note 14: Stock-based compensation, Note 7: Assets held for rent, and Note 8: Property and equipment.
Other expense items not individually significant in net loss from continuing operations are changes in inventory values due to changes in its carrying basis, costs associated with the Company’s acquisitions or divestitures in the period these take place, and gain or loss on disposal of fixed assets. The information provided to the Company’s CODM for purposes of making decisions and assessing segment performance excludes asset information.
Concentrations of risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
 Accounts ReceivableRevenue
 March 31,December 31,Three Months Ended March 31,
 2025202420252024
Customer A18 % * **
Customer B*18 %18 %19 %
Customer C*21 %11 %*
Customer D13 %***
*less than 10%
The following is a summary of revenue by major product family representing over 10% of the Company's total revenue:
Three Months Ended
March 31,
Product revenue concentration20252024
CryoStor77 %73 %
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
March 31,
Revenue by customers’ geographic locations
20252024
United States81 %81 %
Europe, Middle East, Africa (EMEA)14 %14 %
Other5 %5 %
Total revenue100 %100 %
All of the Company's long-lived assets, totaling $22.4 million as of March 31, 2025, are located within the United States. Though the Company's evo shippers under rental arrangements may be outside of the United States, all are shipped back to our United States warehouse upon completion of the applicable rental arrangement.
In the three months ended March 31, 2025 and 2024, no suppliers accounted for more than 10% of purchases.
As of March 31, 2025, three different suppliers accounted for 17%, 16%, and 11% of accounts payable. As of December 31, 2024, no suppliers accounted for more than 10% of accounts payable.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Employee benefit plan
 3 Months Ended
Mar. 31, 2025
Retirement Benefits [Abstract]  
Employee benefit plan Employee benefit plan
The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.2 million in contributions to this plan for both the three months ended March 31, 2025 and 2024.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent events
 3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]  
Subsequent events Subsequent events
The Company has evaluated events subsequent to March 31, 2025 through the date of this filing to assess the need for potential recognition or disclosure.
Stock Purchase Agreement for PanTHERA Acquisition
On April 4, 2025, the Company entered into the PanTHERA Purchase Agreement for the purchase by the Company of all of the issued and outstanding shares of common stock of PanTHERA from the Sellers for an aggregate purchase price of $22.7 million, net of cash acquired, which included $10.0 million in cash, subject to any adjustments pursuant to the purchase price adjustment provision in the PanTHERA Purchase Agreement, 213,361 shares of our common stock, and an additional $7.2 million in earnout payments over the next three years contingent on the achievement of certain scientific and revenue milestones (the “PanTHERA Transaction”). Following the execution of the PanTHERA Purchase Agreement, the PanTHERA Transaction was consummated on April 4, 2025 (the “Closing Date”). The PanTHERA Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto.
The Company acquired PanTHERA's portfolio of molecules and other assets including certain technology under development. Management is in the process of determining the purchase price allocation and accounting treatment. The
preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax incurred thus far were $0.2 million.
Consent and Fourth Amendment to Loan and Security Agreement with Silicon Valley Bank
On April 4, 2025, the Company entered into a Consent and Fourth Amendment to Loan and Security Agreement (the “Fourth Amendment”), by and among Bank, the Company, SAVSU, SciSafe Parent, and Sexton. Pursuant to the Fourth Amendment and subject to the conditions set forth therein, Bank consented to the PanTHERA Transaction and the SciSafe Dissolution as required pursuant to the Loan Agreement. The Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of the Company, SAVSU, SciSafe Parent, and Sexton and provides for a release of Bank by the Company, SAVSU, SciSafe Parent, and Sexton for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net loss $ (448) $ (10,221)
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Organization and significant accounting policies (Policies)
 3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Use of estimates
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s valuation of market-based stock awards, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.
The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation
The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2025 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2025 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”) and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
Consolidation
The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 2: Discontinued operations for additional details about the divestitures.
Foreign currency exchange
Foreign currency exchange
The Company's sales are primarily denominated in the U.S. dollar. Accordingly, our sales are not generally impacted by foreign currency exchange rates. For any transactions denominated in a foreign currency, which were immaterial during the three months ended March 31, 2025 and 2024, the Company remeasures foreign currency transactions into U.S. dollars on its Unaudited Condensed Consolidated Financial Statements in the Other income line item.
Segment reporting
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional information on the Company's segment considerations, see Note 17: Segment, customer, and geographic information.
Recent accounting pronouncements
Recent accounting pronouncements
Recently issued accounting pronouncements not yet adopted
In November 2024, the Financial Accounting Standards Board ("FASB") issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures - Clarifying the Effective Date to clarify the effective date for non-calendar year-end entities. The amendments in this ASU will be effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the effects adoption of this guidance will have on the Consolidated Financial Statements.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations (Tables)
 3 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$- 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Less: Global Cooling carrying basis as of April 17, 20241,650 
Less: Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balances of loans under Global Cooling as of the date of the Global Cooling Divestiture.
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees- 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 
The Company recognized a gain on disposal of SciSafe, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$71,291 
Cash proceeds from escrow483 
Costs to sell(1)
(506)
Total proceeds71,268 
Less: SciSafe carrying basis as of November 12, 202442,507 
Less: Release of SciSafe currency translation adjustment622 
Net gain on disposal$28,139 
(1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million.
The Company recognized a loss on disposal of CBS, calculated as follows:
(In thousands)
Cash proceeds received from Buyer$2,785 
Cash proceeds from escrow615 
Net price adjustment(1)
179 
Costs to sell(2)
(148)
Total proceeds3,431 
Less: CBS carrying basis as of November 14, 20246,796 
Net loss on disposal$(3,365)
(1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the CBS Divestiture.
(2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million.
The table below summarizes the key components of loss from discontinued operations as follows:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Revenue$4,948 $5,135 $3,210 $13,293 
Cost of revenue6,600 3,725 2,648 12,973 
Gross profit(1,652)1,410 562 320 
Operating expenses(4,314)(1,663)(1,175)(7,152)
Other income (expense), net(33)(18)(25)(76)
Loss before income taxes(5,999)(271)(638)(6,908)
Income tax expense(10)(100)(4)(114)
Loss from discontinued operations, net of income taxes$(6,009)$(371)$(642)$(7,022)
Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations:
Three Months Ended March 31, 2024
(In thousands)Global CoolingSciSafeCBSTotal
Depreciation$— $667 $— $667 
Amortization$— $227 $— $227 
Stock-based compensation$947 $706 $402 $2,055 
Interest expense, net$38 $2 $26 $66 
Capital expenditures$26 $255 $— $281 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Fair value measurement (Tables)
 3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis he following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, based on the three-tier fair value hierarchy:
(In thousands)
As of March 31, 2025Level 1Level 2 Total
Assets:
Cash equivalents:
Money market accounts$61,852 $-  $61,852 
Available-for-sale securities:    
U.S. government securities8,297 -  8,297 
Corporate debt securities2,796 21,496  24,292 
Other debt securities- 8,101  8,101 
Total$72,945 $29,597  $102,542 
As of December 31, 2024
Assets:
Cash equivalents:
Money market accounts$89,119 $-  $89,119 
Available-for-sale securities:
U.S. government securities1,494 -  1,494 
Corporate debt securities398 8,602  9,000 
Other debt securities- 3,332  3,332 
Total$91,011 $11,934  $102,945 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Marketable Securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
March 31, 2025
Amortized
Cost		 Gross unrealized Estimated
Fair Value
(In thousands) GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$6,509 $3 $- $6,512 
Corporate debt securities11,638 13 (1)11,650 
Other debt securities3,472 2 (1)3,473 
Total short-term21,619 18 (2)21,635 
     
Available-for-sale securities, long-term    
U.S. government securities1,779 7 - 1,786 
Corporate debt securities12,631 14 (4)12,641 
Other debt securities4,628 3 (3)4,628 
Total long-term19,038 24 (7)19,055 
Total marketable securities$40,657 $42 $(9)$40,690 
December 31, 2024
Amortized
Cost		Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$1,493 $1 $- $1,494 
Corporate debt securities5,775 14 (1)5,788 
Other debt securities1,912 4 - 1,916 
Total short-term9,180 19 (1)9,198 
Available-for-sale securities, long-term
Corporate debt securities3,210 4 (2)3,212 
Other debt securities1,412 5 (1)1,416 
Total long-term4,622 9 (3)4,628 
Total marketable securities$13,802 $28 $(4)$13,826 
March 31, 2025
(In thousands)Amortized
Cost		Estimated
Fair Value
Due in one year or less$21,619 $21,636 
Due after one year through five years19,038 19,054 
Total$40,657 $40,690 
Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value
The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:
March 31, 2025
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$4,913 $(4)$4,913 $(4)
Other debt securities5,082 (2)5,082 (2)
Total$9,995 $(6)$9,995 $(6)
December 31, 2024
Less than 12 monthsTotal
(In thousands)Fair ValueUnrealized LossesFair ValueUnrealized Losses
Corporate debt securities$2,091 $(3)$2,091 $(3)
Other debt securities1,030 (1)1,030 (1)
Total$3,121 $(4)$3,121 $(4)
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2025
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventories consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Raw materials$9,846 $11,768 
Work in progress4,489 4,082 
Finished goods13,231 13,163 
Total inventories$27,566 $29,013 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Schedule of Operating and Finance Lease Terms and Discount Rates
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Weighted average discount rate - operating leases6.4 %6.4 %
Weighted average remaining lease term in years - operating leases5.96.1
Schedule of Lease Expense
The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended
March 31,
(In thousands)20252024
Operating lease costs$625 $385 
Short-term lease costs31 17 
Total operating lease costs656 402 
 
Variable lease costs298 239 
Total lease costs$954 $641 
Schedule of Maturities of Operating Lease Liabilities
Maturities of our lease liabilities as of March 31, 2025 are as follows:
(In thousands)Operating
Leases
2025 (9 months remaining)$1,900 
20263,029 
20272,583 
20282,642 
20292,724 
Thereafter3,946 
Total lease payments16,824 
Less: interest(2,824)
Total present value of lease liabilities$14,000 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Assets held for rent (Tables)
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Assets Held for Rent
Assets held for rent consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Shippers placed in service$8,994 $9,505 
Accumulated depreciation(6,350)(6,499)
Net2,644 3,006 
Shippers and related components in production3,046 3,097 
Total$5,690 $6,103 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Property and equipment (Tables)
 3 Months Ended
Mar. 31, 2025
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Property and equipment  
Leasehold improvements$3,587 $3,527 
Furniture and computer equipment306 306 
Manufacturing and other equipment4,116 4,073 
Construction in-progress3,094 2,478 
Subtotal11,103 10,384 
Less: Accumulated depreciation(4,498)(4,300)
Property and equipment, net$6,605 $6,084 
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Goodwill and intangible assets (Tables)
 3 Months Ended
Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net consisted of the following as of March 31, 2025 and December 31, 2024:
(In thousands, except weighted average useful life)March 31, 2025
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,512)$4 0.3
Tradenames4,114 (1,901)2,213 5.6
Technology - acquired18,672 (12,032)6,640 2.9
Non-compete agreements90 (90)- 0.0
Total intangible assets$25,392 $(16,535)$8,857 3.1
(In thousands, except weighted average useful life)December 31, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization		 
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$2,516 $(2,508) $8  0.6
Tradenames4,114 (1,799) 2,315  5.9
Technology - acquired18,672 (11,436) 7,236  3.1
Non-compete agreements90 (90) -  0.0
Total intangible assets$25,392 $(15,833) $9,559  3.3
Schedule of Amortization Expense for Finite-Lived Intangible Assets As of March 31, 2025, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2025 (9 months remaining)$2,105 
20262,692 
20271,938 
2028828 
2029530 
Thereafter764 
Total$8,857 
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued expenses and other current liabilities (Tables)
 3 Months Ended
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)20252024
Accrued expenses$4,341  $7,116 
Accrued compensation3,755  5,232 
Deferred revenue, current117  103 
Total accrued expenses and other current liabilities$8,213  $12,451 
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term debt (Tables)
 3 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Debt
Long-term debt consisted of the following as of March 31, 2025 and December 31, 2024:
March 31,December 31,
(In thousands)Maturity DateInterest Rate20252024
Term Loan(1)
Jun-267.0 %$12,500 $15,000 
Insurance premium financingVarious8.3 %473 975 
Total debt, excluding unamortized debt issuance costs12,973 15,975 
Less: unamortized debt issuance costs(25)(35)
Total debt12,948 15,940 
Less: current portion of debt(10,449)(10,943)
Total long-term debt$2,499 $4,997 
Schedule of Maturities of Long-Term Debt
As of March 31, 2025, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2025 (9 months remaining)$7,951 
20264,997 
2027- 
2028- 
2029- 
Thereafter- 
Total debt$12,948 
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Bioproduction Tools and Service Revenues
Total bioproduction tools and services revenue for the three months ended March 31, 2025 and 2024 were composed of the following:
Three Months Ended
March 31,
(In thousands, except percentages)20252024
Product revenue
Cell processing$21,574 $16,186 
evo and Thaw725 557 
Service revenue
evo and Thaw60 25 
Rental revenue
evo and Thaw1,582 1,665 
Total revenue$23,941 $18,433 
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation (Tables)
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Service Vesting-Based Stock Option Activity
The following is a summary of service-based vesting stock option activity for the three months ended March 31, 2025, and the status of service-based vesting stock options outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period127,000 $2.19 
Exercised— — 
Outstanding as of March 31, 2025127,000 $2.19 
Stock options exercisable as of March 31, 2025127,000 $2.19 
Schedule of Service Vesting-Based and Market Based Restricted Stock Activity
The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2025, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period1,295,640 $16.00 
Granted290,333 25.33 
Vested(171,379)19.47 
Forfeited(15,151)14.17 
Non-vested as of March 31, 20251,399,443 $17.53 
The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2025 and the status of market-based restricted stock outstanding as of March 31, 2025:
Three Months Ended
March 31, 2025
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period495,686 $25.69 
Granted451,801 32.91 
Vested(470,287)25.19 
Non-vested as of March 31, 2025477,200 $33.02 
Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption
The following is a summary of key inputs to our market-based restricted stock awards as of March 31, 2025:
Fair Value Assumptions
Grant DateTarget SharesVesting RangeMarket Condition PeriodFV of Award
(in millions)		VolatilityRisk Free RateDividend RateAttainment %Vested Shares
2023 TSR(1)
1/3/2023268,738
0% - 200%
1/1/2023 - 12/31/2024$6.8 78 %4.4 %— %175 %470,287
2024 TSR(2)
3/8/2024239,464
0% - 200%
1/1/2024 - 12/31/2025$6.3 80 %4.6 %— %N/AN/A
2025 TSR3/18/2025250,252
0% - 200%
1/1/2025 - 12/31/2026$9.8 60 %4.1 %— %N/AN/A
(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.
(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.
Schedule of Stock Compensation Expense We recorded total stock compensation expense for the three months ended March 31, 2025 and 2024, as follows:
 Three Months Ended
March 31,
(In thousands)20252024
Cost of revenue$292 $308 
General and administrative costs2,967 2,833 
Sales and marketing costs388 424 
Research and development costs506 563 
Total$4,153 $4,128 
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Net loss from continuing operations per common share (Tables)
 3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Computations of Basic and Diluted Earnings Per Share
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
March 31,
(In thousands, except share and earnings per share data)20252024
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(448)$(3,199)
Denominator:
Weighted-average common shares issued and outstanding47,134,72045,432,426
Basic and diluted loss from continuing operations per common share$(0.01)$(0.07)
Anti-dilutive shares1,232,8361,070,693
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Concentrations of Credit Risk and Business Risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
 Accounts ReceivableRevenue
 March 31,December 31,Three Months Ended March 31,
 2025202420252024
Customer A18 % * **
Customer B*18 %18 %19 %
Customer C*21 %11 %*
Customer D13 %***
Schedule of Product Revenue Concentration
The following is a summary of revenue by major product family representing over 10% of the Company's total revenue:
Three Months Ended
March 31,
Product revenue concentration20252024
CryoStor77 %73 %
Schedule of Revenue by Geographic Areas
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
March 31,
Revenue by customers’ geographic locations
20252024
United States81 %81 %
Europe, Middle East, Africa (EMEA)14 %14 %
Other5 %5 %
Total revenue100 %100 %
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Organization and significant accounting policies (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2025
USD ($)
reportable_segment
reporting_unit
Dec. 31, 2024
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of reportable segments | reportable_segment 1  
Number of reporting units | reporting_unit 1  
Cash, cash equivalents, and available-for-sale securities | $ $ 107.6 $ 109.2
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Narrative (Details)
$ in Thousands
 3 Months Ended
Nov. 14, 2024
USD ($)
Nov. 12, 2024
USD ($)
Apr. 17, 2024
USD ($)
employee
Mar. 31, 2025
USD ($)
reportable_segment
Discontinued Operations [Line Items]        
Number of reportable segments | reportable_segment       1
Discontinued operations, outstanding minimum lease payments for the lease terminations       $ 2,500
Discontinued Operations, Disposed of by Sale | Global Cooling        
Discontinued Operations [Line Items]        
Cash required on closing date, funded by entity     $ 6,652  
Repayment of indebtedness     2,600  
Other liabilities     $ 2,643  
Expected reduction of workforce | employee     47  
Expected reduction of workforce (percent)     11.00%  
Loss contingency accrual       4,000
Period of transition services     90 days  
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Severance        
Discontinued Operations [Line Items]        
Restructuring costs   $ 400    
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Earn-Out Payment        
Discontinued Operations [Line Items]        
Restructuring costs   3,300    
Discontinued Operations, Disposed of by Sale | SciSafe Holdings, Inc | Stock Compensation        
Discontinued Operations [Line Items]        
Restructuring costs   $ 4,000    
Discontinued Operations, Disposed of by Sale | SciSafe        
Discontinued Operations [Line Items]        
Disposal group, including discontinued operation, goodwill       $ 11,300
Transition services period       6 months
Competition covenant period       5 years
Discontinued Operations, Disposed of by Sale | CBS        
Discontinued Operations [Line Items]        
Disposal group, including discontinued operation, goodwill       $ 1,100
Competition covenant period       2 years
Discontinued Operations, Disposed of by Sale | CBS | Stock Compensation        
Discontinued Operations [Line Items]        
Restructuring costs $ 2,000      
Global Cooling        
Discontinued Operations [Line Items]        
Cash required on closing date     $ 7,000  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details) - Discontinued Operations, Disposed of by Sale - Global Cooling
$ / shares in Units, $ in Thousands
Apr. 17, 2024
USD ($)
$ / shares
Discontinued Operations [Line Items]  
Selling price per share (in dollars per share) | $ / shares $ 1
Selling price: $1 $ 0
Cash to Global Cooling funded by Company (6,652)
Costs to sell Global Cooling (582)
Negative selling price (7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities (3,589)
Assumed liabilities: Accounts payable 2,643
Assumed liabilities: Debt 2,596
Less: Global Cooling carrying basis as of April 17, 2024 1,650
Less: Release of Global Cooling currency translation adjustment (13)
Net loss on disposal (8,897)
Accounts payable 500
Accrued expenses $ 2,100
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
Discontinued Operations [Line Items]  
RIF employee costs $ 1,546
Former Global Cooling employees 1,925
Total employment related divestiture expenditures 3,471
Severance  
Discontinued Operations [Line Items]  
RIF employee costs 291
Former Global Cooling employees 0
Total employment related divestiture expenditures 291
Stock Compensation  
Discontinued Operations [Line Items]  
RIF employee costs 1,255
Former Global Cooling employees 1,925
Total employment related divestiture expenditures $ 3,180
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Schedule of Gain on Disposal (Details) - Discontinued Operations, Disposed of by Sale - USD ($)
$ in Thousands
Nov. 14, 2024
Nov. 12, 2024
SciSafe    
Discontinued Operations [Line Items]    
Cash proceeds received from Buyer   $ 71,291
Cash proceeds from escrow   483
Costs to sell   (506)
Total proceeds   71,268
Less: SciSafe carrying basis as of November 12, 2024   42,507
Less: Release of SciSafe currency translation adjustment   622
Net gain on disposal   28,139
Discontinued operation, gross selling costs   2,100
Discontinued operation, selling costs paid by divested entity   $ 1,600
CBS    
Discontinued Operations [Line Items]    
Cash proceeds received from Buyer $ 2,785  
Cash proceeds from escrow 615  
Net price adjustment 179  
Costs to sell (148)  
Total proceeds 3,431  
Less: CBS carrying basis as of November 14, 2024 6,796  
Net gain on disposal (3,365)  
Discontinued operation, gross selling costs 1,400  
Discontinued operation, selling costs paid by divested entity $ 1,300  
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Discontinued Operations [Line Items]    
Loss from discontinued operations before income tax expense $ 0 $ (6,908)
Income tax expense 0 (114)
Loss from discontinued operations $ 0 (7,022)
Discontinued Operations, Disposed of by Sale    
Discontinued Operations [Line Items]    
Revenue   13,293
Cost of revenue   12,973
Gross profit   320
Operating expenses   (7,152)
Other income (expense), net   (76)
Loss from discontinued operations before income tax expense   (6,908)
Income tax expense   (114)
Loss from discontinued operations   (7,022)
Discontinued Operations, Disposed of by Sale | Global Cooling    
Discontinued Operations [Line Items]    
Revenue   4,948
Cost of revenue   6,600
Gross profit   (1,652)
Operating expenses   (4,314)
Other income (expense), net   (33)
Loss from discontinued operations before income tax expense   (5,999)
Income tax expense   (10)
Loss from discontinued operations   (6,009)
Discontinued Operations, Disposed of by Sale | SciSafe    
Discontinued Operations [Line Items]    
Revenue   5,135
Cost of revenue   3,725
Gross profit   1,410
Operating expenses   (1,663)
Other income (expense), net   (18)
Loss from discontinued operations before income tax expense   (271)
Income tax expense   (100)
Loss from discontinued operations   (371)
Discontinued Operations, Disposed of by Sale | CBS    
Discontinued Operations [Line Items]    
Revenue   3,210
Cost of revenue   2,648
Gross profit   562
Operating expenses   (1,175)
Other income (expense), net   (25)
Loss from discontinued operations before income tax expense   (638)
Income tax expense   (4)
Loss from discontinued operations   $ (642)
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Discontinued Operations [Line Items]  
Depreciation $ 667
Amortization 227
Stock-based compensation 2,055
Interest expense, net 66
Capital expenditures 281
Global Cooling  
Discontinued Operations [Line Items]  
Depreciation 0
Amortization 0
Stock-based compensation 947
Interest expense, net 38
Capital expenditures 26
SciSafe  
Discontinued Operations [Line Items]  
Depreciation 667
Amortization 227
Stock-based compensation 706
Interest expense, net 2
Capital expenditures 255
CBS  
Discontinued Operations [Line Items]  
Depreciation 0
Amortization 0
Stock-based compensation 402
Interest expense, net 26
Capital expenditures $ 0
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Fair value measurement (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Assets:    
Available-for-sale securities $ 40,690 $ 13,826
Fair Value, Recurring    
Assets:    
Assets 102,542 102,945
Fair Value, Recurring | U.S. government securities    
Assets:    
Available-for-sale securities 8,297 1,494
Fair Value, Recurring | Corporate debt securities    
Assets:    
Available-for-sale securities 24,292 9,000
Fair Value, Recurring | Other debt securities    
Assets:    
Available-for-sale securities 8,101 3,332
Fair Value, Recurring | Level 1    
Assets:    
Assets 72,945 91,011
Fair Value, Recurring | Level 1 | U.S. government securities    
Assets:    
Available-for-sale securities 8,297 1,494
Fair Value, Recurring | Level 1 | Corporate debt securities    
Assets:    
Available-for-sale securities 2,796 398
Fair Value, Recurring | Level 1 | Other debt securities    
Assets:    
Available-for-sale securities 0 0
Fair Value, Recurring | Level 2    
Assets:    
Assets 29,597 11,934
Fair Value, Recurring | Level 2 | U.S. government securities    
Assets:    
Available-for-sale securities 0 0
Fair Value, Recurring | Level 2 | Corporate debt securities    
Assets:    
Available-for-sale securities 21,496 8,602
Fair Value, Recurring | Level 2 | Other debt securities    
Assets:    
Available-for-sale securities 8,101 3,332
Fair Value, Recurring | Money market accounts    
Assets:    
Cash equivalents 61,852 89,119
Fair Value, Recurring | Money market accounts | Level 1    
Assets:    
Cash equivalents 61,852 89,119
Fair Value, Recurring | Money market accounts | Level 2    
Assets:    
Cash equivalents $ 0 $ 0
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Investments - Schedule of Available-for-Sale Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion $ 21,619 $ 9,180
Gross unrealized Gains, current portion 18 19
Gross unrealized Losses, current portion (2) (1)
Available-for-sale securities, current portion 21,635 9,198
Amortized Cost, long term 19,038 4,622
Gross unrealized Gains, long term 24 9
Gross unrealized Losses, long term (7) (3)
Available-for-sale securities, long-term 19,055 4,628
Total 40,657 13,802
Total marketable securities, Gross Unrealized Gains 42 28
Total marketable securities, Gross Unrealized Losses (9) (4)
Estimated Fair Value, Total marketable securities 40,690 13,826
Amortized Cost    
Due in one year or less 21,619 9,180
Due after one year through five years 19,038 4,622
Total 40,657 13,802
Estimated Fair Value    
Due in one year or less 21,635 9,198
Total 40,690 13,826
Reported Value Measurement    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 21,619  
Amortized Cost, long term 19,038  
Total 40,657  
Amortized Cost    
Due in one year or less 21,619  
Due after one year through five years 19,038  
Total 40,657  
Estimate of Fair Value Measurement    
Debt Securities, Available-for-Sale [Line Items]    
Available-for-sale securities, current portion 21,636  
Estimated Fair Value, Total marketable securities 40,690  
Estimated Fair Value    
Due in one year or less 21,636  
Due after one year through five years 19,054  
Total 40,690  
U.S. government securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 6,509 1,493
Gross unrealized Gains, current portion 3 1
Gross unrealized Losses, current portion 0 0
Available-for-sale securities, current portion 6,512 1,494
Amortized Cost, long term 1,779  
Gross unrealized Gains, long term 7  
Gross unrealized Losses, long term 0  
Available-for-sale securities, long-term 1,786  
Amortized Cost    
Due in one year or less 6,509 1,493
Due after one year through five years 1,779  
Estimated Fair Value    
Due in one year or less 6,512 1,494
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 11,638 5,775
Gross unrealized Gains, current portion 13 14
Gross unrealized Losses, current portion (1) (1)
Available-for-sale securities, current portion 11,650 5,788
Amortized Cost, long term 12,631 3,210
Gross unrealized Gains, long term 14 4
Gross unrealized Losses, long term (4) (2)
Available-for-sale securities, long-term 12,641 3,212
Amortized Cost    
Due in one year or less 11,638 5,775
Due after one year through five years 12,631 3,210
Estimated Fair Value    
Due in one year or less 11,650 5,788
Other debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 3,472 1,912
Gross unrealized Gains, current portion 2 4
Gross unrealized Losses, current portion (1) 0
Available-for-sale securities, current portion 3,473 1,916
Amortized Cost, long term 4,628 1,412
Gross unrealized Gains, long term 3 5
Gross unrealized Losses, long term (3) (1)
Available-for-sale securities, long-term 4,628 1,416
Amortized Cost    
Due in one year or less 3,472 1,912
Due after one year through five years 4,628 1,412
Estimated Fair Value    
Due in one year or less $ 3,473 $ 1,916
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Securities, Available-for-Sale [Line Items]    
Fair value, less than 12 months $ 9,995 $ 3,121
Unrealized losses, less than 12 months (6) (4)
Total fair value 9,995 3,121
Total unrealized Losses (6) (4)
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Fair value, less than 12 months 4,913 2,091
Unrealized losses, less than 12 months (4) (3)
Total fair value 4,913 2,091
Total unrealized Losses (4) (3)
Other debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Fair value, less than 12 months 5,082 1,030
Unrealized losses, less than 12 months (2) (1)
Total fair value 5,082 1,030
Total unrealized Losses $ (2) $ (1)
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Investments - Narrative (Details) - USD ($)
$ in Millions
Apr. 04, 2025
Mar. 31, 2025
Dec. 31, 2024
PanTHERA Cryosolutions Investment | Subsequent Event      
Debt and Equity Securities, FV-NI [Line Items]      
Payments to acquire businesses, gross $ 10.0    
Business acquisition, equity interest issued or issuable, number of shares 213,361    
PanTHERA CryoSolutions, Inc. | PanTHERA Cryosolutions Investment | Subsequent Event      
Debt and Equity Securities, FV-NI [Line Items]      
Percentage of voting interests acquired 90.00%    
PanTHERA CryoSolutions, Inc. | Series E Preferred Stock      
Debt and Equity Securities, FV-NI [Line Items]      
Fair value of non-marketable equity securities without readily determinable fair value   $ 1.0 $ 1.0
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Inventory Disclosure [Abstract]    
Raw materials $ 9,846 $ 11,768
Work in progress 4,489 4,082
Finished goods 13,231 13,163
Total inventories $ 27,566 $ 29,013
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Leases - Narrative (Details) - Real Estate Lease
Mar. 31, 2025
Minimum  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 2 years
Operating lease, remaining lease term 2 years
Operating lease, renewal term 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 11 years
Operating lease, remaining lease term 6 years
Operating lease, renewal term 5 years
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)
Mar. 31, 2025
Dec. 31, 2024
Leases [Abstract]    
Weighted average discount rate - operating leases 6.40% 6.40%
Weighted average remaining lease term in years - operating leases 5 years 10 months 24 days 6 years 1 month 6 days
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Leases - Schedule of Lease Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Leases [Abstract]    
Operating lease costs $ 625 $ 385
Short-term lease costs 31 17
Total operating lease costs 656 402
Variable lease costs 298 239
Total lease costs $ 954 $ 641
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Operating Leases  
2025 (9 months remaining) $ 1,900
2026 3,029
2027 2,583
2028 2,642
2029 2,724
Thereafter 3,946
Total lease payments 16,824
Less: interest (2,824)
Total present value of lease liabilities $ 14,000
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Assets held for rent - Schedule of Assets Held for Rent (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Shippers placed in service $ 8,994 $ 9,505
Accumulated depreciation (6,350) (6,499)
Net 2,644 3,006
Shippers and related components in production 3,046 3,097
Total $ 5,690 $ 6,103
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Assets held for rent - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Assets held for rent, depreciation expense $ 0.5 $ 0.6
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Property and equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Property, Plant and Equipment [Line Items]    
Subtotal $ 11,103 $ 10,384
Less: Accumulated depreciation (4,498) (4,300)
Property and equipment, net 6,605 6,084
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Subtotal 3,587 3,527
Furniture and computer equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 306 306
Manufacturing and other equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 4,116 4,073
Construction in-progress    
Property, Plant and Equipment [Line Items]    
Subtotal $ 3,094 $ 2,478
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Property and equipment - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Property, Plant and Equipment [Abstract]    
Property and equipment, depreciation expense $ 0.2 $ 0.2
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Accumulated Amortization $ (16,535) $ (15,833)
Net Carrying Value $ 8,857  
Weighted Average Useful Life (in years) 3 years 1 month 6 days 3 years 3 months 18 days
Intangible assets, gross $ 25,392 $ 25,392
Intangible assets, net 8,857 9,559
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,516 2,516
Accumulated Amortization (2,512) (2,508)
Net Carrying Value $ 4 $ 8
Weighted Average Useful Life (in years) 3 months 18 days 7 months 6 days
Tradenames    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 4,114 $ 4,114
Accumulated Amortization (1,901) (1,799)
Net Carrying Value $ 2,213 $ 2,315
Weighted Average Useful Life (in years) 5 years 7 months 6 days 5 years 10 months 24 days
Technology - acquired    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 18,672 $ 18,672
Accumulated Amortization (12,032) (11,436)
Net Carrying Value $ 6,640 $ 7,236
Weighted Average Useful Life (in years) 2 years 10 months 24 days 3 years 1 month 6 days
Non-compete agreements    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 90 $ 90
Accumulated Amortization (90) (90)
Net Carrying Value $ 0 $ 0
Weighted Average Useful Life (in years) 0 years 0 years
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Goodwill and intangible assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible asset amortization $ 702 $ 688
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.25.1
Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2025 (9 months remaining) $ 2,105
2026 2,692
2027 1,938
2028 828
2029 530
Thereafter 764
Net Carrying Value $ 8,857
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]    
Accrued expenses $ 4,341 $ 7,116
Accrued compensation 3,755 5,232
Deferred revenue, current 117 103
Total accrued expenses and other current liabilities $ 8,213 $ 12,451
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and contingencies (Details)
$ in Millions
Mar. 31, 2025
USD ($)
lawsuit
Dec. 31, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Number of pending litigation claims | lawsuit 1  
Short-term purchase obligations $ 10.0  
Sales and excise tax payable $ 3.9 $ 4.3
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term debt - Narrative (Details) - USD ($)
$ in Thousands
Sep. 20, 2022
Mar. 31, 2025
Nov. 11, 2024
Apr. 17, 2024
The 2023 Term Loan        
Debt Instrument [Line Items]        
Debt instrument, maximum borrowing capacity $ 60,000      
Maximum borrowing capacity 30,000      
Options to borrow 10,000      
Debt instrument, additional maximum amount upon certain milestone achievements 10,000      
Debt instrument, additional maximum at discretion of lender 10,000      
Proceeds from term loans $ 20,000      
Debt instrument, variable interest rate, type [extensible enumeration] Prime Rate [Member]      
Debt instrument, interest rate, maximum stated percentage for each tranche borrowed 1.00%      
Debt instrument, balloon payment due $ 1,200      
Interest rate   11.10%    
Debt instrument, face amount   $ 13,400    
The 2023 Term Loan | Variable Rate Component Two        
Debt Instrument [Line Items]        
Debt instrument, basis spread on variable rate 0.50%      
Second Amendment Term Loan        
Debt Instrument [Line Items]        
Termination fee, amount     $ 750 $ 500
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Instrument [Line Items]    
Total debt, excluding unamortized debt issuance costs $ 12,973 $ 15,975
Less: unamortized debt issuance costs (25) (35)
Total debt 12,948 15,940
Less: current portion of debt (10,449) (10,943)
Total long-term debt $ 2,499 $ 4,997
Term Loan    
Debt Instrument [Line Items]    
Interest Rate 7.00% 7.00%
Total debt, excluding unamortized debt issuance costs $ 12,500 $ 15,000
Insurance premium financing    
Debt Instrument [Line Items]    
Interest Rate 8.30% 8.30%
Total debt, excluding unamortized debt issuance costs $ 473 $ 975
Total long-term debt    
Debt Instrument [Line Items]    
Total long-term debt $ 2,499 $ 4,997
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Disclosure [Abstract]    
2025 (9 months remaining) $ 7,951  
2026 4,997  
2027 0  
2028 0  
2029 0  
Thereafter 0  
Total debt $ 12,948 $ 15,940
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]    
Deferred revenue $ 100 $ 100
Deferred revenue, revenue recognized $ 18  
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Total product, rental, and service revenue $ 23,941 $ 18,433
Cell processing    
Disaggregation of Revenue [Line Items]    
Total product, rental, and service revenue 21,574 16,186
evo and Thaw    
Disaggregation of Revenue [Line Items]    
Total product, rental, and service revenue 725 557
evo and Thaw    
Disaggregation of Revenue [Line Items]    
Total product, rental, and service revenue 60 25
evo and Thaw    
Disaggregation of Revenue [Line Items]    
Total product, rental, and service revenue $ 1,582 $ 1,665
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details)
 3 Months Ended
Mar. 31, 2025
$ / shares
shares
Options  
Outstanding as of beginning of period (in shares) | shares 127,000
Exercised (in shares) | shares 0
Outstanding as of end of period (in shares) | shares 127,000
Stock options exercisable at end of period (in shares) | shares 127,000
Wtd. Avg. Exercise Price  
Outstanding as of beginning of period (in dollars per share) | $ / shares $ 2.19
Exercised (in dollars per share) | $ / shares 0
Outstanding as of end of period (in dollars per share) | $ / shares 2.19
Stock options exercisable at end of period (in dollars per share) | $ / shares $ 2.19
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 18, 2025
Mar. 08, 2024
Jan. 03, 2023
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Aggregate intrinsic value of exercisable service vesting-based stock options       $ 2,600,000        
Intrinsic value of service vesting-based awards exercised       $ 0        
Service based-vesting options granted (in shares)       0        
Weighted average remaining contractual life (year)       1 year 2 months 12 days        
Stock based compensation expense       $ 4,153,000   $ 4,128,000    
Vesting period (year)       4 years        
Options                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       $ 0        
Restricted Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       22,500,000        
Aggregate fair value of the service vesting-based awards granted       7,400,000        
Aggregate fair value of the service vesting-based awards that vested       4,500,000        
Stock based compensation expense       $ 2,700,000        
Period for recognition (year)       2 years 9 months 18 days        
Granted (in shares)       290,333        
Grant date fair value (in dollars per share)       $ 17.53 $ 16.00   $ 16.00  
Performance Shares                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       $ 2,700,000        
Service based-vesting options granted (in shares)       0        
Stock based compensation expense       $ 400,000 $ 400,000      
Period for recognition (year)       9 months 18 days        
Granted (in shares)   109,512            
Grant date fair value (in dollars per share)   $ 17.36            
Shares granted percentage       200.00% 100.00%      
Incremental cost       $ 1,600,000        
Performance Shares | Minimum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent)   0.00%            
Performance Shares | Maximum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent)   200.00%            
Market-based Restricted Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       12,000,000.0        
Stock based compensation expense       $ 1,000,000.0   1,100,000 $ 300,000 $ 1,600,000
Period for recognition (year)       1 year 6 months        
Granted (in shares)       451,801        
Grant date fair value (in dollars per share)       $ 33.02 $ 25.69   $ 25.69  
Measurement date with a maturity period (year)       2 years        
Dividend yield (percent) 0.00% 0.00% 0.00% 0.00%        
Aggregate fair value of the market-based awards granted       $ 6,300,000   6,300,000    
Aggregate fair value of the market-based awards that vested       $ 11,500,000   $ 5,100,000    
Market-based Restricted Stock | Minimum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent) 0.00% 0.00% 0.00%          
Market-based Restricted Stock | Maximum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent) 200.00% 200.00% 200.00%          
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) - $ / shares
 3 Months Ended
Jan. 03, 2023
Mar. 31, 2025
Restricted Stock    
Shares    
Outstanding as of beginning of period (in shares)   1,295,640
Granted (in shares)   290,333
Vested (in shares)   (171,379)
Forfeited (in shares)   (15,151)
Outstanding as of end of period (in shares)   1,399,443
Wtd. Avg. Grant Date Fair Value    
Outstanding as of beginning of period (in dollars per share)   $ 16.00
Granted (in dollars per share)   25.33
Vested (in dollars per share)   19.47
Forfeited (in dollars per share)   14.17
Outstanding as of end of period (in dollars per share)   $ 17.53
Market-based Restricted Stock    
Shares    
Outstanding as of beginning of period (in shares)   495,686
Granted (in shares)   451,801
Vested (in shares) (470,287) (470,287)
Outstanding as of end of period (in shares)   477,200
Wtd. Avg. Grant Date Fair Value    
Outstanding as of beginning of period (in dollars per share)   $ 25.69
Granted (in dollars per share)   32.91
Vested (in dollars per share)   25.19
Outstanding as of end of period (in dollars per share)   $ 33.02
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 18, 2025
Mar. 08, 2024
Jan. 03, 2023
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Stock based compensation expense       $ 4,153 $ 4,128    
Market-based Restricted Stock              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Target Shares (in shares) 250,252 239,464 268,738        
Fair value $ 9,800 $ 6,300 $ 6,800     $ 6,300 $ 6,800
Historical volatility (percent) 60.00% 80.00% 78.00%        
Risk-free interest rate (percent) 4.10% 4.60% 4.40%        
Dividend yield (percent) 0.00% 0.00% 0.00% 0.00%      
Attainment (percent)     175.00%        
Vested (in shares)     470,287 470,287      
Stock based compensation expense       $ 1,000 $ 1,100 $ 300 $ 1,600
Market-based Restricted Stock | Minimum              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Total shareholder return attainment (percent) 0.00% 0.00% 0.00%        
Market-based Restricted Stock | Maximum              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Total shareholder return attainment (percent) 200.00% 200.00% 200.00%        
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-based compensation - Schedule of Stock Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total $ 4,153 $ 4,128
Cost of revenue    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total 292 308
General and administrative costs    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total 2,967 2,833
Sales and marketing costs    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total 388 424
Research and development costs    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Total $ 506 $ 563
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.25.1
Income taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ 14,000.0 $ 17,000
Effective income tax rate reconciliation, percent (3.20%)  
Effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount $ (500,000)  
Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent (5.30%)  
Effective income tax rate reconciliation, at federal statutory income tax rate, percent 21.00%  
XML 92 R80.htm IDEA: XBRL DOCUMENT v3.25.1
Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Numerator:    
Net loss from continuing operations $ (448) $ (3,199)
Denominator:    
Weighted-average common shares issued, basic (in shares) 47,134,720 45,432,426
Weighted-average common shares outstanding, basic (in shares) 47,134,720 45,432,426
Weighted-average common shares outstanding, diluted (in shares) 47,134,720 45,432,426
Weighted-average common shares outstanding, diluted (in shares) 47,134,720 45,432,426
Basic loss from continuing operations per common share (in dollars per share) $ (0.01) $ (0.07)
Diluted loss from continuing operations per common share (in dollars per share) $ (0.01) $ (0.07)
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 1,232,836 1,070,693
XML 93 R81.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
reportable_segment
reporting_unit
Segment Reporting Information [Line Items]  
Number of reportable segments | reportable_segment 1
Number of reporting units | reporting_unit 1
Accounts Payable | Supplier Concentration Risk | One Supplier  
Segment Reporting Information [Line Items]  
Concentration risk, percent 17.00%
Accounts Payable | Supplier Concentration Risk | Two Supplier  
Segment Reporting Information [Line Items]  
Concentration risk, percent 16.00%
Accounts Payable | Supplier Concentration Risk | Three Supplier  
Segment Reporting Information [Line Items]  
Concentration risk, percent 11.00%
United States  
Segment Reporting Information [Line Items]  
Long-lived assets | $ $ 22,400
XML 94 R82.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details) - Customer Concentration Risk
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Customer A | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percent 18.00%    
Customer B | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percent     18.00%
Customer B | Revenue      
Concentration Risk [Line Items]      
Concentration risk, percent 18.00% 19.00%  
Customer C | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percent     21.00%
Customer C | Revenue      
Concentration Risk [Line Items]      
Concentration risk, percent 11.00%    
Customer D | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percent 13.00%    
XML 95 R83.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
CryoStor | Revenue | Product revenue concentration    
Concentration Risk [Line Items]    
Concentration risk, percent 77.00% 73.00%
XML 96 R84.htm IDEA: XBRL DOCUMENT v3.25.1
Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details) - Revenue - Revenue by customers' geographic locations
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Concentration Risk [Line Items]    
Concentration risk, percent 100.00% 100.00%
United States    
Concentration Risk [Line Items]    
Concentration risk, percent 81.00% 81.00%
Europe, Middle East, Africa (EMEA)    
Concentration Risk [Line Items]    
Concentration risk, percent 14.00% 14.00%
Other    
Concentration Risk [Line Items]    
Concentration risk, percent 5.00% 5.00%
XML 97 R85.htm IDEA: XBRL DOCUMENT v3.25.1
Employee benefit plan (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Retirement Benefits [Abstract]    
Defined contribution plan, employer matching contribution, percent of employees' gross pay 100.00%  
Defined contribution plan, employer discretionary contribution amount $ 0.2 $ 0.2
XML 98 R86.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent events (Details) - PanTHERA Cryosolutions Investment - Subsequent Event
$ in Millions
Apr. 04, 2025
USD ($)
shares
Subsequent Event [Line Items]  
Aggregate principal amount $ 22.7
Payments to acquire businesses, gross $ 10.0
Business acquisition, equity interest issued or issuable, number of shares | shares 213,361
Earnout payments $ 7.2
Earnout payment period 3 years
Business combination, acquisition related costs $ 0.2
EXCEL 99 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 100 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 101 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 103 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 198 394 1 false 78 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.biolifesolutions.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations Unaudited Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss Unaudited Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity Unaudited Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 9952158 - Disclosure - Organization and significant accounting policies Sheet http://www.biolifesolutions.com/role/Organizationandsignificantaccountingpolicies Organization and significant accounting policies Notes 8 false false R9.htm 9952159 - Disclosure - Discontinued operations Sheet http://www.biolifesolutions.com/role/Discontinuedoperations Discontinued operations Notes 9 false false R10.htm 9952160 - Disclosure - Fair value measurement Sheet http://www.biolifesolutions.com/role/Fairvaluemeasurement Fair value measurement Notes 10 false false R11.htm 9952161 - Disclosure - Investments Sheet http://www.biolifesolutions.com/role/Investments Investments Notes 11 false false R12.htm 9952162 - Disclosure - Inventories Sheet http://www.biolifesolutions.com/role/Inventories Inventories Notes 12 false false R13.htm 9952163 - Disclosure - Leases Sheet http://www.biolifesolutions.com/role/Leases Leases Notes 13 false false R14.htm 9952164 - Disclosure - Assets held for rent Sheet http://www.biolifesolutions.com/role/Assetsheldforrent Assets held for rent Notes 14 false false R15.htm 9952165 - Disclosure - Property and equipment Sheet http://www.biolifesolutions.com/role/Propertyandequipment Property and equipment Notes 15 false false R16.htm 9952166 - Disclosure - Goodwill and intangible assets Sheet http://www.biolifesolutions.com/role/Goodwillandintangibleassets Goodwill and intangible assets Notes 16 false false R17.htm 9952167 - Disclosure - Accrued expenses and other current liabilities Sheet http://www.biolifesolutions.com/role/Accruedexpensesandothercurrentliabilities Accrued expenses and other current liabilities Notes 17 false false R18.htm 9952168 - Disclosure - Commitments and contingencies Sheet http://www.biolifesolutions.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 18 false false R19.htm 9952169 - Disclosure - Long-term debt Sheet http://www.biolifesolutions.com/role/Longtermdebt Long-term debt Notes 19 false false R20.htm 9952170 - Disclosure - Revenue Sheet http://www.biolifesolutions.com/role/Revenue Revenue Notes 20 false false R21.htm 9952171 - Disclosure - Stock-based compensation Sheet http://www.biolifesolutions.com/role/Stockbasedcompensation Stock-based compensation Notes 21 false false R22.htm 9952172 - Disclosure - Income taxes Sheet http://www.biolifesolutions.com/role/Incometaxes Income taxes Notes 22 false false R23.htm 9952173 - Disclosure - Net loss from continuing operations per common share Sheet http://www.biolifesolutions.com/role/Netlossfromcontinuingoperationspercommonshare Net loss from continuing operations per common share Notes 23 false false R24.htm 9952174 - Disclosure - Segment, customer, and geographic information Sheet http://www.biolifesolutions.com/role/Segmentcustomerandgeographicinformation Segment, customer, and geographic information Notes 24 false false R25.htm 9952175 - Disclosure - Employee benefit plan Sheet http://www.biolifesolutions.com/role/Employeebenefitplan Employee benefit plan Notes 25 false false R26.htm 9952176 - Disclosure - Subsequent events Sheet http://www.biolifesolutions.com/role/Subsequentevents Subsequent events Notes 26 false false R27.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 27 false false R28.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 28 false false R29.htm 9955511 - Disclosure - Organization and significant accounting policies (Policies) Sheet http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies Organization and significant accounting policies (Policies) Policies 29 false false R30.htm 9955512 - Disclosure - Discontinued operations (Tables) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsTables Discontinued operations (Tables) Tables http://www.biolifesolutions.com/role/Discontinuedoperations 30 false false R31.htm 9955513 - Disclosure - Fair value measurement (Tables) Sheet http://www.biolifesolutions.com/role/FairvaluemeasurementTables Fair value measurement (Tables) Tables http://www.biolifesolutions.com/role/Fairvaluemeasurement 31 false false R32.htm 9955514 - Disclosure - Investments (Tables) Sheet http://www.biolifesolutions.com/role/InvestmentsTables Investments (Tables) Tables http://www.biolifesolutions.com/role/Investments 32 false false R33.htm 9955515 - Disclosure - Inventories (Tables) Sheet http://www.biolifesolutions.com/role/InventoriesTables Inventories (Tables) Tables http://www.biolifesolutions.com/role/Inventories 33 false false R34.htm 9955516 - Disclosure - Leases (Tables) Sheet http://www.biolifesolutions.com/role/LeasesTables Leases (Tables) Tables http://www.biolifesolutions.com/role/Leases 34 false false R35.htm 9955517 - Disclosure - Assets held for rent (Tables) Sheet http://www.biolifesolutions.com/role/AssetsheldforrentTables Assets held for rent (Tables) Tables http://www.biolifesolutions.com/role/Assetsheldforrent 35 false false R36.htm 9955518 - Disclosure - Property and equipment (Tables) Sheet http://www.biolifesolutions.com/role/PropertyandequipmentTables Property and equipment (Tables) Tables http://www.biolifesolutions.com/role/Propertyandequipment 36 false false R37.htm 9955519 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://www.biolifesolutions.com/role/GoodwillandintangibleassetsTables Goodwill and intangible assets (Tables) Tables http://www.biolifesolutions.com/role/Goodwillandintangibleassets 37 false false R38.htm 9955520 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesTables Accrued expenses and other current liabilities (Tables) Tables http://www.biolifesolutions.com/role/Accruedexpensesandothercurrentliabilities 38 false false R39.htm 9955521 - Disclosure - Long-term debt (Tables) Sheet http://www.biolifesolutions.com/role/LongtermdebtTables Long-term debt (Tables) Tables http://www.biolifesolutions.com/role/Longtermdebt 39 false false R40.htm 9955522 - Disclosure - Revenue (Tables) Sheet http://www.biolifesolutions.com/role/RevenueTables Revenue (Tables) Tables http://www.biolifesolutions.com/role/Revenue 40 false false R41.htm 9955523 - Disclosure - Stock-based compensation (Tables) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://www.biolifesolutions.com/role/Stockbasedcompensation 41 false false R42.htm 9955524 - Disclosure - Net loss from continuing operations per common share (Tables) Sheet http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareTables Net loss from continuing operations per common share (Tables) Tables http://www.biolifesolutions.com/role/Netlossfromcontinuingoperationspercommonshare 42 false false R43.htm 9955525 - Disclosure - Segment, customer, and geographic information (Tables) Sheet http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationTables Segment, customer, and geographic information (Tables) Tables http://www.biolifesolutions.com/role/Segmentcustomerandgeographicinformation 43 false false R44.htm 9955526 - Disclosure - Organization and significant accounting policies (Details) Sheet http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesDetails Organization and significant accounting policies (Details) Details http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies 44 false false R45.htm 9955527 - Disclosure - Discontinued operations - Narrative (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails Discontinued operations - Narrative (Details) Details 45 false false R46.htm 9955528 - Disclosure - Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details) Details 46 false false R47.htm 9955529 - Disclosure - Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details) Details 47 false false R48.htm 9955530 - Disclosure - Discontinued operations - Schedule of Gain on Disposal (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails Discontinued operations - Schedule of Gain on Disposal (Details) Details 48 false false R49.htm 9955531 - Disclosure - Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details) Details 49 false false R50.htm 9955532 - Disclosure - Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details) Sheet http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details) Details 50 false false R51.htm 9955533 - Disclosure - Fair value measurement (Details) Sheet http://www.biolifesolutions.com/role/FairvaluemeasurementDetails Fair value measurement (Details) Details http://www.biolifesolutions.com/role/FairvaluemeasurementTables 51 false false R52.htm 9955534 - Disclosure - Investments - Schedule of Available-for-Sale Marketable Securities (Details) Sheet http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails Investments - Schedule of Available-for-Sale Marketable Securities (Details) Details 52 false false R53.htm 9955535 - Disclosure - Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details) Sheet http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details) Details 53 false false R54.htm 9955536 - Disclosure - Investments - Narrative (Details) Sheet http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 54 false false R55.htm 9955537 - Disclosure - Inventories (Details) Sheet http://www.biolifesolutions.com/role/InventoriesDetails Inventories (Details) Details http://www.biolifesolutions.com/role/InventoriesTables 55 false false R56.htm 9955538 - Disclosure - Leases - Narrative (Details) Sheet http://www.biolifesolutions.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 56 false false R57.htm 9955539 - Disclosure - Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details) Sheet http://www.biolifesolutions.com/role/LeasesScheduleofOperatingandFinanceLeaseTermsandDiscountRatesDetails Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details) Details 57 false false R58.htm 9955540 - Disclosure - Leases - Schedule of Lease Expense (Details) Sheet http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails Leases - Schedule of Lease Expense (Details) Details 58 false false R59.htm 9955541 - Disclosure - Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) Sheet http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details) Details 59 false false R60.htm 9955542 - Disclosure - Assets held for rent - Schedule of Assets Held for Rent (Details) Sheet http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails Assets held for rent - Schedule of Assets Held for Rent (Details) Details 60 false false R61.htm 9955543 - Disclosure - Assets held for rent - Narrative (Details) Sheet http://www.biolifesolutions.com/role/AssetsheldforrentNarrativeDetails Assets held for rent - Narrative (Details) Details 61 false false R62.htm 9955544 - Disclosure - Property and equipment - Schedule of Property and Equipment (Details) Sheet http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails Property and equipment - Schedule of Property and Equipment (Details) Details 62 false false R63.htm 9955545 - Disclosure - Property and equipment - Narrative (Details) Sheet http://www.biolifesolutions.com/role/PropertyandequipmentNarrativeDetails Property and equipment - Narrative (Details) Details 63 false false R64.htm 9955546 - Disclosure - Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) Details 64 false false R65.htm 9955547 - Disclosure - Goodwill and intangible assets - Narrative (Details) Sheet http://www.biolifesolutions.com/role/GoodwillandintangibleassetsNarrativeDetails Goodwill and intangible assets - Narrative (Details) Details 65 false false R66.htm 9955548 - Disclosure - Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) Sheet http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) Details 66 false false R67.htm 9955549 - Disclosure - Accrued expenses and other current liabilities (Details) Sheet http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails Accrued expenses and other current liabilities (Details) Details http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesTables 67 false false R68.htm 9955550 - Disclosure - Commitments and contingencies (Details) Sheet http://www.biolifesolutions.com/role/CommitmentsandcontingenciesDetails Commitments and contingencies (Details) Details http://www.biolifesolutions.com/role/Commitmentsandcontingencies 68 false false R69.htm 9955551 - Disclosure - Long-term debt - Narrative (Details) Sheet http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails Long-term debt - Narrative (Details) Details 69 false false R70.htm 9955552 - Disclosure - Long-term debt - Schedule of Debt (Details) Sheet http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails Long-term debt - Schedule of Debt (Details) Details 70 false false R71.htm 9955553 - Disclosure - Long-term debt - Schedule of Maturities of Long-Term Debt (Details) Sheet http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails Long-term debt - Schedule of Maturities of Long-Term Debt (Details) Details 71 false false R72.htm 9955554 - Disclosure - Revenue - Narrative (Details) Sheet http://www.biolifesolutions.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 72 false false R73.htm 9955555 - Disclosure - Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) Sheet http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) Details 73 false false R74.htm 9955556 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) Details 74 false false R75.htm 9955557 - Disclosure - Stock-based compensation - Narrative (Details) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation - Narrative (Details) Details 75 false false R76.htm 9955558 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) Details 76 false false R77.htm 9955559 - Disclosure - Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details) Details 77 false false R78.htm 9955560 - Disclosure - Stock-based compensation - Schedule of Stock Compensation Expense (Details) Sheet http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails Stock-based compensation - Schedule of Stock Compensation Expense (Details) Details 78 false false R79.htm 9955561 - Disclosure - Income taxes (Details) Sheet http://www.biolifesolutions.com/role/IncometaxesDetails Income taxes (Details) Details http://www.biolifesolutions.com/role/Incometaxes 79 false false R80.htm 9955562 - Disclosure - Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details) Sheet http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details) Details 80 false false R81.htm 9955563 - Disclosure - Segment, customer, and geographic information - Narrative (Details) Sheet http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails Segment, customer, and geographic information - Narrative (Details) Details 81 false false R82.htm 9955564 - Disclosure - Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details) Sheet http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details) Details 82 false false R83.htm 9955565 - Disclosure - Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details) Sheet http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details) Details 83 false false R84.htm 9955566 - Disclosure - Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details) Sheet http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details) Details 84 false false R85.htm 9955567 - Disclosure - Employee benefit plan (Details) Sheet http://www.biolifesolutions.com/role/EmployeebenefitplanDetails Employee benefit plan (Details) Details http://www.biolifesolutions.com/role/Employeebenefitplan 85 false false R86.htm 9955568 - Disclosure - Subsequent events (Details) Sheet http://www.biolifesolutions.com/role/SubsequenteventsDetails Subsequent events (Details) Details http://www.biolifesolutions.com/role/Subsequentevents 86 false false All Reports Book All Reports blfs-20250331.htm blfs-20250331.xsd blfs-20250331_cal.xml blfs-20250331_def.xml blfs-20250331_lab.xml blfs-20250331_pre.xml blfs-20250331_g1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 106 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "blfs-20250331.htm": { "nsprefix": "blfs", "nsuri": "http://www.biolifesolutions.com/20250331", "dts": { "inline": { "local": [ "blfs-20250331.htm" ] }, "schema": { "local": [ "blfs-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "blfs-20250331_cal.xml" ] }, "definitionLink": { "local": [ "blfs-20250331_def.xml" ] }, "labelLink": { "local": [ "blfs-20250331_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20250331_pre.xml" ] } }, "keyStandard": 316, "keyCustom": 78, "axisStandard": 27, "axisCustom": 1, "memberStandard": 46, "memberCustom": 31, "hidden": { "total": 9, "http://fasb.org/us-gaap/2024": 4, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 198, "entityCount": 1, "segmentCount": 78, "elementCount": 714, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 750, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.biolifesolutions.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R5": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952155 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R6": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity", "longName": "9952156 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Unaudited Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-28", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows", "longName": "9952157 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R8": { "role": "http://www.biolifesolutions.com/role/Organizationandsignificantaccountingpolicies", "longName": "9952158 - Disclosure - Organization and significant accounting policies", "shortName": "Organization and significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.biolifesolutions.com/role/Discontinuedoperations", "longName": "9952159 - Disclosure - Discontinued operations", "shortName": "Discontinued operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.biolifesolutions.com/role/Fairvaluemeasurement", "longName": "9952160 - Disclosure - Fair value measurement", "shortName": "Fair value measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.biolifesolutions.com/role/Investments", "longName": "9952161 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.biolifesolutions.com/role/Inventories", "longName": "9952162 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.biolifesolutions.com/role/Leases", "longName": "9952163 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.biolifesolutions.com/role/Assetsheldforrent", "longName": "9952164 - Disclosure - Assets held for rent", "shortName": "Assets held for rent", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "blfs:AssetsHeldForRentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blfs:AssetsHeldForRentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.biolifesolutions.com/role/Propertyandequipment", "longName": "9952165 - Disclosure - Property and equipment", "shortName": "Property and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.biolifesolutions.com/role/Goodwillandintangibleassets", "longName": "9952166 - Disclosure - Goodwill and intangible assets", "shortName": "Goodwill and intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.biolifesolutions.com/role/Accruedexpensesandothercurrentliabilities", "longName": "9952167 - Disclosure - Accrued expenses and other current liabilities", "shortName": "Accrued expenses and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.biolifesolutions.com/role/Commitmentsandcontingencies", "longName": "9952168 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.biolifesolutions.com/role/Longtermdebt", "longName": "9952169 - Disclosure - Long-term debt", "shortName": "Long-term debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.biolifesolutions.com/role/Revenue", "longName": "9952170 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.biolifesolutions.com/role/Stockbasedcompensation", "longName": "9952171 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.biolifesolutions.com/role/Incometaxes", "longName": "9952172 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.biolifesolutions.com/role/Netlossfromcontinuingoperationspercommonshare", "longName": "9952173 - Disclosure - Net loss from continuing operations per common share", "shortName": "Net loss from continuing operations per common share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.biolifesolutions.com/role/Segmentcustomerandgeographicinformation", "longName": "9952174 - Disclosure - Segment, customer, and geographic information", "shortName": "Segment, customer, and geographic information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.biolifesolutions.com/role/Employeebenefitplan", "longName": "9952175 - Disclosure - Employee benefit plan", "shortName": "Employee benefit plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.biolifesolutions.com/role/Subsequentevents", "longName": "9952176 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies", "longName": "9955511 - Disclosure - Organization and significant accounting policies (Policies)", "shortName": "Organization and significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsTables", "longName": "9955512 - Disclosure - Discontinued operations (Tables)", "shortName": "Discontinued operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.biolifesolutions.com/role/FairvaluemeasurementTables", "longName": "9955513 - Disclosure - Fair value measurement (Tables)", "shortName": "Fair value measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.biolifesolutions.com/role/InvestmentsTables", "longName": "9955514 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.biolifesolutions.com/role/InventoriesTables", "longName": "9955515 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.biolifesolutions.com/role/LeasesTables", "longName": "9955516 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "blfs:LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blfs:LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.biolifesolutions.com/role/AssetsheldforrentTables", "longName": "9955517 - Disclosure - Assets held for rent (Tables)", "shortName": "Assets held for rent (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "blfs:ScheduleOfAssetsHeldForRentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blfs:ScheduleOfAssetsHeldForRentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.biolifesolutions.com/role/PropertyandequipmentTables", "longName": "9955518 - Disclosure - Property and equipment (Tables)", "shortName": "Property and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsTables", "longName": "9955519 - Disclosure - Goodwill and intangible assets (Tables)", "shortName": "Goodwill and intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesTables", "longName": "9955520 - Disclosure - Accrued expenses and other current liabilities (Tables)", "shortName": "Accrued expenses and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.biolifesolutions.com/role/LongtermdebtTables", "longName": "9955521 - Disclosure - Long-term debt (Tables)", "shortName": "Long-term debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.biolifesolutions.com/role/RevenueTables", "longName": "9955522 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "blfs:RevenuesByProductLineTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blfs:RevenuesByProductLineTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationTables", "longName": "9955523 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareTables", "longName": "9955524 - Disclosure - Net loss from continuing operations per common share (Tables)", "shortName": "Net loss from continuing operations per common share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationTables", "longName": "9955525 - Disclosure - Segment, customer, and geographic information (Tables)", "shortName": "Segment, customer, and geographic information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesDetails", "longName": "9955526 - Disclosure - Organization and significant accounting policies (Details)", "shortName": "Organization and significant accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportable_segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R45": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "longName": "9955527 - Disclosure - Discontinued operations - Narrative (Details)", "shortName": "Discontinued operations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportable_segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "blfs:DiscontinuedOperationsOutstandingMinimumLeasePaymentsForTheLeaseTerminations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R46": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "longName": "9955528 - Disclosure - Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details)", "shortName": "Discontinued operations - Schedule of Loss on Disposal of Global Cooling (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-46", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationSellingPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationSellingPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails", "longName": "9955529 - Disclosure - Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details)", "shortName": "Discontinued operations - Schedule of RIF and Stock Compensation Expense Acceleration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherRestructuringCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherRestructuringCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "longName": "9955530 - Disclosure - Discontinued operations - Schedule of Gain on Disposal (Details)", "shortName": "Discontinued operations - Schedule of Gain on Disposal (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-53", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationCashProceedsFromBuyer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationCashProceedsFromBuyer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "longName": "9955531 - Disclosure - Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details)", "shortName": "Discontinued operations - Schedule of Key Components of Loss from Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-63", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R50": { "role": "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails", "longName": "9955532 - Disclosure - Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details)", "shortName": "Discontinued operations - Schedule of Noncash Related Costs For Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-63", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-63", "name": "blfs:DisposalGroupIncludingDiscontinuedOperationDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "longName": "9955533 - Disclosure - Fair value measurement (Details)", "shortName": "Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R52": { "role": "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "longName": "9955534 - Disclosure - Investments - Schedule of Available-for-Sale Marketable Securities (Details)", "shortName": "Investments - Schedule of Available-for-Sale Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "blfs:DebtSecuritiesAvailableforsaleUnrealizedGainCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R53": { "role": "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails", "longName": "9955535 - Disclosure - Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details)", "shortName": "Investments - Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "longName": "9955536 - Disclosure - Investments - Narrative (Details)", "shortName": "Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-105", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R55": { "role": "http://www.biolifesolutions.com/role/InventoriesDetails", "longName": "9955537 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.biolifesolutions.com/role/LeasesNarrativeDetails", "longName": "9955538 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-107", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.biolifesolutions.com/role/LeasesScheduleofOperatingandFinanceLeaseTermsandDiscountRatesDetails", "longName": "9955539 - Disclosure - Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)", "shortName": "Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "blfs:LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "blfs:LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails", "longName": "9955540 - Disclosure - Leases - Schedule of Lease Expense (Details)", "shortName": "Leases - Schedule of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails", "longName": "9955541 - Disclosure - Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details)", "shortName": "Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails", "longName": "9955542 - Disclosure - Assets held for rent - Schedule of Assets Held for Rent (Details)", "shortName": "Assets held for rent - Schedule of Assets Held for Rent (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "blfs:ShippersPlacedInService", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "blfs:ScheduleOfAssetsHeldForRentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "blfs:ShippersPlacedInService", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "blfs:ScheduleOfAssetsHeldForRentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.biolifesolutions.com/role/AssetsheldforrentNarrativeDetails", "longName": "9955543 - Disclosure - Assets held for rent - Narrative (Details)", "shortName": "Assets held for rent - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "blfs:AssetsHeldForRentDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "blfs:AssetsHeldForRentDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails", "longName": "9955544 - Disclosure - Property and equipment - Schedule of Property and Equipment (Details)", "shortName": "Property and equipment - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.biolifesolutions.com/role/PropertyandequipmentNarrativeDetails", "longName": "9955545 - Disclosure - Property and equipment - Narrative (Details)", "shortName": "Property and equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails", "longName": "9955546 - Disclosure - Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details)", "shortName": "Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsNarrativeDetails", "longName": "9955547 - Disclosure - Goodwill and intangible assets - Narrative (Details)", "shortName": "Goodwill and intangible assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails", "longName": "9955548 - Disclosure - Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details)", "shortName": "Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails", "longName": "9955549 - Disclosure - Accrued expenses and other current liabilities (Details)", "shortName": "Accrued expenses and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.biolifesolutions.com/role/CommitmentsandcontingenciesDetails", "longName": "9955550 - Disclosure - Commitments and contingencies (Details)", "shortName": "Commitments and contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyPendingClaimsNumber", "unitRef": "lawsuit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyPendingClaimsNumber", "unitRef": "lawsuit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "longName": "9955551 - Disclosure - Long-term debt - Narrative (Details)", "shortName": "Long-term debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-124", "name": "blfs:DebtInstrumentMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "blfs:DebtInstrumentMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails", "longName": "9955552 - Disclosure - Long-term debt - Schedule of Debt (Details)", "shortName": "Long-term debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails", "longName": "9955553 - Disclosure - Long-term debt - Schedule of Maturities of Long-Term Debt (Details)", "shortName": "Long-term debt - Schedule of Maturities of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.biolifesolutions.com/role/RevenueNarrativeDetails", "longName": "9955554 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:ContractWithCustomerLiability", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:ContractWithCustomerLiability", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails", "longName": "9955555 - Disclosure - Revenue - Schedule of Bioproduction Tools and Service Revenues (Details)", "shortName": "Revenue - Schedule of Bioproduction Tools and Service Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "blfs:RevenuesByProductLineTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R74": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails", "longName": "9955556 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details)", "shortName": "Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "longName": "9955557 - Disclosure - Stock-based compensation - Narrative (Details)", "shortName": "Stock-based compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "longName": "9955558 - Disclosure - Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details)", "shortName": "Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-145", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "longName": "9955559 - Disclosure - Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details)", "shortName": "Stock-based compensation - Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-164", "name": "blfs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTargetShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "blfs:ScheduleOfShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R78": { "role": "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails", "longName": "9955560 - Disclosure - Stock-based compensation - Schedule of Stock Compensation Expense (Details)", "shortName": "Stock-based compensation - Schedule of Stock Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R79": { "role": "http://www.biolifesolutions.com/role/IncometaxesDetails", "longName": "9955561 - Disclosure - Income taxes (Details)", "shortName": "Income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R80": { "role": "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "longName": "9955562 - Disclosure - Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details)", "shortName": "Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R81": { "role": "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "longName": "9955563 - Disclosure - Segment, customer, and geographic information - Narrative (Details)", "shortName": "Segment, customer, and geographic information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "reportable_segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "unique": true } }, "R82": { "role": "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "longName": "9955564 - Disclosure - Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details)", "shortName": "Segment, customer, and geographic information - Schedule of Concentrations of Credit Risk and Business Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-178", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "longName": "9955565 - Disclosure - Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details)", "shortName": "Segment, customer, and geographic information - Schedule of Product Revenue Concentration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-185", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-185", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails", "longName": "9955566 - Disclosure - Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details)", "shortName": "Segment, customer, and geographic information - Schedule of Revenue by Geographic Areas (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-193", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.biolifesolutions.com/role/EmployeebenefitplanDetails", "longName": "9955567 - Disclosure - Employee benefit plan (Details)", "shortName": "Employee benefit plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.biolifesolutions.com/role/SubsequenteventsDetails", "longName": "9955568 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-105", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "blfs-20250331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Accruedexpensesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r483" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r96", "r862" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r154", "r1111" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r97" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r784" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, trade, net of allowance for credit losses of $117 and $153 as of March\u00a031, 2025 and December\u00a031, 2024, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of available-for-sale investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r130" ] }, "blfs_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "blfs_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r98" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r52", "r189", "r665" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss, net of taxes", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r26", "r27", "r115", "r198", "r662", "r690", "r691" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r14", "r27", "r519", "r522", "r576", "r686", "r687", "r999", "r1000", "r1001", "r1011", "r1012", "r1013", "r1014" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r928" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r107" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r701", "r1011", "r1012", "r1013", "r1014", "r1081", "r1148" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r941" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r941" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r58", "r59", "r446" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r974" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r900", "r910", "r920", "r952" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r903", "r913", "r923", "r955" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r975" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r941" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r948" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r904", "r914", "r924", "r948", "r956", "r960", "r968" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r966" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation expense", "verboseLabel": "Total", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r475", "r481" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r199", "r296", "r337" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsNarrativeDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r355", "r362", "r827" ] }, "blfs_AmortizationOfIntangibleAssetsConsolidatedBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "AmortizationOfIntangibleAssetsConsolidatedBasis", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of intangible assets", "label": "Amortization Of Intangible Assets, Consolidated Basis", "documentation": "Amortization Of Intangible Assets, Consolidated Basis" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r254" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r152", "r164", "r192", "r220", "r258", "r266", "r283", "r286", "r334", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r514", "r516", "r550", "r657", "r738", "r818", "r819", "r862", "r891", "r1072", "r1073", "r1101" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r184", "r201", "r220", "r334", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r514", "r516", "r550", "r862", "r1072", "r1073", "r1101" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r529", "r530", "r849" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "blfs_AssetsHeldForRentDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "AssetsHeldForRentDepreciation", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for rent, depreciation expense", "label": "Assets Held For Rent, Depreciation", "documentation": "The amount of depreciation expenses recognized for assets held for rent." } } }, "auth_ref": [] }, "blfs_AssetsHeldForRentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "AssetsHeldForRentNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for rent, net", "label": "Assets Held For Rent, Net", "documentation": "Amount of assets held for rent classified as noncurrent." } } }, "auth_ref": [] }, "blfs_AssetsHeldForRentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "AssetsHeldForRentTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Assetsheldforrent" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for rent", "label": "Assets Held For Rent [Text Block]", "documentation": "The entire disclosure for assets held for rent." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total marketable securities, Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r303" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total marketable securities, Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r304" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r300", "r343", "r656" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale securities", "terseLabel": "Estimated Fair Value, Total marketable securities", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r301", "r343", "r529", "r649", "r849", "r853", "r1025", "r1085", "r1086", "r1087" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, current portion", "verboseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r298", "r343" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r187", "r298", "r343" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r963" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r964" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r959" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r961" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r960" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Organizationandsignificantaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and significant accounting policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r131" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r360", "r509", "r844", "r845" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r61", "r63", "r356", "r357", "r358", "r359", "r360", "r509", "r844", "r845" ] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, equity interest issued or issuable, number of shares", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r149" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r62" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, acquisition related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r13" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout payments", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r0", "r1", "r67", "r511" ] }, "blfs_CBSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CBSMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CBS", "label": "CBS [Member]", "documentation": "CBS" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment not yet paid", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r33", "r34", "r35" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reported Value Measurement", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r70", "r71" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r32", "r186", "r800" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r186" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1083", "r1084" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and available-for-sale securities", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r998" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2013 beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2013 end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r32", "r128", "r219" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r128" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r939" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r936" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r934" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r180", "r195", "r196", "r197", "r220", "r243", "r244", "r251", "r253", "r260", "r261", "r334", "r383", "r385", "r386", "r387", "r390", "r391", "r411", "r412", "r414", "r415", "r417", "r550", "r695", "r696", "r697", "r698", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r726", "r748", "r766", "r778", "r779", "r780", "r781", "r782", "r978", "r1006", "r1016" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r940" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r940" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 11)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r103", "r156", "r659", "r725" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r141", "r376", "r377", "r785", "r1061", "r1067" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r881", "r882", "r883", "r885", "r886", "r887", "r888", "r1011", "r1012", "r1014", "r1081", "r1146", "r1148" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r106" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r106", "r726" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r106" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Beginning balance, common stock, outstanding (in shares)", "periodEndLabel": "Ending balance, common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r106", "r726", "r744", "r1148", "r1149" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized, 47,548,431 and 46,906,765 shares issued and outstanding, respectively, as of March\u00a031, 2025 and December\u00a031, 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r106", "r661", "r862" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r945" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r944" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r946" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r943" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "blfs_CompetitionCovenantPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CompetitionCovenantPeriod", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Competition covenant period", "label": "Competition Covenant Period", "documentation": "Competition Covenant Period" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r28", "r205", "r207", "r211", "r650", "r671", "r672" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r42", "r44", "r72", "r73", "r294", "r784" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r42", "r44", "r72", "r73", "r294", "r693", "r784" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r42", "r44", "r72", "r73", "r294", "r784", "r983" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r784" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percent", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r42", "r44", "r72", "r73", "r294" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r41", "r42", "r44", "r45", "r72", "r151", "r784" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r42", "r44", "r72", "r73", "r294", "r784" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r69", "r808" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in-progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r419", "r420", "r431" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "blfs_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r419", "r420", "r431" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r432" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r841", "r843", "r849", "r863", "r879", "r1143" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods and services sold (exclusive of intangible assets amortization)", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r120", "r121", "r614" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r126" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r222", "r223", "r395", "r413", "r577", "r597", "r655", "r805", "r807" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "blfs_CryoStorProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CryoStorProductsMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CryoStor", "label": "CryoStor Products [Member]", "documentation": "Information pertaining to CryoStor products." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "blfs_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CustomerAMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer A", "label": "Customer A [Member]", "documentation": "Information about customer A." } } }, "auth_ref": [] }, "blfs_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CustomerBMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer B", "label": "Customer B [Member]", "documentation": "Represents information about major customer B." } } }, "auth_ref": [] }, "blfs_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CustomerCMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer C", "label": "Customer C [Member]", "documentation": "Represents information about major customer C." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r132", "r294" ] }, "blfs_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "CustomerDMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer D", "label": "Customer D [Member]", "documentation": "Customer D" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r66", "r1049", "r1050", "r1051", "r1052", "r1054", "r1056", "r1059", "r1060" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "blfs_DebtInstrumentAdditionalMaximumAmountUponCertainMilestoneAchievements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentAdditionalMaximumAmountUponCertainMilestoneAchievements", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, additional maximum amount upon certain milestone achievements", "label": "Debt Instrument, Additional Maximum Amount Upon Certain Milestone Achievements", "documentation": "Amount of additional maximum capacity upon achievement of certain milestones." } } }, "auth_ref": [] }, "blfs_DebtInstrumentAdditionalMaximumAmountWithinNineMonthsAfterClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentAdditionalMaximumAmountWithinNineMonthsAfterClosing", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options to borrow", "label": "Debt Instrument, Additional Maximum Amount Within Nine Months After Closing", "documentation": "The maximum amount of additional borrowing capacity within 9 months of closing." } } }, "auth_ref": [] }, "blfs_DebtInstrumentAdditionalMaximumAtDiscretionOfLender": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentAdditionalMaximumAtDiscretionOfLender", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, additional maximum at discretion of lender", "label": "Debt Instrument, Additional Maximum At Discretion of Lender", "documentation": "Amount of additional maximum borrowing at the discretion of the lender." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r97", "r98", "r153", "r155", "r224", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r828", "r829", "r830", "r831", "r832", "r860", "r1007", "r1062", "r1063", "r1064", "r1095", "r1096" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt, excluding unamortized debt issuance costs", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r155", "r409" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r392", "r559", "r560", "r829", "r830", "r860" ] }, "blfs_DebtInstrumentInterestRateMaximumStatedPercentageForEachTrancheBorrowed": { "xbrltype": "percentItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentInterestRateMaximumStatedPercentageForEachTrancheBorrowed", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, maximum stated percentage for each tranche borrowed", "label": "Debt Instrument, Interest Rate, Maximum Stated Percentage for Each Tranche Borrowed", "documentation": "Represents maximum stated interest rate for each tranche borrowed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate", "terseLabel": "Interest Rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r100", "r393" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r828", "r829", "r830", "r831", "r832", "r860", "r1007", "r1095", "r1096" ] }, "blfs_DebtInstrumentMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, maximum borrowing capacity", "label": "Debt Instrument, Maximum Borrowing Capacity", "documentation": "Represents maximum borrowing capacity." } } }, "auth_ref": [] }, "blfs_DebtInstrumentMaximumBorrowingCapacityAtClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentMaximumBorrowingCapacityAtClosing", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Debt Instrument, Maximum Borrowing Capacity At Closing", "documentation": "Represents maximum borrowing capacity at closing." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r224", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r828", "r829", "r830", "r831", "r832", "r860", "r1007", "r1062", "r1063", "r1064", "r1095", "r1096" ] }, "blfs_DebtInstrumentNonRefundableTerminationFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtInstrumentNonRefundableTerminationFeeAmount", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee, amount", "label": "Debt Instrument, Non-Refundable Termination Fee, Amount", "documentation": "Debt Instrument, Non-Refundable Termination Fee, Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, balloon payment due", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r20", "r53", "r54", "r75", "r143", "r144", "r224", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r828", "r829", "r830", "r831", "r832", "r860", "r1007", "r1095", "r1096" ] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, variable interest rate, type [extensible enumeration]", "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": [ "r654" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities, long-term", "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r306", "r343", "r344" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost, current portion", "verboseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r343", "r1026" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost, long term", "verboseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r343", "r1026" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r168", "r348", "r825" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-Sale Marketable Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on available-for-sale securities", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1029", "r1030" ] }, "blfs_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized Losses, current portion", "label": "Debt Securities, Available-for-Sale, Unrealized Loss, Current", "documentation": "Current portion of amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [] }, "blfs_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized Losses, long term", "label": "Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent", "documentation": "The non-current portion of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r166", "r346", "r825" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r167", "r347" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r165", "r825", "r1043" ] }, "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]" } } }, "auth_ref": [] }, "blfs_DebtSecuritiesAvailableforsaleUnrealizedGainCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized Gains, current portion", "label": "Debt Securities, Available-for-Sale, Unrealized Gain, Current", "documentation": "The unrealized gain of debt securities available-for-sale classified as current." } } }, "auth_ref": [] }, "blfs_DebtSecuritiesAvailableforsaleUnrealizedGainNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainNoncurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized Gains, long term", "label": "Debt Securities, Available-for-Sale, Unrealized Gain, Noncurrent", "documentation": "The amount of unrealized gain of debt securities available-for-sale classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "blfs_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Deferred Compensation Liability, Current", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [ "r55", "r146" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1075", "r1094", "r1095", "r1096" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax expense", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r177", "r1009" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r486", "r487", "r658" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/EmployeebenefitplanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, employer discretionary contribution amount", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.biolifesolutions.com/role/EmployeebenefitplanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, employer matching contribution, percent of employees' gross pay", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Employeebenefitplan" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit plan", "label": "Defined Contribution Plan [Text Block]", "documentation": "The entire disclosure for defined contribution plan." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deposits and other assets", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r995" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r51" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r258", "r269", "r286", "r818", "r819" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r430", "r834", "r835", "r836", "r837", "r838", "r839", "r840" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r430", "r834", "r835", "r836", "r837", "r838", "r839", "r840" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Stockbasedcompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r444", "r448", "r476", "r477", "r480", "r847" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "blfs_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationCurrencyTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationCurrencyTranslationAdjustment", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Release of Global Cooling currency translation adjustment", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Currency Translation Adjustment", "documentation": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Currency Translation Adjustment" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss on disposal", "terseLabel": "Net gain on disposal", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r78", "r80", "r82", "r93" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations before income tax expense", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r89", "r119", "r1113" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of transition services", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r86" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r89", "r93", "r488", "r499", "r501" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": [ "r6" ] }, "blfs_DiscontinuedOperationsOutstandingMinimumLeasePaymentsForTheLeaseTerminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DiscontinuedOperationsOutstandingMinimumLeasePaymentsForTheLeaseTerminations", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, outstanding minimum lease payments for the lease terminations", "label": "Discontinued Operations, Outstanding Minimum Lease Payments For the Lease Terminations", "documentation": "Discontinued Operations, Outstanding Minimum Lease Payments For the Lease Terminations" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r182" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationAmortization", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Disposal Group, Including Discontinued Operation, Amortization", "documentation": "Disposal Group, Including Discontinued Operation, Amortization" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationAssumedLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationAssumedLiabilitiesAccountsPayable", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasisExcludingAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "terseLabel": "Assumed liabilities: Accounts payable", "label": "Disposal Group, Including Discontinued Operation, Assumed Liabilities, Accounts Payable", "documentation": "Disposal Group, Including Discontinued Operation, Assumed Liabilities, Accounts Payable" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationAssumedLiabilitiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationAssumedLiabilitiesDebt", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasisExcludingAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed liabilities: Debt", "label": "Disposal Group, Including Discontinued Operation, Assumed Liabilities, Debt", "documentation": "Disposal Group, Including Discontinued Operation, Assumed Liabilities, Debt" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCapitalExpendituresCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCapitalExpendituresCost", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Disposal Group, Including Discontinued Operation, Capital Expenditures Cost", "documentation": "Disposal Group, Including Discontinued Operation, Capital Expenditures Cost" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCarryingBasis", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasisExcludingAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities", "verboseLabel": "Less: SciSafe carrying basis as of November 12, 2024", "label": "Disposal Group, Including Discontinued Operation, Carrying Basis", "documentation": "Disposal Group, Including Discontinued Operation, Carrying Basis" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasisExcludingAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCarryingBasisExcludingAssumedLiabilities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Less: Global Cooling carrying basis as of April 17, 2024", "label": "Disposal Group, Including Discontinued Operation, Carrying Basis Excluding Assumed Liabilities", "documentation": "Disposal Group, Including Discontinued Operation, Carrying Basis Excluding Assumed Liabilities" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCarryingBasisIncludingAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCarryingBasisIncludingAssumedLiabilities", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: CBS carrying basis as of November 14, 2024", "label": "Disposal Group, Including Discontinued Operation, Carrying Basis, Including Assumed Liabilities", "documentation": "Disposal Group, Including Discontinued Operation, Carrying Basis, Including Assumed Liabilities" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCashProceedsFromBuyer": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCashProceedsFromBuyer", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds received from Buyer", "label": "Disposal Group, Including Discontinued Operation, Cash Proceeds From Buyer", "documentation": "Disposal Group, Including Discontinued Operation, Cash Proceeds From Buyer" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCashProceedsFromEscrow": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCashProceedsFromEscrow", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from escrow", "label": "Disposal Group, Including Discontinued Operation, Cash Proceeds From Escrow", "documentation": "Disposal Group, Including Discontinued Operation, Cash Proceeds From Escrow" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationCashRequiredOnClosingDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationCashRequiredOnClosingDate", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash required on closing date", "label": "Disposal Group, Including Discontinued Operation, Cash Required On Closing Date", "documentation": "Disposal Group, Including Discontinued Operation, Cash Required On Closing Date" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationChargesRelatedToCashFundedByEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationChargesRelatedToCashFundedByEntity", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationNegativeSellingPrice", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash required on closing date, funded by entity", "negatedLabel": "Cash to Global Cooling funded by Company", "label": "Disposal Group, Including Discontinued Operation, Charges Related To Cash Funded By Entity", "documentation": "Disposal Group, Including Discontinued Operation, Charges Related To Cash Funded By Entity" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r90", "r183" ] }, "blfs_DisposalGroupIncludingDiscontinuedOperationDebtRepaymentCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationDebtRepaymentCost", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of indebtedness", "label": "Disposal Group, Including Discontinued Operation, Debt Repayment Cost", "documentation": "Disposal Group, Including Discontinued Operation, Debt Repayment Cost" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciation", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Disposal Group, Including Discontinued Operation, Depreciation", "documentation": "Disposal Group, Including Discontinued Operation, Depreciation" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Release of SciSafe currency translation adjustment", "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)", "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity." } } }, "auth_ref": [ "r74" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, including discontinued operation, goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r77", "r91", "r139" ] }, "blfs_DisposalGroupIncludingDiscontinuedOperationGrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfit", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross profit", "label": "Disposal Group Including Discontinued Operation, Gross Profit", "documentation": "Disposal Group Including Discontinued Operation, Gross Profit" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationGrossSellingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossSellingCosts", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operation, gross selling costs", "label": "Disposal Group, Including Discontinued Operation, Gross Selling Costs", "documentation": "Disposal Group, Including Discontinued Operation, Gross Selling Costs" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r21", "r22", "r24", "r90" ] }, "blfs_DisposalGroupIncludingDiscontinuedOperationNegativeSellingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationNegativeSellingPrice", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Negative selling price", "label": "Disposal Group, Including Discontinued Operation, Negative Selling Price", "documentation": "Disposal Group, Including Discontinued Operation, Negative Selling Price" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationNetPriceAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationNetPriceAdjustment", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net price adjustment", "label": "Disposal Group, Including Discontinued Operation, Net Price Adjustment", "documentation": "Disposal Group, Including Discontinued Operation, Net Price Adjustment" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating expenses", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r90" ] }, "blfs_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)", "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationPositiveNegativeSellingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationPositiveNegativeSellingPrice", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total proceeds", "label": "Disposal Group, Including Discontinued Operation, Positive (Negative) Selling Price", "documentation": "Disposal Group, Including Discontinued Operation, Positive (Negative) Selling Price" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r90", "r183" ] }, "blfs_DisposalGroupIncludingDiscontinuedOperationSellingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingCosts", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationNegativeSellingPrice", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Costs to sell Global Cooling", "negatedTerseLabel": "Costs to sell", "label": "Disposal Group, Including Discontinued Operation, Selling Costs", "documentation": "Disposal Group, Including Discontinued Operation, Selling Costs" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationSellingCostsPaidByDivestedEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingCostsPaidByDivestedEntity", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operation, selling costs paid by divested entity", "label": "Disposal Group, Including Discontinued Operation, Selling Costs Paid By Divested Entity", "documentation": "Disposal Group, Including Discontinued Operation, Selling Costs Paid By Divested Entity" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationSellingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingPrice", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails": { "parentTag": "blfs_DisposalGroupIncludingDiscontinuedOperationNegativeSellingPrice", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling price: $1", "label": "Disposal Group, Including Discontinued Operation, Selling Price", "documentation": "Disposal Group, Including Discontinued Operation, Selling Price" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationSellingPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingPricePerShare", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling price per share (in dollars per share)", "label": "Disposal Group, Including Discontinued Operation, Selling Price, Per Share", "documentation": "Disposal Group, Including Discontinued Operation, Selling Price, Per Share" } } }, "auth_ref": [] }, "blfs_DisposalGroupIncludingDiscontinuedOperationStockBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "DisposalGroupIncludingDiscontinuedOperationStockBasedCompensation", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Disposal Group, Including Discontinued Operation, Stock-Based Compensation", "documentation": "Disposal Group, Including Discontinued Operation, Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Discontinuedoperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r76", "r137" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r844", "r845" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r895" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r927" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East, Africa (EMEA)", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1150", "r1151", "r1152", "r1153" ] }, "blfs_EarnOutPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "EarnOutPaymentMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earn-Out Payment", "label": "Earn-Out Payment [Member]", "documentation": "Earn-Out Payment" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to common shareholders:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r230", "r231", "r232", "r233", "r234", "r235", "r240", "r243", "r251", "r252", "r253", "r257", "r507", "r513", "r526", "r527", "r651", "r673", "r810" ] }, "blfs_EarningsPerShareContinuingOperationsAttributableToCommonShareholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "EarningsPerShareContinuingOperationsAttributableToCommonShareholdersAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share from continuing operations, attributable to common shareholders:", "label": "Earnings Per Share, Continuing Operations, Attributable to Common Shareholders [Abstract]", "documentation": "Earnings Per Share, Continuing Operations, Attributable to Common Shareholders" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r230", "r231", "r232", "r233", "r234", "r235", "r243", "r251", "r252", "r253", "r257", "r507", "r513", "r526", "r527", "r651", "r673", "r810" ] }, "blfs_EarningsPerShareDiscontinuedOperationsAttributableToCommonShareholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "EarningsPerShareDiscontinuedOperationsAttributableToCommonShareholdersAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share from discontinued operations, attributable to common shareholders:", "label": "Earnings Per Share, Discontinued Operations, Attributable to Common Shareholders [Abstract]", "documentation": "Earnings Per Share, Discontinued Operations, Attributable to Common Shareholders" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common shareholders:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Netlossfromcontinuingoperationspercommonshare" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss from continuing operations per common share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r239", "r254", "r255", "r256" ] }, "blfs_EarnoutPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "EarnoutPaymentPeriod", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout payment period", "label": "Earnout Payment Period", "documentation": "Earnout Payment Period" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of currency translation on cash, cash equivalents, and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1093" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.biolifesolutions.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r489", "r848" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.biolifesolutions.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, at federal statutory income tax rate, percent", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r221", "r489", "r497", "r848" ] }, "blfs_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateWithoutDiscreteItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateWithoutDiscreteItemsPercent", "presentation": [ "http://www.biolifesolutions.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Without Discrete Items Percent", "documentation": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Without Discrete Items, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r980", "r1079", "r1080" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs for service vesting-based stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r479" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period for recognition (year)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r479" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r893" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r893" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r893" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r977" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r893" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r893" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r893" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r893" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r973" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r973" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r973" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r181", "r208", "r209", "r210", "r225", "r226", "r227", "r229", "r234", "r236", "r238", "r259", "r335", "r336", "r367", "r418", "r495", "r496", "r504", "r505", "r506", "r508", "r512", "r513", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r552", "r553", "r554", "r555", "r556", "r557", "r561", "r563", "r576", "r669", "r686", "r687", "r688", "r701", "r766" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r258", "r271", "r286", "r333", "r994", "r1041" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of non-marketable equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r332" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r942" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r900", "r910", "r920", "r952" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r897", "r907", "r917", "r949" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r400", "r549", "r829", "r830" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r948" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r529", "r530", "r540", "r849" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r529", "r530", "r540", "r849" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r400", "r435", "r436", "r437", "r438", "r439", "r440", "r528", "r530", "r531", "r532", "r533", "r539", "r540", "r542", "r584", "r585", "r586", "r829", "r830", "r841", "r842", "r843", "r849", "r853" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r400", "r829", "r830" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r529", "r530", "r531", "r533", "r849", "r1086", "r1089" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r400", "r829", "r830" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Fairvaluemeasurement" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value measurement", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r535", "r537", "r538", "r539", "r542", "r543", "r544", "r545", "r546", "r647", "r849", "r854" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r400", "r435", "r440", "r530", "r540", "r584", "r841", "r842", "r843", "r849" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r400", "r435", "r440", "r530", "r531", "r540", "r585", "r829", "r830", "r841", "r842", "r843", "r849" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r529", "r530", "r531", "r533", "r849", "r1086", "r1089" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r400", "r435", "r436", "r437", "r438", "r439", "r440", "r528", "r530", "r531", "r532", "r533", "r539", "r540", "r542", "r584", "r585", "r586", "r829", "r830", "r841", "r842", "r843", "r849", "r853" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r849", "r1083", "r1084", "r1085", "r1086", "r1087", "r1089" ] }, "blfs_FinancedInsurancePremiumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "FinancedInsurancePremiumMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance premium financing", "label": "Financed Insurance Premium [Member]", "documentation": "Represents financed insurance premium." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r338", "r339", "r340", "r341", "r342", "r345", "r349", "r350", "r408", "r416", "r524", "r547", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r670", "r825", "r849", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r863", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r1037", "r1038", "r1039", "r1040", "r1082", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "blfs_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Finite-lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Useful Life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r352", "r361", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r363", "r797", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025 (9 months remaining)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1154" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r363", "r797", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r363", "r797", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r363", "r797", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r354", "r356", "r357", "r358", "r360", "r361", "r364", "r365", "r615", "r616", "r797" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r352", "r361", "r616", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r361", "r364", "r365", "r366", "r615", "r797", "r827" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r354", "r356", "r357", "r358", "r360", "r361", "r364", "r365", "r797" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofAmortizationExpenseforFiniteLivedIntangibleAssetsDetails", "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Value", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r615", "r1056" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on currency translation", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r130", "r746", "r889", "r1091", "r1092", "r1147" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r551" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r904", "r914", "r924", "r956" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r904", "r914", "r924", "r956" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r904", "r914", "r924", "r956" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r904", "r914", "r924", "r956" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r904", "r914", "r924", "r956" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r937" ] }, "blfs_FurnitureAndComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "FurnitureAndComputerEquipmentMember", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and computer equipment", "label": "Furniture and Computer Equipment [Member]", "documentation": "Represents the furniture and computer equipment." } } }, "auth_ref": [] }, "blfs_GainLossOnDispositionOfAssetsHeldForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "GainLossOnDispositionOfAssetsHeldForRent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of assets held for rent, net", "label": "Gain (Loss) On Disposition Of Assets, Held For Rent", "documentation": "Amount of gain (loss) on sale or disposal of assets held for rent." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on disposal of property and equipment, net", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r9" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r123", "r750" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative costs", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r123" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by customers' geographic locations", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r43", "r784" ] }, "blfs_GeographicOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "GeographicOtherMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Geographic, Other [Member]", "documentation": "Represents other geographic location." } } }, "auth_ref": [] }, "blfs_GlobalCoolingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "GlobalCoolingMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Cooling", "label": "Global Cooling [Member]", "documentation": "Global Cooling" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r190", "r353", "r648", "r819", "r826", "r850", "r862", "r1046", "r1047" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Goodwillandintangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and intangible assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1045", "r1048" ] }, "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized losses, less than 12 months", "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for less than 12 months." } } }, "auth_ref": [ "r167", "r168" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss from continuing operations", "terseLabel": "Net loss from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r68", "r118", "r130", "r230", "r231", "r232", "r233", "r234", "r249", "r253", "r513" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax expense", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r117", "r158", "r163", "r652", "r667", "r812", "r818", "r1017", "r1019", "r1020", "r1021", "r1022" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic loss from continuing operations per common share (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r118", "r159", "r212", "r228", "r230", "r231", "r232", "r233", "r234", "r243", "r251", "r252", "r507", "r513", "r527", "r651", "r1114" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted loss from continuing operations per common share (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r118", "r212", "r228", "r230", "r231", "r232", "r233", "r234", "r243", "r251", "r252", "r253", "r513", "r527", "r651", "r1114" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations:", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from discontinued operations", "terseLabel": "Loss from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r78", "r79", "r80", "r81", "r82", "r89", "r93", "r150" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r844", "r845" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofLossonDisposalofGlobalCoolingDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disposal Groups, Including Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r12", "r18", "r23", "r77", "r83", "r84", "r85", "r87", "r88", "r92", "r94", "r95", "r140" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r368", "r369", "r372", "r534", "r536", "r541", "r683", "r685", "r751", "r797", "r852", "r1116" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r369", "r372", "r534", "r536", "r541", "r683", "r685", "r751", "r797", "r852", "r1116" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Incometaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r221", "r485", "r489", "r490", "r491", "r492", "r493", "r494", "r498", "r500", "r502", "r503", "r700", "r848" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/IncometaxesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r169", "r178", "r237", "r238", "r258", "r270", "r286", "r488", "r489", "r499", "r674", "r848" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, trade, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Sales taxes payable", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities, net of effects of acquisitions", "label": "Increase (Decrease) in Operating Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "blfs_IncreaseDecreaseInPrepaidExpenseOtherCurrentAssetsAndLongTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "IncreaseDecreaseInPrepaidExpenseOtherCurrentAssetsAndLongTermDeposits", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) In Prepaid Expense, Other Current Assets, And Long-term Deposits", "documentation": "Amount of increase (decrease) in prepaid expenses, other current assets and long-term deposits during the period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r904", "r914", "r924", "r948", "r956", "r960", "r968" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r966" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r896", "r972" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r896", "r972" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r896", "r972" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, gross", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r190" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r354", "r1056", "r1058" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income (expense), net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r818", "r1002", "r1019" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r215", "r217", "r218" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r351" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r136", "r802" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/InventoriesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r200", "r801", "r862" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r136", "r804" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r136", "r803" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r985", "r986", "r1024" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r575", "r984" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r575", "r984" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r567", "r861" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1099" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r138", "r574" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r562" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r566", "r575" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r566", "r575" ] }, "blfs_LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "LesseeOperatingAndFinanceLeaseTermAndDiscountRateTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating and Finance Lease Terms and Discount Rates", "label": "Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]", "documentation": "Tabular disclosure represents the operating and finance lease term and discount rate of leases." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r573" ] }, "blfs_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 (9 months remaining)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r573" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r575", "r1097" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1098" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1098" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r562" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r97", "r98", "r99", "r101", "r102", "r103", "r104", "r220", "r334", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r515", "r516", "r517", "r550", "r724", "r811", "r891", "r1072", "r1101", "r1102" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r111", "r157", "r664", "r862", "r1008", "r1042", "r1090" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r99", "r185", "r220", "r334", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r515", "r516", "r517", "r550", "r862", "r1072", "r1101", "r1102" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails", "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r155", "r399", "r410", "r829", "r830", "r860", "r1112" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, current portion", "negatedTerseLabel": "Less: current portion of debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r193" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r224", "r403" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r224", "r403" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r224", "r403" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r11", "r224", "r403" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 (9 months remaining)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1010" ] }, "blfs_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofMaturitiesofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Represents amount of long-term debt maturity that takes place after year four." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, long-term", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Longtermdebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r142" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r378", "r979" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.biolifesolutions.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of pending litigation claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1068", "r1069" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r294", "r836", "r873", "r877", "r1077", "r1115", "r1117", "r1118", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "us-gaap_ManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManufacturingFacilityMember", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and other equipment", "label": "Manufacturing Facility [Member]", "documentation": "Structure used in the manufacturing of goods." } } }, "auth_ref": [ "r138" ] }, "blfs_MarketbasedRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "MarketbasedRestrictedStockMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market-based Restricted Stock", "label": "Market-based Restricted Stock [Member]", "documentation": "Represents information related to market-based restricted stock." } } }, "auth_ref": [] }, "blfs_MaturitiesOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "MaturitiesOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of available-for-sale securities", "label": "Maturities Of Available-For-Sale Securities", "documentation": "The amount of cash inflow from proceeds from maturity of marketable securities." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r443", "r482", "r533", "r613", "r682", "r684", "r692", "r716", "r717", "r769", "r771", "r773", "r774", "r776", "r795", "r796", "r824", "r833", "r846", "r853", "r854", "r858", "r859", "r874", "r1074", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r940" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r940" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r443", "r482", "r533", "r613", "r682", "r684", "r692", "r716", "r717", "r769", "r771", "r773", "r774", "r776", "r795", "r796", "r824", "r833", "r846", "r853", "r854", "r858", "r874", "r1074", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r959" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market accounts", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1078" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r967" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r294", "r836", "r873", "r877", "r1077", "r1115", "r1117", "r1118", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r128", "r129", "r130" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r122", "r130", "r160", "r183", "r204", "r206", "r210", "r220", "r228", "r230", "r231", "r232", "r233", "r234", "r237", "r238", "r249", "r334", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r507", "r513", "r527", "r550", "r668", "r747", "r764", "r765", "r889", "r1072" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation_1": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r213", "r230", "r231", "r232", "r233", "r240", "r241", "r250", "r253", "r513" ] }, "blfs_NetIncomeLossAvailableToCommonStockholdersContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "NetIncomeLossAvailableToCommonStockholdersContinuingOperationsAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from continuing operations, attributable to common shareholders:", "label": "Net Income (Loss) Available to Common Stockholders, Continuing Operations [Abstract]", "documentation": "Net Income (Loss) Available to Common Stockholders, Continuing Operations" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r213", "r242", "r245", "r246", "r247", "r248", "r250", "r253" ] }, "blfs_NetIncomeLossAvailableToCommonStockholdersDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "NetIncomeLossAvailableToCommonStockholdersDiscontinuedOperationsAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from discontinued operations, attributable to common shareholders:", "label": "Net Income (Loss) Available to Common Stockholders, Discontinued Operations [Abstract]", "documentation": "Net Income (Loss) Available to Common Stockholders, Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r241", "r253" ] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r242", "r246", "r247", "r248", "r253" ] }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperationsAlternativeCalculation": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from discontinued operations available to common shareholders." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r940" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r904", "r914", "r924", "r948", "r956" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r948" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r967" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r967" ] }, "blfs_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense (benefit)", "label": "Non-cash lease expense", "documentation": "Amount of noncash lease expense." } } }, "auth_ref": [] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-compete agreements", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r65", "r1049", "r1050", "r1051", "r1052", "r1054", "r1056", "r1059", "r1060" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r293" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r124" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r813", "r823", "r1018" ] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportingUnits", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "blfs_OneSupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "OneSupplierMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Supplier", "label": "One Supplier [Member]", "documentation": "Information pertaining to one supplier." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r163", "r812", "r1017", "r1019", "r1020", "r1021", "r1022" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "blfs_OperatingLeaseCostsAndShortTermLeaseCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r568", "r861" ] }, "blfs_OperatingLeaseCostsAndShortTermLeaseCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "OperatingLeaseCostsAndShortTermLeaseCosts", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease costs", "label": "Operating Lease Costs And Short-term Lease Costs", "documentation": "Represents the amount of operating lease costs along with short-term lease costs." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofMaturitiesOperatingandFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r565" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, operating, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r565" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, operating, long-term", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r565" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r564" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofOperatingandFinanceLeaseTermsandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r572", "r861" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofOperatingandFinanceLeaseTermsandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term in years - operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r571", "r861" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r14", "r150" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment, net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r669" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss on available-for-sale securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r202", "r203", "r331" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r202", "r203", "r331" ] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/AccruedexpensesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other debt securities", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r1044", "r1078" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r125" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r940" ] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RIF employee costs", "label": "Other Restructuring Costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r902", "r912", "r922", "r954" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r905", "r915", "r925", "r957" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r905", "r915", "r925", "r957" ] }, "blfs_PanTHERACryoSolutionsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "PanTHERACryoSolutionsInc.Member", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PanTHERA CryoSolutions, Inc.", "label": "PanTHERA CryoSolutions, Inc. [Member]", "documentation": "PanTHERA CryoSolutions, Inc." } } }, "auth_ref": [] }, "blfs_PanTHERAheraCryosolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "PanTHERAheraCryosolutionsMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PanTHERA Cryosolutions Investment", "label": "PanTHERA Cryosolutions Investment [Member]", "documentation": "Information pertaining to PanTHERA Cryosolutions investment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r929" ] }, "blfs_PaymentsForProceedsFromPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "PaymentsForProceedsFromPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments for (Proceeds from) Property, Plant, And Equipment", "documentation": "Payments for (Proceeds from) Property, Plant, And Equipment" } } }, "auth_ref": [] }, "blfs_PaymentsToAcquireAssetsHeldForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "PaymentsToAcquireAssetsHeldForRent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of assets held for rent", "label": "Payments To Acquire Assets, Held For Rent", "documentation": "The cash outflow for payments to acquire assets held for rent." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of available-for-sale securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r30", "r214", "r297" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire businesses, gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r31", "r510" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r939" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r948" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r941" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r932" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r976" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r931" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r548" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r881", "r882", "r885", "r886", "r887", "r888", "r1146", "r1148" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r105", "r411" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r105", "r726" ] }, "blfs_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, designated (in shares)", "label": "Preferred stock, shares designated (in shares)", "documentation": "The number of nonredeemable preferred shares designated." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r105", "r411" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (in shares)", "periodStartLabel": "Beginning balance, preferred stock, outstanding (in shares)", "periodEndLabel": "Ending balance, preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r105", "r726", "r744", "r1148", "r1149" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March\u00a031, 2025 and December\u00a031, 2024", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r105", "r660", "r862" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r998" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loans", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1004" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r981", "r1003" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of available-for-sale securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r29", "r214", "r297", "r330" ] }, "blfs_ProductCellProcessingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ProductCellProcessingMember", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cell processing", "label": "Product, Cell Processing [Member]", "documentation": "Related to cell processing product." } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue concentration", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r133" ] }, "blfs_ProductEvoAndThawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ProductEvoAndThawMember", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "evo and Thaw", "label": "Product, Evo And Thaw [Member]", "documentation": "" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r834" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r290", "r614", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r798", "r834", "r872", "r874", "r875", "r878", "r880", "r1070", "r1071", "r1077", "r1115", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r290", "r614", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r798", "r834", "r872", "r874", "r875", "r878", "r880", "r1070", "r1071", "r1077", "r1115", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10", "r574" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Propertyandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r137", "r172", "r175", "r176" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Subtotal", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r138", "r188", "r666" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r574" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r574", "r653", "r666", "r862" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r138", "r574" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term purchase obligations", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r929" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r929" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r434", "r443", "r471", "r472", "r473", "r482", "r533", "r587", "r596", "r613", "r682", "r684", "r692", "r716", "r717", "r769", "r771", "r773", "r774", "r776", "r795", "r796", "r824", "r833", "r846", "r853", "r854", "r858", "r859", "r874", "r883", "r1065", "r1074", "r1086", "r1104", "r1105", "r1106", "r1107", "r1108" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r434", "r443", "r471", "r472", "r473", "r482", "r533", "r587", "r596", "r613", "r682", "r684", "r692", "r716", "r717", "r769", "r771", "r773", "r774", "r776", "r795", "r796", "r824", "r833", "r846", "r853", "r854", "r858", "r859", "r874", "r883", "r1065", "r1074", "r1086", "r1104", "r1105", "r1106", "r1107", "r1108" ] }, "blfs_RealEstateLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "RealEstateLeaseMember", "presentation": [ "http://www.biolifesolutions.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Lease", "label": "Real Estate Lease [Member]", "documentation": "Leases related to real estate." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r897", "r907", "r917", "r949" ] }, "blfs_RentalRevenueEvoAndThawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "RentalRevenueEvoAndThawMember", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "evo and Thaw", "label": "Rental Revenue, Evo And Thaw [Member]", "documentation": "Related to storage and storage services rental revenue." } } }, "auth_ref": [] }, "blfs_RentalRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "RentalRevenueMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Rental revenue", "label": "Rental Revenue [Member]", "documentation": "Represents information pertaining to rental revenue." } } }, "auth_ref": [] }, "blfs_RepaymentsOfFinancedInsurancePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "RepaymentsOfFinancedInsurancePremium", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on financed insurance premium", "label": "Repayments Of Financed Insurance Premium", "documentation": "Repayments Of Financed Insurance Premium" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on equipment loans", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r127" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on term loans", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r127" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r222", "r223", "r395", "r413", "r577", "r597", "r655", "r806", "r807" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r484", "r797", "r818", "r1109" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r898", "r908", "r918", "r950" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r899", "r909", "r919", "r951" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r906", "r916", "r926", "r958" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r186" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r39" ] }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected reduction of workforce", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "documentation": "The expected number of positions to be eliminated as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected reduction of workforce (percent)", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent", "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total employment related divestiture expenditures", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r373", "r374", "r1066" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r370", "r371", "r374", "r375" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r108", "r145", "r663", "r689", "r691", "r699", "r727", "r862" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r181", "r225", "r226", "r227", "r229", "r234", "r236", "r238", "r335", "r336", "r367", "r495", "r496", "r504", "r505", "r506", "r508", "r512", "r513", "r518", "r520", "r521", "r523", "r525", "r561", "r563", "r686", "r688", "r701", "r1148" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Total product, rental, and service revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r161", "r162", "r258", "r267", "r268", "r282", "r286", "r290", "r292", "r294", "r429", "r430", "r614" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r179", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r433" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Geographic Areas", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r134" ] }, "blfs_RevenuesByProductLineTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "RevenuesByProductLineTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Bioproduction Tools and Service Revenues", "label": "Revenues By Product Line [Table Text Block]", "documentation": "Tabular disclosure of revenues by product line." } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r967" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r967" ] }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and excise tax payable", "label": "Sales and Excise Tax Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax." } } }, "auth_ref": [ "r154" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofConcentrationsofCreditRiskandBusinessRiskDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofProductRevenueConcentrationDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r294", "r982" ] }, "blfs_ScheduleOfAssetsHeldForRentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ScheduleOfAssetsHeldForRentTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Held for Rent", "label": "Schedule Of Assets Held For Rent [Table Text Block]", "documentation": "Tabular disclosure of assets held for rent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disposal Groups, Including Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r12", "r18", "r23", "r77", "r83", "r84", "r85", "r87", "r88", "r92", "r94", "r95", "r140" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computations of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r38", "r40", "r1015" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Revenue Concentration", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1083", "r1084" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r354", "r361", "r364", "r365", "r366", "r615", "r797", "r827" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r827", "r1055" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r25", "r112", "r113", "r114" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.biolifesolutions.com/role/PropertyandequipmentScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10", "r574" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r50", "r116" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r445", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Service Vesting-Based Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r147" ] }, "blfs_ScheduleOfShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ScheduleOfShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Payment Award, Market-Based Awards Valuation Assumption", "label": "Schedule Of Share-Based Payment Award, Market-Based Awards Valuation Assumption [Table Text Block]", "documentation": "Schedule Of Share-Based Payment Award, Market-Based Awards Valuation Assumption" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Service Vesting-Based and Market Based Restricted Stock Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]", "label": "Debt and Equity Securities, FV-NI [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r547" ] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r547" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortization Expense for Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r827", "r1057" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Concentrations of Credit Risk and Business Risk", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r41", "r42", "r44", "r45", "r72", "r151" ] }, "blfs_SciSafeDivestitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "SciSafeDivestitureMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SciSafe Holdings, Inc", "label": "SciSafe Divestiture [Member]", "documentation": "Represents information related to SciSafe Holdings, Inc." } } }, "auth_ref": [] }, "blfs_SciSafeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "SciSafeMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofGainonDisposalDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofKeyComponentsofLossfromDiscontinuedOperationsDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofNoncashRelatedCostsForDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SciSafe", "label": "SciSafe [Member]", "documentation": "Information pertaining to SciSafe." } } }, "auth_ref": [] }, "blfs_SecondAmendmentTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "SecondAmendmentTermLoanMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Amendment Term Loan", "label": "Second Amendment Term Loan [Member]", "documentation": "Second Amendment Term Loan" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r892" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r894" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r292", "r293", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r713", "r714", "r715", "r770", "r772", "r775", "r777", "r783", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r799", "r835", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r876", "r883", "r1077", "r1115", "r1117", "r1118", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Segmentcustomerandgeographicinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment, customer, and geographic information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r164", "r258", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r294", "r813", "r816", "r817", "r818", "r820", "r822", "r823" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r289", "r292", "r814", "r815", "r821" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing costs", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r123" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r996", "r997", "r1076" ] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesEPreferredStockMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series E Preferred Stock", "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": [ "r996", "r997", "r1076" ] }, "blfs_ServiceEvoAndThawMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ServiceEvoAndThawMember", "presentation": [ "http://www.biolifesolutions.com/role/RevenueScheduleofBioproductionToolsandServiceRevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "evo and Thaw", "label": "Service, Evo And Thaw [Member]", "documentation": "Related to storage and storage services." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Service revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r834" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former Global Cooling employees", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period (year)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r847" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r465" ] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r463" ] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of the market-based awards granted", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period, Aggregate Fair Value", "documentation": "Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of the service vesting-based awards granted", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "documentation": "Fair value of non-vested equity-based payment instruments, excluding stock (or unit) options, vested." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding as of beginning of period (in shares)", "periodEndLabel": "Outstanding as of end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in dollars per share)", "periodStartLabel": "Outstanding as of beginning of period (in dollars per share)", "periodEndLabel": "Outstanding as of end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wtd. Avg. Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTargetShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsTargetShares", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Shares", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Target Shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "terseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of the service vesting-based awards that vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r464" ] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAttainmentRate": { "xbrltype": "percentItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAttainmentRate", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attainment (percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Attainment Rate", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Attainment Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r472" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Historical volatility (percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r471" ] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRatePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRatePeriod", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement date with a maturity period (year)", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Period", "documentation": "Represents expected volatility rate period for share based payment award by share based payment." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofStockCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r445", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of service vesting-based awards exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service based-vesting options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of exercisable service vesting-based stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding as of beginning of period (in shares)", "periodEndLabel": "Outstanding as of end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r452", "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding as of beginning of period (in dollars per share)", "periodEndLabel": "Outstanding as of end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r452", "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wtd. Avg. Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "blfs_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwards": { "xbrltype": "percentItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwards", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total shareholder return attainment (percent)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Percentage Of Awards", "documentation": "Percent of shares that may be issued in accordance with the plan as a proportion of outstanding awards." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental cost", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedandMarketBasedRestrictedStockActivityDetails", "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofShareBasedPaymentAwardMarketBasedAwardsValuationAssumptionDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "blfs_ShareBasedPaymentArrangementSharesGrantedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShareBasedPaymentArrangementSharesGrantedPercentage", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares granted percentage", "label": "Share-Based Payment Arrangement, Shares Granted Percentage", "documentation": "Share-Based Payment Arrangement, Shares Granted Percentage" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of the market-based awards that vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life (year)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r148" ] }, "blfs_ShippersAndRelatedComponentsInProduction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShippersAndRelatedComponentsInProduction", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails": { "parentTag": "blfs_ShippersPlacedInServiceAndFixedAssetsHeldForRentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shippers and related components in production", "label": "Shippers And Related Components In Production", "documentation": "The carrying value of shippers and related components in production." } } }, "auth_ref": [] }, "blfs_ShippersPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShippersPlacedInService", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails": { "parentTag": "blfs_ShippersPlacedInServiceNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shippers placed in service", "label": "Shippers Placed In Service", "documentation": "The gross value of shippers placed in service." } } }, "auth_ref": [] }, "blfs_ShippersPlacedInServiceAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShippersPlacedInServiceAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails": { "parentTag": "blfs_ShippersPlacedInServiceNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Shippers Placed In Service Accumulated Depreciation", "documentation": "The cumulative amount of depreciation, related to related to shippers placed in service and fixed assets held for rent." } } }, "auth_ref": [] }, "blfs_ShippersPlacedInServiceAndFixedAssetsHeldForRentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShippersPlacedInServiceAndFixedAssetsHeldForRentNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Shippers Placed In Service And Fixed Assets Held For Rent, Net", "documentation": "Represents shippers placed in service and fixed assets held for rent, net" } } }, "auth_ref": [] }, "blfs_ShippersPlacedInServiceNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ShippersPlacedInServiceNet", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails": { "parentTag": "blfs_ShippersPlacedInServiceAndFixedAssetsHeldForRentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/AssetsheldforrentScheduleofAssetsHeldforRentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Shippers Placed In Service, Net", "documentation": "The carrying value of shippers placed in service, net of accumulated depreciation." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "blfs_OperatingLeaseCostsAndShortTermLeaseCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r569", "r861" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r180", "r195", "r196", "r197", "r220", "r243", "r244", "r251", "r253", "r260", "r261", "r334", "r383", "r385", "r386", "r387", "r390", "r391", "r411", "r412", "r414", "r415", "r417", "r550", "r695", "r696", "r697", "r698", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r726", "r748", "r766", "r778", "r779", "r780", "r781", "r782", "r978", "r1006", "r1016" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r106", "r109", "r110", "r181", "r208", "r209", "r210", "r225", "r226", "r227", "r229", "r234", "r236", "r238", "r259", "r335", "r336", "r367", "r418", "r495", "r496", "r504", "r505", "r506", "r508", "r512", "r513", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r552", "r553", "r554", "r555", "r556", "r557", "r561", "r563", "r576", "r669", "r686", "r687", "r688", "r701", "r766" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r292", "r293", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r713", "r714", "r715", "r770", "r772", "r775", "r777", "r783", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r799", "r835", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r876", "r883", "r1077", "r1115", "r1117", "r1118", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1144", "r1145" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r226", "r227", "r259", "r563", "r614", "r694", "r712", "r718", "r719", "r720", "r721", "r722", "r723", "r726", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r884" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r225", "r226", "r227", "r259", "r295", "r563", "r614", "r694", "r712", "r718", "r719", "r720", "r721", "r722", "r723", "r726", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r766", "r884" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r901", "r911", "r921", "r953" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "blfs_StockCompensationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "StockCompensationExpenseMember", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Compensation", "label": "Stock Compensation Expense [Member]", "documentation": "Stock Compensation Expense" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued - on vested RSAs (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r105", "r106", "r145" ] }, "blfs_StockIssuedDuringPeriodSharesRestrictedStockUnitNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "StockIssuedDuringPeriodSharesRestrictedStockUnitNetOfForfeitures", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued \u2013 on vested RSUs (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Unit, Net of Forfeitures", "documentation": "Stock Issued During Period, Shares, Restricted Stock Unit, Net of Forfeitures" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.biolifesolutions.com/role/StockbasedcompensationScheduleofServiceVestingBasedStockOptionActivityDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r105", "r106", "r145", "r457" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r105", "r106", "r145", "r701", "r766", "r779", "r890" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued \u2013 on vested RSAs", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r145" ] }, "blfs_StockIssuedDuringPeriodValueRestrictedStockUnitNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued \u2013 on vested RSUs", "label": "Stock Issued During Period, Value, Restricted Stock Unit, Net of Forfeitures", "documentation": "Stock Issued During Period, Value, Restricted Stock Unit, Net of Forfeitures" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r106", "r109", "r110", "r145" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r106", "r109", "r110", "r135", "r728", "r744", "r767", "r768", "r862", "r891", "r1008", "r1042", "r1090", "r1148" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r558", "r579" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r558", "r579" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r558", "r579" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r558", "r579" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.biolifesolutions.com/role/InvestmentsNarrativeDetails", "http://www.biolifesolutions.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r558", "r579" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.biolifesolutions.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r578", "r580" ] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r132" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r947" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Sales taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r97", "r98" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology - acquired", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r19", "r1049", "r1050", "r1051", "r1052", "r1054", "r1056", "r1059", "r1060" ] }, "blfs_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "TermLoanMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "blfs_The2023TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "The2023TermLoanMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2023 Term Loan", "label": "The 2023 Term Loan [Member]", "documentation": "Represents the 2023 term loan 3." } } }, "auth_ref": [] }, "blfs_ThreeSupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "ThreeSupplierMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Supplier", "label": "Three Supplier [Member]", "documentation": "Three Supplier" } } }, "auth_ref": [] }, "blfs_TotalDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "TotalDebtMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term debt", "label": "Total Debt [Member]", "documentation": "Related to total debgt." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r946" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.biolifesolutions.com/role/GoodwillandintangibleassetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tradenames", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r64", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1056", "r1058", "r1059", "r1060" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r966" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r968" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.biolifesolutions.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofDebtSecuritiesAvailableforSaleUnrealizedLossPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r408", "r416", "r524", "r547", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r670", "r849", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r863", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r1037", "r1038", "r1039", "r1040", "r1082", "r1085", "r1086", "r1087", "r1088", "r1089" ] }, "blfs_TransitionServicesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "TransitionServicesPeriod", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition services period", "label": "Transition Services Period", "documentation": "Transition Services Period" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r969" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r970" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r970" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r968" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r968" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r971" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r969" ] }, "blfs_TwoSupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "TwoSupplierMember", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Two Supplier", "label": "Two Supplier [Member]", "documentation": "Two Supplier" } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.biolifesolutions.com/role/DiscontinuedoperationsNarrativeDetails", "http://www.biolifesolutions.com/role/DiscontinuedoperationsScheduleofRIFandStockCompensationExpenseAccelerationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r370", "r371", "r374", "r375" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationNarrativeDetails", "http://www.biolifesolutions.com/role/SegmentcustomerandgeographicinformationScheduleofRevenuebyGeographicAreasDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.biolifesolutions.com/role/FairvaluemeasurementDetails", "http://www.biolifesolutions.com/role/InvestmentsScheduleofAvailableforSaleMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r809", "r841", "r1110" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r965" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.biolifesolutions.com/role/OrganizationandsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r46", "r47", "r48", "r170", "r171", "r173", "r174" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biolifesolutions.com/role/LeasesScheduleofLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r570", "r861" ] }, "blfs_VariableRateComponentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "VariableRateComponentAxis", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Axis]", "label": "Variable Rate Component [Axis]", "documentation": "Variable Rate Component" } } }, "auth_ref": [] }, "blfs_VariableRateComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "VariableRateComponentDomain", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "documentation": "Variable Rate Component [Domain]" } } }, "auth_ref": [] }, "blfs_VariableRateComponentTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "VariableRateComponentTwoMember", "presentation": [ "http://www.biolifesolutions.com/role/LongtermdebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component Two", "label": "Variable Rate Component Two [Member]", "documentation": "Variable Rate Component Two" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r935" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r242", "r253" ] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares issued, basic (in shares)", "label": "Weighted Average Number of Shares Issued, Basic", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r36", "r37" ] }, "blfs_WeightedAverageNumberOfSharesIssuedDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://www.biolifesolutions.com/20250331", "localname": "WeightedAverageNumberOfSharesIssuedDiluted", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Issued, Diluted", "documentation": "Weighted Average Number of Shares Issued, Diluted" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares used to compute loss per share attributable to common shareholders:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails", "http://www.biolifesolutions.com/role/UnauditedCondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r240", "r253" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.biolifesolutions.com/role/NetlossfromcontinuingoperationspercommonshareScheduleofComputationsofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r933" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-70/tableOfContent" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r978": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r979": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 107 0001628280-25-023833-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-25-023833-xbrl.zip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

[+0?-_-L'=)%E7@N$)"LI(L:2E56]K?^XL3*BG M#D%7F/[\?O'Y6WKT%N'TQ0VP'WCAV!=T.P3$HHUV1@;6ENKO%Q_#=$XQ79V= MD3+P.M=:F9+!221O6P1?D--O]5/&\WE4[;YM'$B=K*Y% ]F-7??YE]DBAMG+ M!7E.\_=_Q1IY32(:D8,5X**G>-ZCA>"8 RY-T(I"L'BWQ?XCA9L//'P\51^O MHD5#>740F=ZRAIL"C4W:=*.#N@:"(_ 'D2$H"J]5UA%"'?UEI-V =;MFDGY3OOM013)?V76EMLE:Q7B+=Y'40HA$U?91\=%RD MU+SDZ!#ZNH7=,="X#[QA]-0!!H??5S;K7H6@/,LDD.@+*$?AMXO&@74J&DP\ M86EM*<_#V;B9Z:_!*^@081VLNX,8_"5\Q$L[%I,3F(N"%+D!97--[TL&$J7P M%I40LG6U^9&D_MY3-(>C[BE_9B (]!C9:R')YZ/0-'/':C/M0,;$UZX_UFCM M*%;U=^HP>X_LSZK1YQ(!AXAW;'B\3=.WH>#WTWI^.:T=62^90%UH89$#%;*T M=5T%<,$P$I"W04B6M4][8>2Q-XQ^V?R\0&DBZ$[0=9V?9"B4 M+#H##Z7.F8V9IWP(1 [ Q9"7LD?!Q1$B'1L,+[][>TFU$$6BCPI*$;0'QRCJ M>+4"3)&:H]3U&ME>0+A^Y.AWC\\+@N-$V8$3O6F#<9%JO[_Y^WK9>=L: Y>? M<>.=(0O9,;^YVH=DW!2#Z+D%QFWA+D6-V+H1XS,DC8NLKR%<;*G3#B#ZCCY7 MJPAWF+I>%'2!D71(T4 MO6@O];$]I7HW_M7%^K))R=5QL54E 0*6X$D87FQ3 KG=W+:7KH MZ>,&5VV1T$:$8V-@TR9LMVW,Y;232U:",SS[)* H+T$5X<"1+PC1IL)X+,G$ M_8HMGG[/N,'5 +AH*-8.MICAW<.?IW/\B9Z^FEB6>:E'<8QD -5F@L/B@"6) MS&A92FP]'>V,[.T%=/U'=O-[Q=K8AOH6BT]S6"^$O*FC6HG$5_.7)*7Z21+H M!*V*TH<$&6O_:9D\!._]'.A(G"W&5/K7A/(/8?D> M5Y>-]]XMJ@!^O*AW8K[[LJVFG ARMH12!;2L(XH<*O#::O#.I9183"+MY[TT M)>OW7B]X9MRWA<%7M #J[)(W^&D;>M3LR"2*D'.V%@0Z38&'BQ "$U!KZ[01 M+J2[M[-.Q_L]*G[OA2_GA?=I2OZ*T+QIXDO4W['MD[&BX'KC548AE:"= M#'2J%_FUUQ"B%^15HE1,EV)1MD;WLU3]WO/VYT5[6Q 14]RYN&3AI#2!'D5@B M6Q!:A\.G4?Q[CW!/6Q CH**#_-$3W#[!)2D"MUW=%S6.>8W+VM=P(M (Z4L MZ86K;0OKD$"L_5R<444*^J?UL.V6].^U/LP_UL=(B.E@M?R\6*U>;@3['N?I MRV9X=9B]6+\,R^47^F&=>X 3&7S(/DNP42IBRCCPGF50H@@R#TD9T[IIY5Z$ M[85O^T?'=WL==P#SS1C\O"KW]2OP3)QGC/GG: MQB1%-L%+"*D4R(:D$+C1T;5NB7$BR7N!W?W1P7Y.7'2P#.Y5K:PFCA:LHGT& M4D@6E$7:@;Q((+4O3EGRY>X>JK>O-]OO[,G_T<%ZHO8ZP-\3O1"UTMQY*T F M*T%%#!!,3*"MP&",=#JTK@DZM6OV@\?0N1^8_["GF6>#P-@9[W?+,-_&I5?M MYK>.SB1YQRW/=7X-8]L9]@$M R%19FML5'MFKQ][PWX(_&.?*S;1SM@0VY25 MK3=K4.\RJ_OT[GTX\7'W_&L,*K.8<_+I;O/N#F1[7];,W* MU;^:6(SD.BL&3-42E)@=1*^]PS=BT^1Q$B]C86QS"1C@6/PH# 6\ $= M$#*U4<(Q]V2KTG_T-KZN_S7:*Z.2!&&R 64B JWP#%9(6Z+WR0K36)+_Z&U\ M(J+'ZFU\"%9ZRV$\T,>.T19G1+2@=:EGC9G8L38#)AZ*,FA4\TG;SY#T>R^S M/@)&![:G/$2G?4/TJB& M%JY8$'84AL"F'I=42,(EX7@O#CO_]&>\G@('-R> M\A!]] &P_=L>&EF"C=Z $[QVCO 6O+$"4B86,RLQY=:3PPZAKUO8'0.-4]I3 M'J*G#C!XIC9NOMC ' \0'"^'^B^6?3=[^O]I0':?2Y]I2' MB+<#0WC.]+U*044;(ABN:IV'UL:WT =4D;W%6;P%O/Q X)DFAEXYTDG,]D+)*@ZO?DL&V66+" M>\FZTV\4/D3([]WE.!)=1UXB/%G57RFL:ZZ ,1,R).EB;=D;(6#D8+QRZ,@ MR;NIEK9P_KW'E./!^"#5?D7PW:-Y0Q9>IAQ9O>:K03$TX OMFZ58PU+6,9GF M-KI1#X^OV&"W"V".[RL!8UCP[4T#$3S6,UN@8(B#XECYY0JT M<2(J7DJ)S1MX[!+PQ^EF<$8+?KAJORH _U+?.?V,M_8K[DR)3EI(49?: M.! MIT '=$%7HB%YR^:NR$.$_'&Z$9P#T">K^E1@OUNLP^S,O?2V%W*_"ZOI:N(2 M"BZ%!*LH@%"N5C!FK&7B4BO+$\MZOPDUQU+PQ^D> [1NA[DG<'ZK?DU?7=DE?E89%<$+WS]&5S^7.V15;^/Q>K=57XQ%FELS8%HJ[' MSF@21!4#?:6$%MEPG?>;%C<@D7^@3@FGK)$N,-)!:<)IHO@%UZ_*N_#;Q"<> M13TH0^WJ[9%0P#/+Z5\Z2>^T\:IUZ\DVE/^!>C$(D\ZTO7NY'V1^H;\2) MV&VMYJ_](OV;GWX,\_S8/"T2&,ZN6^4/=JO^<"+.>L7^1!F-=-]>4I3I/5K MY!(M%,F ? D#-@J1!.Z;W\(5CJ(99\; >QUJ4<3&8R087MH5V?,@2LL.-) M,K9UTXX6D[R_XN#S"!@=.,G[$)UV -''QX=*99C-A4$H%! KYC.%&=E#04;1 M1A0^->^#\I5.\CY(Y7M/\CY$_AT Z;&9TAQ5*O5"-H6EO/8?MK2M> 8ZJJA9 M,MXUGP'SE4WR/DC1>T[R/D3J8Y\9/C-NV$FO3#(!I(D"E"X:@M,"C(E9!)T% M\_ZY$*G5%.<1IGL?@X[68NW O)PS"9)DU-ZZ M:3?%1A!8)"$E(2@D7Q_[/W MILMMY4JZZ!/E#S^+EZO6.O #-^=?FW!Y1 B4FC)9.OI)X^0\M(CF!VALVBOQP[@>.7VK*GG)X9[ MFVL?((:6R/?10A"NCG)719OBT(76C3KND/#2=]'%SKH"],6O$[UBL1IE^-" 4H3Z^0&1<$=:N )8]#&)1X.,C3N^%^1 MN"@:9?3@>*0M@*5$_KX40'&LRM9[07O"T<5LQ_B*- #14[TB#<%*!][&+0X? M:.]JO-96$_UT^ 50(28()FLPM@3,3!7>W/%XAJ27'H/M *.!79N'Z+1OB%ZV M@G79V4+>&2]!DHNF(B %E2!48EE8541JG97X+%&3[ZSM(#"\:_, ??0!L.V[ M 7-CD0( \N/7[9*T(L-46@,&F$F)I_7(YA+YN8;<+-/;IVCQ$3QU@\$#= M3;F014@9(+%47Y-Y :^M!ZU%C)[+*,SQS1_Y>;HV[^,5=(BP#NQN$(,W&KSJ M[(M,W($,-131VM !&AQ$[HRUDB&..RCBGZ[-NZ.N4=?F(1"8/ TBSCYBN3P; M,41KDZ?- Z6L[Y<9T' .4F3C30@BASNGP&-9#S<_MB/78RPM+IJ(=&HPO/[E MXV6>AO=6">XA)_*/%-?K,5@4!@15>Q=ER_AVU>]7'SGM.7QP$.PFR@[.O4.^ MI10TT1LOP0A-HF%.0L"H *VROC#'2GKI*2]'_"9V#)[G;EB;>A^^Q>)SS2M6 M7]XO%S'GM'I+(/CE_ ?M.4)@=$4I(*X+J%0D8 D6(HO,.!6,$'RK[7M?2EZZ MC[DCOG;N5+*OLH\8V6]6I/J_3C+#R.HL\"A\J7(N)&(F(95DT>M"'O[6S4?V M(^6EWRQ,B^T=U'U$X/XSGZU;@=[LF.(M*\4'P,0TD-DZS[9+QTI^6PH-Y3S4<$Z%N-FPUWR3*?080Z1-EX#S[*""G'PK2TUHGFK0)_ MSI[C=SN7G@$XGZ>_MZ'<<-'@,2QFL1)]H)QRQ@XIAPHH3BX6J[(+8]*"J&S M:>[(#&]>_R):>A\,6L#,2;FC2K1WTGY:/B(XW^3Q/TS(R7L/!YQB@I%"L)PAG/NI\P8>(^HFZ=1_Z@G-O M#!Q[\]C_-_^H[7L6%A/(U;P[D3'00M\]Y?45/6_N43%A 4K M"FWEWBIPT27RX(5#CQA-]H?P7X^__C>C%Y$Y!:EH!4IX ZCH9)28/6?:<6-# M8TG^4_^[)Z*GJO\=@I4.\D!O8/*@H*;SQ%-[8Y(RN/B(S MK:'_#$DO/==L!Q@-K/\=HM.^(7J9OAV-QI!4O9?BM>N_K6GX!3R7+'K'A%,C M]$L_YOK?01 87/\[1!]] &Q 76FR/'-30"/7%"!3;.R50Y">%1-<0><.TU7E M8?JZA=TNT-BK_G> GCK X('JY)PSW)I@:\-7.E;L^C%,2-"Z=M^SY$B5?'2> M[,]3_[N/5] APCJPNT$,WJ@8$Q9-3K1[.>]JN5?4%(J4",HHF2V/W/K6@T5V M)/6E^\O#4=>H_G<(!*:^*O_7Z2+@Z>O%HMZ ;D[($)4QDK-*L*43DK["VB%# M1BPR"<>*V"X3_8$/[\@-&4NCBX;BG1H>MVN9B5<34#"H)@7*.0](@0%8KA M M1J[M=AFPP\O#NZL,WAD2NXMT:C!%[G;;QKOQKL4BKCXO3=%(0I1(J0A:HJTNE M:HF:@Q)XD-[3D9Q;7V7M0>Y+OY\Z..+WPL/4+O;0%+WWRT69G9UD45!J84&X M.D";U4SL6%.E4LY%I5)*;%ZGN>4'N0^_-4FA]H]]X+#]-;P%!;7T_$ MNE#C)<,<'1/16'#,"3JN%!U7BG'P@K[A6;88FN_E]\GX>8K+#[&E[ZGF/ASR M^VQ=<%037]\^EOCZ2RZ+9;[XQ5H5P[0-PKD P=?NVU(DP#JIPUBF?9!H!+8> M/MZ(])^GSGS/K?[@..G5/(B/-Z7D>/9(J=B)Y#YB9!*LJ9?_WM%N@** $B1^ MBM:#\R/X.L,)_7FJT)M#ORD&IO=O;NOD28M>759"OCH[6\["^5F]#_ZT^)"_ M+99K!^^BML8:Y$GY J&8VDP"'?B"%KSSRC(10E&MKR6;$?_S%)_O8Q?38.78 MZ[#^7,PCKKY\R*?576F\7RTTMIXF*L)3.$BD (*\? M#:@*:)=1 9D6%NMYKB0=(EWXZ(NP$EK-8_002Z%=(7$+&% 1Q:=#%*VG[CQ M3Q'6GHB>J@AK"%;Z""N>K-90)@5/\1"$7+LQRZ:XAH9!3@E'*!+)FHG1- C7/D< 6K0M9'<2K>IB^;F&W M"S3V*<(:HJ<.,'B@8@6="L6P04.0Q8'"0N*OZ>%"!<85"SS<[9M]!)[LSU.$ MM8]7T"'".K"[00S>R,M64?KD+!V@J0Y=,X4#"IG!6#HY#?ILS @=3OXIPFJ! MND9%6$,@,'76UT-50K75E BY '>UOW*1EH[B;"!K1@*,*"-NUW+[Q11A#=+H MT,@MU$V8%;=,B7 M/\^B01X""%$0E$J&Y*PR2!4*0YW0V-9M3?XIPOJI I/=L#;U/CP@^^_73!3& MV46^1XD\>HX1A,]TUBCZ R4CEI.U1GC:?[;T3P M??6U)F'\WPL>N9*<>ZV!!$M"-2R!B]%!23ZE$@MSN7D[Y)L$O/2;I,/"=V?5 M'A%\/YXMXG]^P55-#OE:N@]R6$@W4'<''OX AG^;T[)Y=7956) B:AT#I**(4^4<8)0(WL7B&''K M^80%5'>H_7GJIW;!_H'1<$2;^FO\-CO#TS67I*6JF9KZ=^+IH'+))K \EOJN M6-N7Q@PZ1>4%3\:)YN[)([3\/!54A]C66RB\]Y3@MSA;?L?3<](85HU4Q>V1 MVOO4QS5-T=V:[D:IMG6]?]?U;H#W.@M1>9MMR.#0)U!H"1#61T@ANB)93MRT M;OG\%#W[.@)7G_UJMQ+_+27%LWP=O=#ZP#.&0OD0Z-429M\ M]\:@'2 ?)ZL30+:"PF-0:Z273J&VNK+8RP=)'TLI/H"O-W!*(@):H2%;&[S& MH(IKW45Z&[HZ 5LK,&P!MKTTTP':7N/J"YT"]3]O_O=\1FYZ96IMEYY"A1"C M(E?%>5#$%'A1$I0<>&%2J^A:%X\\3LVT]_I]G*N-=-4!ZCYD\HYGL19D/LC3 MP]^]S V7 5&2X*PM$I2J@W.Q/JA)'7)$)9EIW;]O'WJGW1-;868QD0([ .L? MBWG^\0=[@LW19'HI..)#I,Z4055 MA!(8DO2$2=X<(B!YC,!.(I.&"-DF.&FBKIZP^-O\V_G9:BTQOMGPF<_2,:Z M:Z5K5I4#3-P!ST:ZY'(I9K1[P/OD=(*S]B!X#&Y[:J13<(D-*R)8+1BOPP!E M)F^B#O#P)4,.FJEDE")H' !@#7;([S.,/3W^;D)Y]7F:VW M^AAB2C9[* HCJ,BPSATK4*+/-O&L8_,F](^0,FV*32<>7 ,M=0"V3TN?E]%DE$[\H#W*T^T4>N'O[1Y4TI4T(I3*!3;:9FQ;J;6P 6K$L\"!]4 MZSRQEO1/?!"W -2B$^UV@.S__OBOQ?>\G*\%^3D34WGU:PYG'^M&L-DKUL<# MHG0YFP2,&SH>(D?PA3$P6&+23M.ITWI?W9:V:1$Y'7H6!U!E!Q!]O5A^6RSQ M+#_(3-&L:!T=>%U#N^(UH/4.I D^T#A"X[B+_ M("/&1.F41K"LCA0MY(>'PB-X9#P:(7(0K6/D1XF9]L:P&^2U458'J&OAP?]^ ME2N<;8RH? 3IN2 O?OTH)1-PP8PH6NH81DNB:<' M%G=G413DR&B W.XX/F! ME-"KC-!$ G3&&B _AD0;LR3[EAZLBDF6Y"0+K2OFGR6JDVO+PP-F,:;V.H#C MP\^O#S!X$E/0QEL+@0XU4#YG$ILB[]M'HSEJ%4WKG7=KXJ:%9V-0;)75LZ^& M=H8>A69AT6HO_(ZSTWJM6]+V[2!TKC0&T4_?2#O,;F=>%%+SEB!E+PA(](CX[4>K6<_KE>_PC@37#C/+877=7YD MTAX"1ZRMO83*M-6A:7TQMSUU>[<)N+6-W]WN+R(]:16W5D? A/42@W9Y=%;2 M'\(JYV7*IOG<]^?)FKH-T2CXN5>WWU@]'<0;CSU\^5*X=CP 2Z;4,LA4>Q]9 M8(RI&"4*(UH7$^SSWCU><]/6*M_R)7N(_#N 4=-K6A.M9\H*$F!M ,EJ/A*: M5)U9YX(HF35OF_[R7[(' 6K,E^PAVNT V5L_?QI?$Z5$@N)+!*4M!Q! M"1:EY[YY?<%/^)(]"#V[OF0/464'$'WZ431ER9QC 8@X1Z<3'4R!& "I;"A> M8"EW&U3^\Y)] #"V4UH'"'S\<31PYYDN'D2T& M9\]QRV4)2/PH PJE 8_DBV"HD^5+%$ZT?I<;2.*T6!P-*O?2$<;36P>P?+,Z MFWVE*(F\X>?EZ(H),;O:-Q0%\99JQW,CH3A;F':Z/GXWQN00^J;U_@X%R-$T MU@$:+U],WY7'4S%^OTILB]D:(3C%9^15UZAHB4$\%($X#E7B0;-]9U7O\=:O0]??-J3>7S8'40IG8)N(\IK M_GY?K%971I6BC13^ 3)B35FNB#^E@+.(WBD3G8W[@.ZIQ:<]?J<%73.E# >= MOP#=/'\F)S5]:E=(LF5R[A67E E>0'9F[6X@^. E,*4$RSZ9DEK?,^Y$Z+0% M?%UZC#MJL=/S^T'_Y":+'GE"K2&@+J""3O4N*X)6TGN?O=?HFON- _%GCA=_ MAU)-I^A[T%&YP2(QP:S)"5*PE455ZV[I+& Y^L*D8.7N5(L&#N1 ]-F7B;Z6 MJNG'C7QFGX]Q>9[3Y52X5X7^^^KT=/%7G09&O_.:Z)Z=W1%$89:7XAQD*R/Y MT[5!1M(CKKE((39TUM M%NTH7ERW&+06G"!.4HI61T!@'%BAH4%PBNY C1F%1"9IC\V*'_3H1O M=SO/7CR,1U#S$6.[GC8WF#9!Q&@32!4]*&%)[#Q9L$)[2P:=-+9N2]&$\.VP M_0*>G@ZOYKV=Z]$@_F@#!;1114-6Z^L$6H5K =<#2GCID\W*-G^Z;]K@@A_Q M8]6HRNK OWWZ,N66CW0]E320DX2F ,90;N]C*"QB9OL@%M!>T LM<:3.XA2"ZY9B+%,"-:!]UZ'+AGJ :\[ MZK(+R Z^)BF(.F-2$&W,M<ZZ\TH5UR'SB8=#:BC:K## MRX '.NG8XG/V7('+M4I>U1FZV4D0H63'4$CF6Y>^/4_5=L?[BTY:V4E!'7B< M0]-PLD:I(G/@;<3:\CB0X&2 )#0SIGC&0^N&&V,D4(W7!K4Q0O;,FAJBKBX/ MZ<<8O.&(J!"<+&B@'A_UQE?7WJ\26&0\A]I\<[*,W8VTOL\-W:?7!N"B#@B*2H6@GDE,K+0.F172EMGT(K2MQ M^^K2FFM,&8J!X@5M'RY'.E28 @HW;5(N!*%;/X.^I"ZM0_"S2Y?6(>KI(#1Z MK*FC#EQAX &L81R4T 5<\1%2UC:3Y%1(K:^%CK9+ZR"5;]FE=8C\.X!1VV%: MWBN92@&M! .E,X> %,\YI&\HH[-*K7>XE]^E=1"@1ITW.D"['2#[Z6Z*3$9N MI5.@?2TH%-R TRQ H^R&NCK Y0-^R](3B1I M+ M\]7#UQ>_Y]7JTQ><<_$'_>:7^EK*DV%2@E18:[=,)A$'1[;(-1>^)%E:!S9M M.3BF1C:#H#8HV!Y5[QV@_K_R:?JT^ //*O\W[C&&\GTCZ[K^VHGR4J58:V&< MT9M3*'D'5J/DW#,O;.ODI)%8.:;..OO800](.)8BUHT9;V=OH,,.]N]=>+QKH=X$%4K*P$3M!B,- M V>S@BA=08$D@D.EY@\A^YAZ^QP:Q?MHN/4>//YC[9^X7-+G?F_TW'KOX\9Z M,'V:[L,_>2IKK*7P#Y@4')1% Q0C(B1N?#&2OG:MKWD.]^1Y;;"?EIAF\\\W MEIBG]77*Y@<7*"OEFQ9+!R$ F&'P@#U=@[6EE?:YU*-OEU#T#J*T)F@9E M;72^&%L!4S<5>X_S3__UYL.KU\L?BX^7WLQO\_C_;%X;M-1<*?(G=8D)E*\W M78'^6DSF3'FAG-VN=]TS"TT'DI'TNAA)R!W$I!]),1=R.L75ZEWY>+:(_UG; MEF+*"9(%4+PC0!4NP%- #=S(Z.O<:MJX6[M3CQ'3R[W>V(=;6ZUT *^;]%]. M1*HMF)S4%%_7L7\L"@A&28A>9"\3DE&V;O5ZGXJ)O:4VZKV;X+"?K#M R\>\ M))MZ\_YR^34KE_NJ9H)+0WMUKNV-DD3PBFQ*!B^LC"I[UCK@?8*<:?&SKZ;O M[C:-Q-X!@GXY7\WF>;5Z%2FHW=RO5;M*%,>*3/NP4]:!$B*!JR]]TCB).@@F M3>OJT4=(Z>5"_U!'60N-= JL^B5YF9<90LBRD(J!%&2&JJ:3>ZZ(O\0SIW@D M^=*Z".%9HJ;=IIJH?@LX[:Z'7B(V,CNL <75'?3E9#1-<:TA3X"BE%#?(@SM MOE) .=J&/YV&5__><9/KF._U1 MTQ;7%N5$L3FAA6P=;=".9?!^/(:67E[Z#16H---(GL#:F M%TP*VDH)%G.LCF4=E",$Y"C(+8R*>]\Z3^)18B:.VEJH^GGX["#W_@"TV5Z- M2\+;9(#G0%%)1 '."05%F:*3EC;;UE4[#Q+2'7!V4?+3T-E!XCW 9N"&_?M5 MFD:RC ?')*0B+2A>$$*Q'H2*AL5LF8U3O_;^/BC3_ !3@PYV*!Y$JQW ]^[3 M^?_,SKXLSL\^9&+N],>OF5;Z.INO4X N2^8O)F:?J!C(YGD]+T0!A0;!,R1I M6VUL,,2S;7TAL3.QQ_6TO".8[LZ5/HAF.X#P \'7^[R,5<.?2>;_7IR19"\G M@*PV<5DZB<($46=[Z4@[@TK.U>G=!J3UA<5B*)#?*M-AO]N.+2@]KJ>C-N ] M@$X[0.Y[_'%1O+?8<'#)=EZMF\F?J!QC29K.+%?'R?)4RZ>L F[(*==)>NU; MNPC/T71D3\>5Y]\W?EXQ=2 MT^:G)R11KAQY_"%63]W6XB.&$I@(UM$)XOPA=M =*#^N*Y[1=M2Q==X,Z2,F M=<_)4M9]QO;*Y;[S*N]4"\)\C9=_>[^N@/^-GJSWSVKGP@72V_ MY]6))' +YSD$X^O$XFP)Y:X ERAE-H4;T7IG>YZJZ;.N6^#C[K[46!L=G*Y7 M'/W/8OF?W^;OEXM(^^YMEAA#%FLG8^$328P<4W"1%[!"N6!I(]?-KQ6W(&O: M2&-TA#721T\0>SN;SU;D3OQKL4AW6!(NHJD]X&11C$1F"R!W$0Q/V5NE1<#6 MV8];D#5M^# ZQ!KIHR>($1FM)_(S;YWQ>'/] M:?WUT4$S5,*]=[;]/2-%QBWJ)!_YI*;^]3;4-O*Q+Y:Z @]'58(V#JQ$TKF) M'+P*&EQ(C'8+57SS_/3;%.R[1]1F##FO/_/7O(K+V;6KU&2]R M#@JY!W0^]W]TT6HE\ZOHQG'^^R#TPVHC@(_E; M*@M0NA:+*VV!82(%TV8:Y%9)A\_5AUTN.#42&JEOL:\L>P# YL4_2"F+(5,( MZTHFXQ,X*15H+J-S.C,A>"L(3%[?M9NR[JI[!\E-K/ _R#/^>O[U,BG?,6XS M8Q"Y-J!2)G='% LB666#LHZ\G@8JO[7HQ$K?166+%O*;6O'X]PW"B5_ER,F$PA)D3=%VIBV&T+TG.)O+CK-M48SQ>\LOPZBR/5)5WMZ577]>X7,6>A&'D^<3WKG4G N&Y8+T7BJ$-LWEKS,5JFO?5J[1$TE7RG M"-KD'J+PP0DMP/B\[FCK +6)X(,NQ)S4S+>^E7BJ:H' MAET4MV@JQ2XVDXU\^WN'43@_=P.K=MURO$.>?UWQ5FWM7+HWPA+R[8ER2X$WA=78N17N:_$"N MK#$Z"D-6. JRGJ)JZEVJ(0@>!%@SC72*L0^Y[NDW^3M)(7B6K(/,ZB"H9 L$ M+R38HK,4V1D;6Z=J;$=9CU[V>%C;4S/=XFV>_[IP)TZX\T6A-4!,10IG0ZE) M&0)2K/=:11OEVS]>/$E2CT?EF C;31>])^5=O)5<3W>\XAKGZ6*Z2;ZRJ15] MKS[*UJJ%#^29[I/&UV3=$1XF6TIBG&?,HJU/4=8>UCX1LBL.LS<@F8Y9"\=, MWNKZ?K)GS-N&]3]Y]OG+64ZOOM-W/^>;4MV4()PPBSS*Q.N86U%3.3B0:4?0 M4D8>E!7M.1Y*X]2NW"GT1F?IC1SU'G^5C MI&-2HO,>"S 3:P<8Y2"(2#M4MMR('#D%GD=T3+Y>K,Y.1(D68\Y '-0&:X)B MFN0U<&U<#,;PHEK7I]VGHJ^C;H"6G]YM!@NX@\/LXY?%\JSNA-<<2)V)6*+; MUBF!R@8&0>=" 7#TW#+K?/,+B?M4]'4@[0&1/04\]5/,?82O1UO>8VIUXE1" M.BL1/&%\,\.$RSIF4D<64RY.;/<\L_624U\?[(V1$27<+.-X]ZWEW[B' M:^"3GZ6DE0R*K$]9-BB2D:H/$,IZEV6QOO5CS3TBILU,;[BQ["?>#HZ>:\(M M)B^1*1 :20S*4 #(@@.'HO;(*RCC2*DE6^)AM#XY#?&PFSB/HS+A.A38S!^< MY=5CEVN_DU7,3M>_TC#FV6G=48.B_24Q3M2$/@7F1 03T8(RA8'+.@++*6E& M6Y-JWKQOS*CIAA OFTK\>GY=3F0,^H)&@RN,SF23)?CH&&0G'?TO,B_&C:>> MIJ^K2&L(,IZ.M!HJI8N#\/YCT26'/R[YN[B[2K6]P]O9*N+I_\FX/"&Q%>'7 M)T2=)DQ_ D8E@-R P$P*/,3V5Q2[4CLM&,=#T!9O?R.H\UB 2V+]DTZ:3W_E MT^]Y,P1;1R^SC8K\$D.>JD //@0!Y.!PM)G\5-;^C-B-UFDO(OH"[;ZJ/"+( M5G/\]-?BA*,FYF2]SF,(RNE",;>V8*Q?=Y J6;3/6!Y$XK2W(-T!=!?%'1LN M"6CYQ*BL;#()#,D0%+>*A)D%))FB2-ISFR8Y^F\2.>UE2Y_8'*R\(T/GV\7Y M\J1XC]SR EDFLCZA2*Y6"]!D>C%IAS$=(GGV*1JGO?CI$IN#53?UZ\2VS+TJ MM. 5A]Z'C)F\;*[J/6E&,KY$@O4Z.1Z M6"UM8,&#R=[55E4*,%L!O@AD.9'+S%K?$6U+VU9@M$<+QE%5U<$3VY-\_?<\ M;9+M)X"N%R$2(R3? _J.3Y&Z%;@="\; MG$V4.!RI_@*I\_P9SS:_.\ZU^H\3EJSWRGB0D>?*C0//> 0TSEDE@V5W3^.1 M;M!_;(4W?_1X:Z&(G?>^[WD9%H?(A;SHQ/PEGZ:R6%;Y7[^<7?SHORY^](%^ MM,<[X2[+-'T6W)O/1J^ M7_B7[/3TU?S]!LQ-/\\"Z?Y@H*'NO Q6T)0"F+V MY.HEEL%5Z#D7T 7MBPRMV_4.(G"OJ.3CE]DWLK'5^U.,F1;[F)??9S&?,*,U MJMJCU,0(2K)$N[7,0/:5"E-1&.VWBCL>66#:]Y7Q ' KM&@AW*G#UD=X>!7C M^=?STWKB_IJ)L#A;*^_$LA!-21&,XG3>,^$A)%ZKT6R.M$,7I?@^N'EDW6E? M/J:%4PM53.IU/<5<[5[J%6W':)X0#HZBI^'L]Y6J2VM\Y77NG;R^\TVHS)B2) M+"I00B=0&")%M<6!TNX[L+GP+#)]EZ>M]K GESFF8&\(&&[M5NT$W7OI+IWQM"V? M_4"RU/\]GWW[>NLFY\9/WUS^=(_]:O?%FNYCC7ANM+]=KD8L4B"3)5D< M.0$%O-5D=O2E"%I;S5O?V&U+V[1;85OLLX2W(ZF4R=4L\W)V>VE@Y/>.M,K3I MM%HH?N;)6^#!DIL2R)7 0G]0;$VL91>2*H?"VS59G>YNNT)A6ZCMJ)<.H+9^ M5OVR.$V_??VV7'S/Z\?;RY;R:*W-V=02*!)5=!Q"2@&8D85$QHW$U!AB3Y#3 M*;1V5?U#!;$-]##U/=K;\^5\=E;CJ?GZ6O")SZ2KRYU5*^X\2@96U)MI&0R@RA9*X1B\CU'%UIG_3]$S[?/1V*!J MIHD.4/6HK'Z_ZLAK8D'I$@-G) 72*GAP1>AZK2A]LD4C;]T_YGFJICT.IXT' M=U--SV#[UW*Q6ITP[TN6.1,/MB;78@3,)H%.3$9E/'';NB'-TQ1UZJGOJ/]M MX35<&0WS4G<'UR/)0_3U:5ZK;)Y>?5TLSV;_=_W]1]D_22;Q.E20=G M:Q.@ M6HIER7 Y]Q1Q&Q5EZPOG5K1W&B2T >PD"NXBB?]15FJ>@#59*QD99"$<'3&% M3#8%#=Y0E!F5(V,]V*XY>?[95'OF4$7TGK#QT"-ABYR-K3YW].?.@V1N//]" MY7EVFL($$*E>AP7D$#RK.Q)GG",OZ%NWQQ_]9?-6JH"TCI?B!.12(VRA$(+S M-2&39X5>4C#4.BKM)UFCK?[O[D0[R[GWE(S+'!>RU]E5C@NN,U*NLQ3>SN:S ML_P[6?#]1)C=-Z=62S?=OT:1QS3):01'%3%#6(_8+(4 *ID&JP)]UZ$-Y2BK MC^Y?"CRACLU,P)2X"62KG)10V^1D0)/J+8$/249;;//6J]M3=U0Y;@,P]7B2 M1U-]=7#/\@0_O_SX _^_Q?+U*6TAZV=DH92/%.I#2%@KN!S%^8K.).:S%GDM+ZS6":O<$,D1TA27^100"F>NL EJ_/5V>+KWFY+ONI_M:7V;?+!YSZ$*A$ MCF!(1*"4*W2D: ')EE@?=KA*K<_F)\CI%F[[P^#NJUHCG70 KT]+3+F*Y9)^ MJUR,6FG@HC Z'7+M#>\3:.XQHM4JZM97RG=IF/9J^)! VDOZ/: GQR_SQ>GB M\X]?N&:H]3 M,VV&R2%AUD@C'6#K":E=/\]X:7S600-#1T;C30 OD@.\C:T6DAN!&J=6KGTQ1U M&SV,#KFAZNB@#^[CW/SW*I?ST]]G)9\P#"*6^C@3B@#%M 2/-JP;[]<2-4.T M'PQBUW1U&S^,#;0=5=/!,?N@K_#F[WAZGF;SSY?OAB?CT2$W@GHZV.,>V*;O\Q0=U]YX3^%][8)I1:W" M%0),""XF@X7QUM>[V] U["=EKL5S46DD=*_L2 M0A2U&U1"P2(WK/DT\:+MI'=-%FD*G%C(YW@.KL:M(0:M'C 8GVR/,B26\>3!]U^G[J5NJ^U MAP?:!JTC=PMTC;4'Q,;?P/!^:]]'J$ M.+X)VV*I.#!^%I/YBQ0;%(@%Z4T6:1D[(!9V$^1>DQS"@X,V,&:/%+(KH>8 M9Y3OMC95SA/B[,O>1G/UT-33J\GK.XS^F7H&FTGP>S%8:-;T]_FW_/J M[&)$;0Z7#2;.?GS,1,=Z]>NQ14JB=35-W-9'5IW7ET4(,=,AZS2BO#L]K,'S M]+;4-6C[595Q8W+OZPL]G&B7';-:@U#<@@I*0BCT5\65\%;+8'3KA[I'B9GV M;G,DK#S0H*N!*CK(-/IULVQM1DPFOMDJ-A.;+WE2,F!AN0!WI@X#\PH"L4E_ MES->"^9_9V9?+6MA[/+DH/1F.AVR2 MJQ/(R345EB2754P9E?*^]3WX-G1->V]X(- U5]#4+>XW^_4F!J]C,-]5/V;# MRHUM_$0XQ7R*G.)P1J;$D8./C$P)152A1".9>\YG&[;DM!=[(R-J1.GW'AW0 MCOUU=B%9\ILCF=1L_CG/XW[QP!:?VC0"&,I%(Y__QK+K40DWE[T?KV*T!9$' MB%[PVH^2XE5+GE>1V4660Q38_JP80.#>$U\6J]7U$C_>YYKQ\OGU*YQ5B:EQ4,H6]:I_]PJ!M-9[VGX?Z^F'^FI;XF5 .]W[_;VD_4 M'9QRMUE8-R-$%7R005&$7*>&%V8A1-1@68XYBU!T:/T&<9^*Z;&REV*?!,I@ M*7>'DQO]D@)W.A6A:NL:2\QP07R$#$9$8PLS1H7VC>,?IJ4GS S7\9.0V5'@ M4U];?OJ227OR$YWOOR]P?MDB4EB=Z?^ 15DKVKT QZP YKS/J2A3I'_.07G\ MXWM"P:YJ6S25X=0H^)CCH@[\(>]MO9W>YJ24()UP"FC_%'4B @>250*I.?HH M&(:"6Z'AR66FC;O;HZ*=3*=&Q[]Q.:L'[ <\R_61<#&_W#YS9AC1&RABW6!* MUA/7&0B9)7Z D5NWL9#<78)1@VMA(%YTPG#R75+<]G3T** M'JQW-2/+HRIA=SA,Z4*T5."SF-A!FEVBXM-?B\UN)Z65.3L&268)RA5'K& ! M1H=DX4(X:_8 QM4ZO6%C%T4^BX[=I-I=@/+[5=L2'B(WEG90(IF#HF@?G$H* MK(R.,V[0RO:Y/P^2,NTE[+@A[6[RGGI?N I@=];H85\C'@9M7 M9Z]/%ROZQDDL1I98A85UT'@,'CQ&!H61["*WWMYME+P7@*X6[LF]/1B2=A-[ M7Y!ZE=*LJ@E/-UR^^KHXGZ_3V6;S/TF2%S79ZPJ82VZE+BA$0BC:&E R]/"D\JR\ A6DLA"]<*4&,&$UTBJ]/D6VQ7,M>$G&DS%*,E_TV_J]OA(O3U0V/)2<07->)R[X6I^*@G9_Y#8RR?7=AXD=(?C XM.6 M#A\<LWRB3[I34UC M6=6BTC=S^L7E17)<)*_ "PIZ7*C)<74D-!:-M#D7G^NP5$3?&&1[D#MM+? 8 M*#R4[KJ#Z2^XFJT^$BV8WLUO7@GRDV0MXY$V;O($UOV?.7A-\HQ.92:=8<*T MSDK?EK:M .B.%X"-M-*7WW;3FC:NP\>S.C_C?5[&JK_/^>UB^0;CET]+.@6^ MY(O8/J>3HK5B7&K03#BRL.@!I:73(-4T39>2U=N]!#8B:"OX^6. WV1JZFXC M).YFBS2+[_''Y8OZZA<\/5TLYI??6OR2W^,LG6 HAF7I*9YG]=6>1?#T+="2 MD]2S*B# N&592H+;F(8%637M&P'J:-XV6@J]K[\O3\7\P^YG,]3=5[KQCR;KW7T M-E_RYC0S03D-RE@2F/4,0JGAD\O2Q((^A;2#7_?LPMOAYUB?*-K*_9A*GZ[; MYJ^K/=K4/SW\H:,506W!P[B54-9&5NIHNXS*$T)* (Q.0O3%2(6!H1\CH_\P ME5 \>.$2%O#24X@24@14.H&0Q'+@VI;F[9V/I1)JB-ZWJ80:(NKNW.UUXF7! M4'.E.8D@T=$;:P]9.F0K5^] M7^:OL_.O&U9T3= M'6R>O'%&0?$:>@[!\3J:7@;P.M!Y*0N/GA44MG6^4NO'@$-?O T"P^YO 4,T MTQWF7N-R^6,V_[RY0@R8'1,R0:FGK)+9U#9-!E+1=3=V4H[\!GJ;GIXVK3%P MM8?TNT#2Q;(;]^WU8G4Q3"$$1%E[?6F>,BCM,[CD(Q3G?/=>_[U Q!]8:\1H/KO%">0D1$ [1MUKK%&&NM& <= M)1<8?#"NM:]T<_T^RPGVPQ<=;+9" $41%A1:"SZLTSTR M$SZ+F&7K=HP/D-%G%4 KG.PBZS[WDQL](16/1I2@(4<7B!D9(:1:-R@P>F,\ M:M&^"_%#E/29Y]\*.SM*O&%^S$$?H__ LTTO^D6Y*8;F#]3/+72 1^M!O([< MTA-5CHG\FY0*@DJYT*:$#I+F@24ND7EL[EV.\9!]4X[7\OV0OUTD.*[>E??+ MV3S.ON'I8S/(R3)MTA!EH".]%B=XX:O-T9FN$^?J;L>UIMO:+C1/?U&P)Z*> MVO]&5V(',=\ ?G^;WYLV[@7GEFL/4M3&:,SRVCI1@8B&E*!J.OF8+OY@@J>_ M?Y@.KGNJ[]BP>CEC7)G I/"%PN<:)Y6 X)C.=8A0XBAS++GU#=@N=$Y_LS$E M,G=1UE$"]KI@;E8'5-G43Q M (<_;L\%M\6Y2#("ED4!Y=""9W0$6.3)AE2T9=LUFWYVJ>FO;!K!9P3)=K9W MG?B4L-3Q\-P% PH9T1Y56G=F#\YD+UCKJX'!+PBC]D\8<:<9)-S>AR!^R-_S M_#RWF*GSV$;_H 37S MEA$=0K8VMBU)&W40\$GFWM".2"Q[I#_H5(7 JT%QFUAV(4C9NI#F28*FO5(; M RV#YOX.TD<'!]:3S&RD^2''Q>?Y[/_F=")9S)I% 2G6MQEE2(+"*LA!"\]4 M0.]:OWD.HW#:*[+)X;>?QGJOPMQP=_T.],ML\6VY2.>Q_N*GQ>*TCM_]F)?? M9S%O?GF?,<)[K3?&B=N \P,?RT86@I_(('TJ%>D(KJ0(,=A/ 0K]Q+16FECPC-YM3RKC0JK4;];;FQY7=B6K!.%$\$!DZ_WR@70^@1. MNU)WJVS\5@DCM, -)-'?KE'TV-H3OY VT^JBH8C[@$@=0;OA8+4I=TF*>2X\ M!QT")P=40^ =. I8U.[P-D3P%/?6NYX>)U/CU= M=S]=U2[AFW(F:W-V23C@!2.HK!@X[A1$:9@R!BW#[<:A/;'(YUW^+$839 M"2C>?%^0<#Y]P;\V/.22BD[:@ R&>! ! 16GO32CK"EW+KKM>A\^LL T8=FX M8-A+B%,#82.+>SQPR47B#D%&90C,T8+WH@ W.M'$I(D^2AT!4)%.->,>0S"6+O=O(\GEYGFH7XD M4+03: ?7@X\XX+]?)6LG*00/5@.W6M4<+$W>5E# ,2[OG906 MMPY91E%%!]!ZYE;@MWD\/4^U&'&U(G+:(_PE(G-&WON7Y:OW)U]>RFT/D MWWEU1E+XI?[B^I^\^[96?SR;?9^=_=CC2KHM 4WOJ$>43:L2CJM\A'?E]0T: M/^336OBUKE[]^(6L;,W%IK/SZNI^4E LE[%D2&@(R#$G"/6FTAN>$]%.^[1:\_>:VHFVN_6BYQ_GD]X.F7']>_LEG\U5^X3!O!.<\A.6YTUAJ!:)Y".P\GD&_VAT'SW M&.@ &!UX, VE\.?Y.CHHP4B>,8.TM>."4070.0F:5&5U*"K&ULD7 M%3O\3YY]_D+Z>O4]+_%SOCQ5WR]K*B#M866SAP597Z*T@!!K#U/-)7A1"K"< MT'IOBPRM4_$.S^7$AT(V7 1\.@"!3,J'K] MWKID_T"LO9C0?A2$3V.0@^#6SV7 <\)9;>< Y-5O\XOP\DD9>6:Y88C@;="@ M7!87.8'!!NFEBAX#/[1)-N7PQ5Q"=&&9TX'O)SHFA9:N:$G"&"> V\N[,WE2-,ZEPM:=%;()=5IC E^\@*P] M3\99'IL7*QV(M8D[ !UO-#@&=(XSMZ=%4X8M/_D V3@':=FP)^Y3B"J3:T3' M1[:@1*%SQ1H#/)4B2TK2Y=;W5!.GV6Q2I-Z5W3W3B_S2D"C>A+U=Q!I7%!.O[RNUI.,1"BY @RU MC,K% IB+!Q$+BX67F%GKW)=;!$Q\N34-"!:M--(!G'87W#7;\_3^%.SJII&..\#Y&W(Y M%S]ROI%*LRDNBB%B<@L)",!:OSOS3&C"%A;MW/^E%B.G\K&!TGBS&4 MU@'Z/F1R>6;Q;).\OV&"12>%20$D-_700;)I3B8NE"HV&FD\;WUX/TA(Y_?@ MAT;=_LKJ ''O\[(LEE_K?+&+',)+PY$F>[9NG:4+J%IJB\EE,-Q+$V3 U'RN MVR.D='[A>VC4M5#8U&71?^#R/_EL'>P];$1>H#:&')C$)1F1=04\KMDJ0L?( M>'9WTL\>J8Q^;J5I[S"[ 5=[K4S#:(19>.V9\!)OK' LB!4*2L8[= MM%E[KT+9ZO!\IFW/U8(3'Y*31KJ[2[X'N&Q0[LA @L( &179CW0>'.TKD(4G M [#&!KM5FO@V@)FZF<^.RKJK[ATD-['"_YC-9U_/OVX(5Y(0+9T&9G*-$I2 MH&4!$@7ZPKQ.>JO:TV=4?FO1B96^B\H6+>0WM>+Q[QN$!VX5ZBB!P!_K0"X# MP18/M+O9(IQ,46\5TS^G^)N+3M>MJ8GB=Y9?!\'.S@^WOU_U=]#&6V1UH(:M MU2%U]CMJID&1BUU<"-S@P9/=GJ5ZXA"JB]OW ^O^F-%^/_GGMSF% _/5+/X; M3\_SB0X>9 VP.ED@"5.7RV M%Q;Z0,B'=A*H_2WZP3OM93N[!^J ME&)L<6 XKT<]*+",\ M+X+PO&]Z)\OZ8C@[??^RR^(YGM;1=^*D2!&X\N2K6D6**BD#2LE!B%)2<;6- M["C5I8=E<]HIJ3U85L>PFOIM=F?UO/G?\]G9C]_FJ[/E^?HNY]W9E[S\] 7G M#^Y);W&VO#BQ@[4A8Q!@22BDPV(A\"(A*8;,B>)+V6Y>PL%)GW9>[$2&= 0H MZ>7T&D5 _U['E[==)A",G1\2XHE%2TTX0@D4+)(C*YQSC#^@97!R;XZG3].SD]+*XW?]X.2T7R\VWZN_Q$YEE#"(%,(DQ\CM- M@."X@"(+=XE;(:1N#.W#(U5O1\SN_*Q5YT$DP.62:V MJ>NUP0/FA) S(E%Z"_B5'-SK M\,J@9\[&7$>HDKIBU."RIVT@*A8#ZB!C-UDU#?G>SN)>:E9!#QH8A+Q^#J!+ M:5S+ZJ(@:LU@OK$KG;AB(^U(!DH2')2I'?"9Y73 2I,23Z[X-/"@V7KQ[>#] MTI[\#Z*J8SXX:M'6'XLT*[.X_B>_S>-R_0_NAV*(V"T&JSTI61M2V;;S>,^&,G;F[+O M&!;'?/0\)9A?9]]G*<]3%P.F!44>P&3G@#&JM$I#-!8R_GSK9, M;6=)+^W-OD_,'.V),_""[]5F8O"-B$OZ($+A&3BK![-F%I S!^ALR*)HBW;G/PW:6]-*>X(\).+T<4KMDVSTKJ2O9W,[_ODA@.(E1)E8;/:$6M75N M'>*%*D/241H??3*L=?N:B5C=S@Q?:IK ,>"K%S/<14OK/S9#Q2_V)'XBN NZ MCNLS&A4HKCQ@T@AJ$)V MZ#(XGAD('XN)7I7H6F^$+Z67NA3&^! ]2!7J0,F:2LJL!BF%U#EZ+,W[4?_3 M2WTH9L?KI3Y$_1VX3[=;+-?F>L4'E[][Z M];AZJ _"QU;=K(?MWGV; M=!4^KD;INT"KO58ZV-0:W-_DV@_39E^3FHAC+B4$%1F@348'*[P0W8P$_'U0 M#\$CZ&N\C]=Y8-T?,]JW3T^MLT[?;F:=U@*^A$) RKH6>7L%+CH+GDDME6#9 MVFXL8R<..WZ'-C M,N]F./10YH[4P Z \,,;XPYPVW,X],)D'!0L@)>D&X+FF+R\9CC/?:.M+'I2[+(_2#W,QCE72=>*J^< MP@)*V4AQ/X\06"[ #4N^&(%>O^R8L;_BJI=DD/O ;<^8\#S M@K-:!N<# VUK3"2U N0B0+:&:YXCR_EX'/J!S+_X6^P7L!&,B><7O1%L;B// M"=7/2TT$(6.N9?^.!U"T:]9A@;4-,T85?2Y%'H\[,(3S%W]M_@*V@-&0_*+M M?TBG3H\*FWMS9#,DIS"K,4.\8$R3:V?\PW]"_ ]D="<=/;_:EZ M!SPHT1NU[Q==LZMP+M1QU61KS.X!>Q-UV/X!;67820!(1KI $ZCE'@:AM$%,F<^KE8!@X P MJ)Y[B%8FA-AJ>7;RH4IP;:C)4=CL*1@MZ]&F@G,2!]99*":2@)!EZ[?9^^A3 M;^Q[]+?K/>_6@B^EFGJ7$WAWR?< EPW*E7)HG67 5!V9(Y, [PQ"%C9&(9@+ M8JL&9ML 9LI-: ]EW57W#I*;6.%_S.:SK^=?+WNAY,2SCPZR]*P.TP@0M.? M>&%.Q)R8VJKOUS,JO[7HQ$K?166+%O*;6O'X]PW"E<\^V5![GP1;NZQZ",71 MT4FV0$1;Q\)6@]F>4_S-1:3NIZ9[D(I!& M3&T>I4JHRJA]HGE(O+H4./6TBYOT=A[N-8;@809;[(R'HS61!Z;BIA*<<%8" M8AWT7+M0A9+KW.=FCU:1&^7"GPGVU?:J@B* M&%DH)!A2D7=)@BTL&BZ+=\).O/6_F&S3K@^ /;%QS''!]I,(3R33:$T,P-:] MDCBW@!0=0?8E1<5M%BSW$CALS]:1IF[N9T^]PN:E6=*'V>H_;Y>YSFG*A*RS MM4",1Q(%,T#1'BG,&@FD* E&2(6D/Q>QFRSI;9DZTB3(#JUH;\B\-!MZ<)2G M%8(7IA1('CDHAO4ACS85H5R*R0=N0]D\>KL M#&?S^BMK.60C!5.<@7)RW62Z7D8F#C&X)*(3.L@))HS?)G(K4^AY?.OA@YS& MFC_F4V1HT[NDE%%D_^ \_:$H\ -7D@6=O/4Z6<'["6S&Z+#8\P#62GO-5/BDEH9&90PXYUC0*!\[&#"DG"N<2T]DUGR6V%65; M@;KG(:G[@'H$Y1W]^-/Z\P>$,&:!TC-+'K;\: C_?10711^5RI$"VL ]J,(T M^"@\1"$C\UE(SUKG<[^4XB+O?/"F)"@,!2C$ $XYVD%E3^2DM?,_5[_0>5W/<.PU/H#"L'E>H:A9PR"*P$D MN5(I><2,K4N-GB#GI10>#0+(8AQM]0N\38F!XLI&*Q,P:>KS7K& T0O@+/HD M;?0NM;X_?)*@:<'73.W;P6D''70 J'H\D'7B:5Y=5I/D5&+*M=J4!**R4!!\ MTL!#3,IIQQ-OO7_=(Z)+X.RBX$5+:7< EW_E>5[BZ:MY>I6^SN:SZD2IK 5H1-FWDU'JS::Z4#J'W, MI_2CS\3410$"Z5RQB;5\\^0].T:4SC M :RI+CK U@=2#!'PA1CZ-7_/IXMO56!W6'+9N&(+:%L0E#,D+VTSQ)P#.0C% M6=[:F=J"K&D3>\9#6&N-= "R%E>JVDDNL$YJKF8510)GE2..T1CTW$3N6F]Q MAZEJ.8)*VWU"S@/KO@.T;WF#;RPF9RT#SID"9;6'4$^+K&NMFR2GI'D[O8;/ M+UV7H S!RV[/+T.4MS,DO^=E6!SB >;B,#O#O_-JCS>5!SZEZ3/)OFX M6.83_GU]G7Q]12P42H8.O)<<5&(4..1L*'"@F"&(Q(1L?0H]04Z;*S3ZZ VJ M?Z'@J/C:;#^Y M=W#.O2DEQQI<7_%3LY!>+^84%)U37/3N6UZN=;4Z"3$Q+=9EUS4]R=>^;3IK MR#&;8 46(UL/D]F>NA[N0MJ#;"3M=(N[#SDNYG%V.KMX/'_D](YYM:)_L+&X M5U\7Y_.S$VU$#LX(L+).A>#20.#H(3+ET3G4I(>#H'-W'GJX;CD4A@^DZ:ES MA+=A_M79VYSJA6>]B#BG#_OQ_[=W9-D&VYQQ%N2V&I M>Z.?%#AESE L3Q7I;OW[!2B2DB@>=8 "U..8Z![;-9#>L I)Q2H--"<\3/K* .U8O+.@DBX^QNUQM[[XT^I9 MPBE/.L,NC=@WXLV/H'%#G'2^"E0('5O0*LB TH("Q*F1%28*T=0%O@G4SMM3 ME=-GI^2S].+&+VX>T&TC 683?-6;X"O\(OS5N_"KN(X]UOS%Q6SQH$5;^["^ M38R:V0^3(-_9<]7,@I0XY9?+WXA-^VNJE_0T(!NNB8X9MK^UF7R("FT-,L R MY\/D,Q0('N:"@A6O*F@1-*FS+?MT&>O; TKH ML%1!)@"6U$KJC>15I^L+>PQPIR)Y#Q>2\+_M?,<#7D!$\#B"CP&UG3M6C,)R M) ,R!H=]*JW"ME4SQ %2SB&M)9(Z]=L%Q[7*:T\)J-]Y3)6,AP(L:^MUF(?W MWE?IL?9B,6_G82T((UPM!X^1T3+ WH#*K,$\C!PXR#&@1#F@.%5 ,:D],<09 MG;HN+(WF>4^Z3N+Q,E!:NB%_:MN%L\O0YD9YZBVC#D!K&*"($J"PK0"I-,). M&29(ZOJSKKKE=91BY3KUW[Z5@7I]9NIF.HC-A8GS@&6N'*;A"]H8$F B$8=:)B@.J' 2J@C&2 M0DA 9(C8+M?8P78WG!<0WPC'(#5(Q'[QL*(9 M,HUCT1^$JG):X-0/CO54,>\Y?;EN,@FE1=CL\>U@".R7B\!RL#=A;\FYEQ 8 MI$V,6C 0A(2=*+8$:2$59J?I_NNL8E[_>I+MT"E)>CM6^'32W2!K%*2. E.A M "?587%@Q($0E>A**694E;J?NK>2>;UG/DL<3%01MG@6QF3C""8_W)4SBV8R MG[CV_"\S75AG'X:]R39<^!

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end XML 108 blfs-20250331_htm.xml IDEA: XBRL DOCUMENT 0000834365 2025-01-01 2025-03-31 0000834365 2025-05-01 0000834365 2025-03-31 0000834365 2024-12-31 0000834365 us-gaap:SeriesAPreferredStockMember 2024-12-31 0000834365 us-gaap:SeriesAPreferredStockMember 2025-03-31 0000834365 us-gaap:ProductMember 2025-01-01 2025-03-31 0000834365 us-gaap:ProductMember 2024-01-01 2024-03-31 0000834365 us-gaap:ServiceMember 2025-01-01 2025-03-31 0000834365 us-gaap:ServiceMember 2024-01-01 2024-03-31 0000834365 blfs:RentalRevenueMember 2025-01-01 2025-03-31 0000834365 blfs:RentalRevenueMember 2024-01-01 2024-03-31 0000834365 2024-01-01 2024-03-31 0000834365 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0000834365 us-gaap:CommonStockMember 2024-12-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000834365 us-gaap:RetainedEarningsMember 2024-12-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000834365 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000834365 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000834365 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0000834365 us-gaap:CommonStockMember 2025-03-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000834365 us-gaap:RetainedEarningsMember 2025-03-31 0000834365 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000834365 us-gaap:CommonStockMember 2023-12-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000834365 us-gaap:RetainedEarningsMember 2023-12-31 0000834365 2023-12-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000834365 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000834365 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000834365 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000834365 us-gaap:CommonStockMember 2024-03-31 0000834365 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000834365 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000834365 us-gaap:RetainedEarningsMember 2024-03-31 0000834365 2024-03-31 0000834365 blfs:GlobalCoolingMember 2024-04-17 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:GlobalCoolingMember 2024-04-17 2024-04-17 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:GlobalCoolingMember 2024-04-17 0000834365 us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000834365 blfs:StockCompensationExpenseMember 2025-01-01 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:GlobalCoolingMember 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeDivestitureMember us-gaap:EmployeeSeveranceMember 2024-11-12 2024-11-12 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeDivestitureMember blfs:EarnOutPaymentMember 2024-11-12 2024-11-12 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeDivestitureMember blfs:StockCompensationExpenseMember 2024-11-12 2024-11-12 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeMember 2024-11-12 2024-11-12 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeMember 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeMember 2025-01-01 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:CBSMember blfs:StockCompensationExpenseMember 2024-11-14 2024-11-14 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:CBSMember 2024-11-14 2024-11-14 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:CBSMember 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:CBSMember 2025-01-01 2025-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:GlobalCoolingMember 2024-01-01 2024-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:SciSafeMember 2024-01-01 2024-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember blfs:CBSMember 2024-01-01 2024-03-31 0000834365 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-03-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000834365 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:CorporateDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:OtherDebtSecuritiesMember 2025-03-31 0000834365 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:OtherDebtSecuritiesMember 2024-12-31 0000834365 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-03-31 0000834365 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-03-31 0000834365 blfs:PanTHERACryoSolutionsInc.Member us-gaap:SeriesEPreferredStockMember 2025-03-31 0000834365 blfs:PanTHERACryoSolutionsInc.Member us-gaap:SeriesEPreferredStockMember 2024-12-31 0000834365 blfs:PanTHERACryoSolutionsInc.Member blfs:PanTHERAheraCryosolutionsMember us-gaap:SubsequentEventMember 2025-04-04 0000834365 blfs:PanTHERAheraCryosolutionsMember us-gaap:SubsequentEventMember 2025-04-04 2025-04-04 0000834365 srt:MinimumMember blfs:RealEstateLeaseMember 2025-03-31 0000834365 srt:MaximumMember blfs:RealEstateLeaseMember 2025-03-31 0000834365 us-gaap:LeaseholdImprovementsMember 2025-03-31 0000834365 us-gaap:LeaseholdImprovementsMember 2024-12-31 0000834365 blfs:FurnitureAndComputerEquipmentMember 2025-03-31 0000834365 blfs:FurnitureAndComputerEquipmentMember 2024-12-31 0000834365 us-gaap:ManufacturingFacilityMember 2025-03-31 0000834365 us-gaap:ManufacturingFacilityMember 2024-12-31 0000834365 us-gaap:ConstructionInProgressMember 2025-03-31 0000834365 us-gaap:ConstructionInProgressMember 2024-12-31 0000834365 us-gaap:CustomerRelationshipsMember 2025-03-31 0000834365 us-gaap:TradeNamesMember 2025-03-31 0000834365 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-03-31 0000834365 us-gaap:NoncompeteAgreementsMember 2025-03-31 0000834365 us-gaap:CustomerRelationshipsMember 2024-12-31 0000834365 us-gaap:TradeNamesMember 2024-12-31 0000834365 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-12-31 0000834365 us-gaap:NoncompeteAgreementsMember 2024-12-31 0000834365 blfs:The2023TermLoanMember 2022-09-20 0000834365 blfs:The2023TermLoanMember 2022-09-20 2022-09-20 0000834365 blfs:The2023TermLoanMember blfs:VariableRateComponentTwoMember 2022-09-20 2022-09-20 0000834365 blfs:The2023TermLoanMember 2025-03-31 0000834365 blfs:SecondAmendmentTermLoanMember 2024-04-17 0000834365 blfs:SecondAmendmentTermLoanMember 2024-11-11 0000834365 blfs:TermLoanMember 2024-12-31 0000834365 blfs:TermLoanMember 2025-03-31 0000834365 blfs:FinancedInsurancePremiumMember 2025-03-31 0000834365 blfs:FinancedInsurancePremiumMember 2024-12-31 0000834365 blfs:TotalDebtMember 2025-03-31 0000834365 blfs:TotalDebtMember 2024-12-31 0000834365 blfs:ProductCellProcessingMember 2025-01-01 2025-03-31 0000834365 blfs:ProductCellProcessingMember 2024-01-01 2024-03-31 0000834365 blfs:ProductEvoAndThawMember 2025-01-01 2025-03-31 0000834365 blfs:ProductEvoAndThawMember 2024-01-01 2024-03-31 0000834365 blfs:ServiceEvoAndThawMember 2025-01-01 2025-03-31 0000834365 blfs:ServiceEvoAndThawMember 2024-01-01 2024-03-31 0000834365 blfs:RentalRevenueEvoAndThawMember 2025-01-01 2025-03-31 0000834365 blfs:RentalRevenueEvoAndThawMember 2024-01-01 2024-03-31 0000834365 us-gaap:EmployeeStockOptionMember 2025-03-31 0000834365 us-gaap:RestrictedStockMember 2024-12-31 0000834365 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0000834365 us-gaap:RestrictedStockMember 2025-03-31 0000834365 us-gaap:PerformanceSharesMember 2024-03-08 2024-03-08 0000834365 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-03-08 2024-03-08 0000834365 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-03-08 2024-03-08 0000834365 us-gaap:PerformanceSharesMember 2024-03-08 0000834365 us-gaap:PerformanceSharesMember 2024-10-01 2024-12-31 0000834365 us-gaap:PerformanceSharesMember 2025-01-01 2025-03-31 0000834365 us-gaap:PerformanceSharesMember 2025-03-31 0000834365 blfs:MarketbasedRestrictedStockMember 2024-12-31 0000834365 blfs:MarketbasedRestrictedStockMember 2025-01-01 2025-03-31 0000834365 blfs:MarketbasedRestrictedStockMember 2025-03-31 0000834365 blfs:MarketbasedRestrictedStockMember 2023-01-03 2023-01-03 0000834365 srt:MinimumMember blfs:MarketbasedRestrictedStockMember 2023-01-03 2023-01-03 0000834365 srt:MaximumMember blfs:MarketbasedRestrictedStockMember 2023-01-03 2023-01-03 0000834365 blfs:MarketbasedRestrictedStockMember 2024-03-08 2024-03-08 0000834365 srt:MinimumMember blfs:MarketbasedRestrictedStockMember 2024-03-08 2024-03-08 0000834365 srt:MaximumMember blfs:MarketbasedRestrictedStockMember 2024-03-08 2024-03-08 0000834365 blfs:MarketbasedRestrictedStockMember 2025-03-18 2025-03-18 0000834365 srt:MinimumMember blfs:MarketbasedRestrictedStockMember 2025-03-18 2025-03-18 0000834365 srt:MaximumMember blfs:MarketbasedRestrictedStockMember 2025-03-18 2025-03-18 0000834365 blfs:MarketbasedRestrictedStockMember 2023-01-01 2023-12-31 0000834365 blfs:MarketbasedRestrictedStockMember 2024-01-01 2024-12-31 0000834365 blfs:MarketbasedRestrictedStockMember 2024-01-01 2024-03-31 0000834365 us-gaap:CostOfSalesMember 2025-01-01 2025-03-31 0000834365 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000834365 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0000834365 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0000834365 us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-03-31 0000834365 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0000834365 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0000834365 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000834365 blfs:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000834365 blfs:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 blfs:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000834365 blfs:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:CryoStorProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:CryoStorProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 blfs:GeographicOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 blfs:GeographicOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-03-31 0000834365 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000834365 country:US 2025-03-31 0000834365 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember blfs:OneSupplierMember 2025-01-01 2025-03-31 0000834365 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember blfs:TwoSupplierMember 2025-01-01 2025-03-31 0000834365 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember blfs:ThreeSupplierMember 2025-01-01 2025-03-31 shares iso4217:USD iso4217:USD shares blfs:reportable_segment blfs:reporting_unit blfs:employee pure blfs:lawsuit 0000834365 --12-31 2025 Q1 false P2Y P2Y P1Y http://fasb.org/us-gaap/2024#PrimeRateMember 10-Q true 2025-03-31 false 001-36362 BioLife Solutions, Inc. DE 94-3076866 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021 425 402-1400 Common stock, par value $0.001 per share BLFS NASDAQ Yes Yes Large Accelerated Filer false false false 47561171 66945000 95386000 21635000 9198000 117000 153000 9167000 9168000 27566000 29013000 5816000 5996000 131129000 148761000 5690000 6103000 6605000 6084000 10128000 10674000 378000 379000 19055000 4628000 995000 995000 8857000 9559000 212304000 212304000 395141000 399487000 3297000 3573000 8213000 12451000 3929000 4256000 1835000 1511000 10449000 10943000 27723000 32734000 12165000 12723000 2499000 4997000 130000 124000 42517000 50578000 0.001 0.001 1000000 1000000 4250 4250 0 0 0 0 0 0 0.001 0.001 150000000 150000000 47548431 47548431 46906765 46906765 48000 47000 688092000 683939000 33000 24000 -335549000 -335101000 352624000 348909000 395141000 399487000 22299000 16743000 60000 25000 1582000 1665000 23941000 18433000 7109000 5136000 10000 0 1036000 1056000 11501000 10397000 2597000 2376000 2204000 2075000 702000 688000 25159000 21728000 -1218000 -3295000 681000 -140000 103000 253000 784000 113000 -434000 -3182000 14000 17000 -448000 -3199000 0 -6908000 0 114000 0 -7022000 -448000 -10221000 -448000 -448000 -3199000 -3199000 0 0 -7022000 -7022000 -0.01 -0.01 -0.07 -0.07 0 0 -0.15 -0.15 -448000 -448000 -10221000 -10221000 -0.01 -0.01 -0.22 -0.22 47134720 47134720 45432426 45432426 -448000 -10221000 0 -203000 9000 -18000 -439000 -10442000 0 0 46906765 47000 683939000 24000 -335101000 348909000 4153000 4153000 641666 1000 1000 9000 9000 -448000 -448000 0 0 47548431 48000 688092000 33000 -335549000 352624000 0 0 45167225 45000 652880000 -345000 -314917000 337663000 6183000 6183000 522358 1000 1000 -203000 -203000 -18000 -18000 -10221000 -10221000 0 0 45689583 46000 659063000 -566000 -325138000 333405000 -448000 -10221000 682000 1364000 702000 914000 4153000 6183000 312000 -83000 6000 5000 105000 182000 0 14000 -187000 -198000 -1000 -65000 -1447000 -42000 -181000 -2392000 -828000 -1956000 -4252000 -2825000 -327000 20000 16000 -377000 1727000 -4475000 30324000 6374000 573000 973000 3000000 6000000 250000 464000 175000 356000 -27176000 -221000 0 241000 2500000 0 502000 727000 10000 16000 -2992000 -952000 -28441000 -5648000 95386000 35438000 0 -65000 66945000 29725000 552000 26000 0 -6000 -9000 18000 265000 445000 Organization and significant accounting policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products include proprietary biopreservation media, automated thawing devices, and cloud-connected shipping containers. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in CGT that can be filled manually or with high throughput systems, CryoCase™ cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement, dated April 17, 2024 (the “Global Cooling Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Global Cooling Purchase Agreement, the Global Cooling business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “SciSafe Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“SciSafe Buyer”), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (“SciSafe Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock (the “SciSafe Shares”) of SciSafe to SciSafe Buyer. Upon the execution of the SciSafe Purchase Agreement, the SciSafe business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2024, the Company entered into a Stock Purchase Agreement (the “CBS Purchase Agreement”), by and among the Company, Standex International Corporation, a Delaware corporation (“CBS Buyer”), and Arctic Solutions, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (doing business as Custom Biogenic Systems, or “CBS”), for the sale by the Company of all of the issued and outstanding shares of common stock (the “CBS Shares”) of CBS to CBS Buyer (the “CBS Divestiture”). Upon the execution of the CBS Purchase Agreement, the CBS business is presented in the accompanying Consolidated Financial Statements as a discontinued operation for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2025, pursuant to a Stock Purchase Agreement (the “PanTHERA Purchase Agreement”), by and among the Company, Casdin Partners Master Fund L.P. and each other person listed on Schedule A thereto (the “PanTHERA Sellers”), Alberta LTD., an Alberta corporation and a wholly owned subsidiary of the Company (“PanTHERA Buyer Sub”), PanTHERA CryoSolutions Inc., an Alberta corporation (“PanTHERA”) and Dr. Jason Acker, solely in his capacity as Sellers’ Representative, the Company acquired all of the issued and outstanding shares of common stock of PanTHERA from the Sellers (the “PanTHERA Transaction”). The acquisition of PanTHERA was considered a subsequent event to the financial results presented as of March 31, 2025. For additional information on the acquisition of PanTHERA see Note 19: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is presenting Global Cooling, SciSafe, and CBS within this Quarterly Report on Form 10-Q (this “Form 10-Q”) as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented in this Form 10-Q reflect only the continuing operations of the Company unless otherwise noted. See Note 2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within this Form 10-Q for further details regarding the divestitures described above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions by management affect the Company’s valuation of market-based stock awards, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2025 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2025 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the “Annual Report”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”) and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details about the divestitures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sales are primarily denominated in the U.S. dollar. Accordingly, our sales are not generally impacted by foreign currency exchange rates. For any transactions denominated in a foreign currency, which were immaterial during the three months ended March 31, 2025 and 2024, the Company remeasures foreign currency transactions into U.S. dollars on its Unaudited Condensed Consolidated Financial Statements in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional information on the Company's segment considerations, see Note 17: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment, customer, and geographic information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three months ended March 31, 2025, as compared to the significant accounting policies described in our Annual Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 31, 2025 and December 31, 2024, we had $107.6 million and $109.2 million in cash, cash equivalents, and available-for-sale securities, respectively. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and uncertainties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, volatility in global trade policies through significant increases in tariffs, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board ("FASB") issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. In January 2025, the FASB issued ASU 2025-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures - Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to clarify the effective date for non-calendar year-end entities. The amendments in this ASU will be effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the effects adoption of this guidance will have on the Consolidated Financial Statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions by management affect the Company’s valuation of market-based stock awards, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, net realizable value of inventory, and provision for income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three months ended March 31, 2025 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2025 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 8, 2025 (the “Annual Report”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”) and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is presenting Global Cooling, SciSafe, and CBS as discontinued operations for all periods presented within the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations. The Condensed Consolidated Statements Of Comprehensive Loss, Condensed Consolidated Statements of Shareholders' Equity, and Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. See Note 2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details about the divestitures.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's sales are primarily denominated in the U.S. dollar. Accordingly, our sales are not generally impacted by foreign currency exchange rates. For any transactions denominated in a foreign currency, which were immaterial during the three months ended March 31, 2025 and 2024, the Company remeasures foreign currency transactions into U.S. dollars on its Unaudited Condensed Consolidated Financial Statements in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income</span> line item. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker ("CODM"), reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. For additional information on the Company's segment considerations, see Note 17: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment, customer, and geographic information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 1 1 107600000 109200000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board ("FASB") issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. In January 2025, the FASB issued ASU 2025-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures - Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to clarify the effective date for non-calendar year-end entities. The amendments in this ASU will be effective for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the effects adoption of this guidance will have on the Consolidated Financial Statements.</span></div> Discontinued operations<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the Company, management, and our board of Directors (the "Board"), made the decision to sell Global Cooling and CBS (the "Freezer Business"), allowing the Company to optimize its product portfolio by focusing on its recurring higher margin revenue streams. Additionally, in November of 2024, the Company, management, and the Board determined the sale of SciSafe would further optimize the Company's product portfolio toward its proprietary high margin cell processing and other bioproduction products. Accordingly, the results of these businesses are reported in the “Loss from </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discontinued operations” line in the Condensed Consolidated Statements of Operations. These changes have been applied to all periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Global Cooling, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings pursuant to the Global Cooling Purchase Agreement. The Company analyzed the quantitative and qualitative factors relevant to the sale of Global Cooling and determined that the conditions for discontinued operations presentation were met during the second quarter of 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of the Global Cooling Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. The Company recognized a loss on disposal of Global Cooling, calculated as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling price: $1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash to Global Cooling funded by Company</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell Global Cooling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative selling price</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed liabilities: Accounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed liabilities: Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Global Cooling carrying basis as of April 17, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Release of Global Cooling currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) As a closing condition, the Company repaid the balances of loans under Global Cooling as of the date of the Global Cooling Divestiture.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company’s entry into the Global Cooling Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing approximately 11% of its full-time employees as of the date of the RIF). The Board approved the RIF on March 29, 2024, and all affected employees of Global Cooling were informed by April 18, 2024, following the execution of the Global Cooling Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Severance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RIF employee costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former Global Cooling employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employment related divestiture expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies. Prior to the Global Cooling Divestiture, a lawsuit was filed by a previous customer related to Global Cooling's commercial freezer products seeking payment of up to $4.0 million for losses the customer claims to have incurred. As of the year ended December 31, 2024, the Company recorded a loss contingency under the discontinued </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations of Global Cooing related to this product liability claim as outlined in the Global Cooling Purchase Agreement. During the fourth quarter of 2024, it became probable this loss would be settled within the next fiscal year. The product liability claim is subject to insurance recovery, which management believes is probable as enforceable under the Company's insurance policy, covering the entirety of the loss contingency aside from the Company's insurance deductibles. The Company estimates the legal expenses to be incurred will be immaterial. There were no changes in the status of this claim during the three months ended March 31, 2025</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement ("Global Cooling TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of the Global Cooling Divestiture. The Global Cooling TSA has since expired pursuant to its terms on the stated expiration date. The Company has no other significant continuing involvement with Global Cooling.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of SciSafe, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2024, the Company entered into the SciSafe Purchase Agreement, and SciSafe, for the sale by SciSafe Seller of all of the issued and outstanding shares of common stock of SciSafe to SciSafe Buyer ("SciSafe Divestiture"). The Company analyzed the quantitative and qualitative factors relevant to the sale of SciSafe and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the SciSafe Divestiture, the Company incurred $0.4 million in severance costs, paid the former stockholders of SciSafe $3.3 million in cash to waive all rights with respect to certain potential earn-out payments, and recognized $4.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with SciSafe upon the closing of this transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a gain on disposal of SciSafe, calculated as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds received from Buyer</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds from escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: SciSafe carrying basis as of November 12, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Release of SciSafe currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gain on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 350, upon the disposal of SciSafe, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to SciSafe was based on the relative fair value of SciSafe to the fair value of the Company as SciSafe was fully integrated into the Company's one reportable segment. The fair value of SciSafe was determined based on the enterprise value per the SciSafe Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $11.3 million of goodwill was to be allocated to SciSafe upon its disposal. The allocated goodwill was included in the carrying basis of SciSafe presented in the above table.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of the SciSafe Divestiture, the Company and SciSafe entered into a transition services agreement ("SciSafe TSA"), pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the closing of the transaction. The SciSafe Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the closing of the SciSafe Divestiture. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the disposal of SciSafe, the Company remains liable and responsible for the full performance and observance of all of the provisions, covenants, and conditions in one of SciSafe's operating leases. In the case of a breach or violation of any provision of the lease by the SciSafe Buyer, the Company is deemed to be in default of the lease provisions. Simultaneously, the Company received indemnification pursuant any obligation owed by the Company under this operating lease. This indicates the Company undertakes the obligation to stand ready to perform over the term of the guarantee in the event of the specified triggering events noted above, or conditions, such as breach or default, occur. However, the non-contingent aspect of the guarantee enables the Company to recover any losses from the SciSafe Buyer. As of March 31, 2025, the fair value of this guarantee is not material. The outstanding minimum lease payments equal approximately $2.5 million and the lease terminates in 2031.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no other significant continuing involvement with SciSafe upon the expiration of its SciSafe and other related covenants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Custom Biogenics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2024, the Company entered into the CBS Purchase Agreement, for the sale by the Company of all of the issued and outstanding shares of common stock of CBS. The Company analyzed the quantitative and qualitative factors relevant to the CBS Divestiture and determined that the conditions for discontinued operations presentation were met during the fourth quarter of 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $2.0 million in stock compensation expense for the acceleration of unvested shares of all the Company's former employees that remained with CBS upon the closing of the CBS Divestiture.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a loss on disposal of CBS, calculated as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds received from Buyer</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds from escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net price adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: CBS carrying basis as of November 14, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,365)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the CBS Divestiture.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 350, upon the disposal of CBS, the Company assessed the goodwill to be allocated to the disposal group. The goodwill allocated to CBS was based on the relative fair value of CBS to the fair value of the Company as CBS was fully integrated into the Company's one reportable segment. The fair value of CBS was determined based on the enterprise value per the CBS Purchase Agreement. The fair value of the Company was determined by calculating the Company's market capitalization as of the disposal date plus any invested capital remaining of the Company, which included outstanding debt and financing lease liabilities, modified by an estimated market acquisition premium. Based on the calculation performed, the Company determined $1.1 million of goodwill was to be allocated to CBS upon its disposal. The allocated goodwill was included in the carrying basis of CBS presented in the above table.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of the CBS Divestiture, the Company and CBS entered into a transition service agreement (the "CBS TSA"), pursuant to which the Company will provide certain transition services to CBS following the closing of the CBS Divestiture. The CBS Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with CBS, soliciting its employees or interfering with its business relationships for two years after the closing of the CBS Divestiture. The Company has no other significant continuing involvement with CBS upon the expiration of its CBS TSA and related covenants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summarized financial data of discontinued operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize financial data of discontinued operations for the three months ended March 31, 2024. Interest expenses directly associated with the debt of a disposed entity is reported in discontinued operations below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the key components of loss from discontinued operations as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Cooling</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SciSafe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CBS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,663)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,175)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(271)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(638)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,908)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from discontinued operations, net of income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,009)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(371)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(642)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,022)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Cooling</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SciSafe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CBS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All divested entities had no remaining balances as of March 31, 2025 or December 31, 2024.</span></div> 7000000 6700000 2600000 2600000 The Company recognized a loss on disposal of Global Cooling, calculated as follows:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling price: $1</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash to Global Cooling funded by Company</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell Global Cooling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative selling price</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,234)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed liabilities: Accounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed liabilities: Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Global Cooling carrying basis as of April 17, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Release of Global Cooling currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) As a closing condition, the Company repaid the balances of loans under Global Cooling as of the date of the Global Cooling Divestiture.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Severance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RIF employee costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former Global Cooling employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employment related divestiture expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a gain on disposal of SciSafe, calculated as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds received from Buyer</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds from escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: SciSafe carrying basis as of November 12, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Release of SciSafe currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gain on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,139 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Gross costs to sell incurred by the Company amounted to $2.1 million. This was offset by additional costs to sell paid on behalf of the Company by the SciSafe Buyer, which amounted to $1.6 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a loss on disposal of CBS, calculated as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds received from Buyer</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash proceeds from escrow</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net price adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to sell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,431 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: CBS carrying basis as of November 14, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss on disposal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,365)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As defined within the CBS Purchase Agreement, the final purchase price was subject to working capital adjustments upon the close of the CBS Divestiture.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Gross costs to sell incurred by the Company amounted to $1.4 million. This was offset by additional costs to sell paid on behalf of the Company by the CBS Buyer, which amounted to $1.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the key components of loss from discontinued operations as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Cooling</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SciSafe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CBS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,663)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,175)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,152)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(271)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(638)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,908)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from discontinued operations, net of income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,009)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(371)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(642)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,022)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of incurred depreciation, amortization, interest expenses, capital expenditures, and other noncash related costs for discontinued operations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Cooling</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SciSafe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CBS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1 0 6652000 582000 7234000 -3589000 2643000 2596000 1650000 -13000 -8897000 500000 2100000 47 0.11 291000 1255000 1546000 0 1925000 1925000 291000 3180000 3471000 4000000.0 P90D 400000 3300000 4000000.0 71291000 483000 506000 71268000 42507000 -622000 28139000 2100000 1600000 1 11300000 P6M P5Y 2500000 2000000.0 2785000 615000 179000 148000 3431000 6796000 -3365000 1400000 1300000 1 1100000 P2Y 4948000 5135000 3210000 13293000 6600000 3725000 2648000 12973000 1652000 -1410000 -562000 -320000 4314000 1663000 1175000 7152000 -33000 -18000 -25000 -76000 -5999000 -271000 -638000 -6908000 10000 100000 4000 114000 -6009000 -371000 -642000 -7022000 0 667000 0 667000 0 227000 0 227000 947000 706000 402000 2055000 38000 2000 26000 66000 26000 255000 0 281000 Fair value measurement<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the FASB ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no remeasurements to fair value during the three months ended March 31, 2025 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, based on the three-tier fair value hierarchy:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,934 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no transfers of assets or liabilities between the fair value measurement levels. We had no financial assets that utilize Level 3 inputs of measurement as of March 31, 2025 and December 31, 2024.</span></div> he following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024, based on the three-tier fair value hierarchy:<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,597 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,934 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,945 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 61852000 0 61852000 8297000 0 8297000 2796000 21496000 24292000 0 8101000 8101000 72945000 29597000 102542000 89119000 0 89119000 1494000 0 1494000 398000 8602000 9000000 0 3332000 3332000 91011000 11934000 102945000 Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-sale securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s portfolio of available-for-sale marketable securities consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,622 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,826 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,121 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,121 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025 and December 31, 2024, all available-for-sale securities investments presented above with unrealized losses have been in an unrealized loss position for less than 12 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, none of our available-for-sale marketable securities exhibited risk of credit loss and therefore no allowance for credit losses was recorded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The Company has adopted the measurement alternative whereby equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series E Preferred Stock in PanTHERA carried at $1.0 million as of March 31, 2025 and December 31, 2024. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2025, the Company purchased the remaining 90% of PanTHERA common shares it did not own as of March 31, 2025 for an $10.0 million in cash and 213,361 shares of the Company's Common stock and other contingent consideration. For additional details on the transaction, see Note 19: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent events</span>. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s portfolio of available-for-sale marketable securities consists of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,916 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total short-term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available-for-sale securities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,622 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,826 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,636 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,657 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6509000 3000 0 6512000 11638000 13000 1000 11650000 3472000 2000 1000 3473000 21619000 18000 2000 21635000 1779000 7000 0 1786000 12631000 14000 4000 12641000 4628000 3000 3000 4628000 19038000 24000 7000 19055000 40657000 42000 9000 40690000 1493000 1000 0 1494000 5775000 14000 1000 5788000 1912000 4000 0 1916000 9180000 19000 1000 9198000 3210000 4000 2000 3212000 1412000 5000 1000 1416000 4622000 9000 3000 4628000 13802000 28000 4000 13826000 21619000 21636000 19038000 19054000 40657000 40690000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the available-for-sale investments that had been in a continuous unrealized loss position for less than 12 months:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,995 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,121 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,121 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4913000 4000 4913000 4000 5082000 2000 5082000 2000 9995000 6000 9995000 6000 2091000 3000 2091000 3000 1030000 1000 1030000 1000 3121000 4000 3121000 4000 1000000.0 1000000.0 0.90 10000000.0 213361 Inventories<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,566 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9846000 11768000 4489000 4082000 13231000 13163000 27566000 29013000 Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of <span style="-sec-ix-hidden:f-597">two</span> to eleven years and have remaining lease terms of <span style="-sec-ix-hidden:f-599">two</span> to six years. The Company excludes options that are not reasonably certain to be exercised from our lease terms, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ranging from <span style="-sec-ix-hidden:f-601">one</span> to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any financing lease arrangements as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term in years - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our lease liabilities as of March 31, 2025 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various operating lease agreements for office space, warehouses, manufacturing, production locations, and other equipment. Our real estate leases had original lease terms of <span style="-sec-ix-hidden:f-597">two</span> to eleven years and have remaining lease terms of <span style="-sec-ix-hidden:f-599">two</span> to six years. The Company excludes options that are not reasonably certain to be exercised from our lease terms, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ranging from <span style="-sec-ix-hidden:f-601">one</span> to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any financing lease arrangements as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term in years - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our lease liabilities as of March 31, 2025 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P11Y P6Y P5Y <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term in years - operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div> 0.064 0.064 P5Y10M24D P6Y1M6D <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the three months ended March 31, 2025 and 2024 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 625000 385000 31000 17000 656000 402000 298000 239000 954000 641000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our lease liabilities as of March 31, 2025 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,824 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total present value of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1900000 3029000 2583000 2642000 2724000 3946000 16824000 2824000 14000000 Assets held for rent<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets held for rent consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shippers placed in service</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shippers and related components in production</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,103 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.5 million and $0.6 million in depreciation expense related to assets held for rent during the three months ended March 31, 2025 and March 31, 2024, respectively <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets held for rent consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shippers placed in service</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shippers and related components in production</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,690 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,103 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8994000 9505000 6350000 6499000 2644000 3006000 3046000 3097000 5690000 6103000 500000 600000 Property and equipment<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and other equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment was $0.2 million and $0.2 million for the three months ended March 31, 2025 and March 31, 2024, respectively.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and other equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,605 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3587000 3527000 306000 306000 4116000 4073000 3094000 2478000 11103000 10384000 4498000 4300000 6605000 6084000 200000 200000 Goodwill and intangible assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except weighted average useful life)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology - acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,535)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except weighted average useful life)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology - acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,833)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,559 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for definite-lived intangible assets was $0.7 million and $0.7 million for the three months ended March 31, 2025 and March 31, 2024, respectively. As of March 31, 2025, the Company expects to record the following amortization expense for definite-lived intangible assets:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization<br/>Expense</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Years Ending December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except weighted average useful life)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology - acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,535)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except weighted average useful life)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradenames</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology - acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,392 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,833)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,559 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td></tr></table></div> 2516000 2512000 4000 P0Y3M18D 4114000 1901000 2213000 P5Y7M6D 18672000 12032000 6640000 P2Y10M24D 90000 90000 0 P0Y 25392000 16535000 8857000 P3Y1M6D 2516000 2508000 8000 P0Y7M6D 4114000 1799000 2315000 P5Y10M24D 18672000 11436000 7236000 P3Y1M6D 90000 90000 0 P0Y 25392000 15833000 9559000 P3Y3M18D 700000 700000 As of March 31, 2025, the Company expects to record the following amortization expense for definite-lived intangible assets:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization<br/>Expense</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Years Ending December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,857 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2105000 2692000 1938000 828000 530000 764000 8857000 Accrued expenses and other current liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,451 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,213 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,451 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4341000 7116000 3755000 5232000 117000 103000 8213000 12451000 Commitments and contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, as our industry is characterized by frequent claims and litigation, including claims regarding intellectual property. Management does not believe any of the current claims are material to the Company’s business. Future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company carries certain insurance policies that may cover the aforementioned costs. The probability of claims that could result in a loss are evaluated and disclosed, as needed, individually and on a gross basis. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company other than those listed below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pending litigation item</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One lawsuit has been filed by a previous customer seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. Pursuant to the Global Cooling Purchase Agreement, the Company is required to indemnify Global Cooling for preexisting legal contingencies and if this previous customer was successful on such claim, then the Company would be responsible for indemnifying Global Cooling for any losses. This lawsuit does not currently have probable outcomes determined and we continue to defend vigorously against the claims made. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential loss incurred to be covered by insurance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase obligations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of March 31, 2025, our total short-term obligations were $10.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-income related taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2024, the Company determined that a sales tax liability related to the periods of 2019 through 2024 was probable and determined an estimated liability. The estimated liability was approximately $3.9 million and $4.3 million as of March 31, 2025 and December 31, 2024, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period.</span></div> 1 10000000 3900000 4300000 Long-term debt<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, the Company and certain of its subsidiaries entered into the Loan and Security Agreement, by and among Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), Global Cooling, and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton”), as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Second Amendment”), that certain Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024 (the “Third Amendment”), and that certain Consent and Fourth Amendment to Loan and Security Agreement, dated April 4, 2025 (the "Fourth Amendment", and the foregoing collectively, the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal <span style="-sec-ix-hidden:f-736">prime rate</span> plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of March 31, 2025, the implied interest rate of the Term Loan is 11.1% and the implied value of the Term Loan is $13.4 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of March 31, 2025, the Company is in compliance with the covenants set forth in the Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2024, the Company entered into the Second Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton (the Company, SAVSU, Arctic, SciSafe Parent, Global Cooling and Sexton, collectively, the “Second Amendment Borrower”). Pursuant to the Second Amendment and subject to the conditions set forth therein, Bank consented to the Global Cooling Divestiture and released its security interests in the assets of Global Cooling and the shares of common stock of Global Cooling arising under the Loan Agreement. In addition, effective as of the closing of the Global Cooling Divestiture, the Second Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Second Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Second Amendment also contains customary representations and warranties of Second Amendment Borrower and provides for a release of Bank by Second Amendment Borrower for any claims existing or arising through the date of the Second Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2024, the Company entered into the Third Amendment by and among Bank, the Company, SAVSU, Arctic, SciSafe Parent and Sexton (the Company, SAVSU, Arctic, SciSafe Parent and Sexton, collectively, the “Third Amendment Borrower”). Pursuant to the Third Amendment and subject to the conditions set forth therein, Bank consented to the SciSafe Divestiture as required pursuant to the Loan Agreement. In addition, effective as of the closing of the SciSafe Divestiture, the Third Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Third Amendment Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date for any reason. The Third Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Third Amendment Borrower and provides for a release of Bank by Third Amendment Borrower for any claims existing or arising through the date of the Third Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2025, the Company entered into the Fourth Amendment by and among Bank, the Company, SAVSU and Sexton. For additional information on the Fourth Amendment, see Note 19: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jun-26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance premium financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt, excluding unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,943)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,499 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) As of March 31, 2025, the Term Loan was secured by substantially all assets of BioLife, SAVSU, and Sexton, other than intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 60000000 30000000 10000000 10000000 10000000 20000000 10000000 0.005 0.010 1200000 0.111 13400000 500000 750000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of March 31, 2025 and December 31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jun-26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance premium financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt, excluding unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,973 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,948 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,940 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,449)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,943)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,499 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,997 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.070 0.070 12500000 15000000 0.083 0.083 473000 975000 12973000 15975000 25000 35000 12948000 15940000 10449000 10943000 2499000 4997000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 (9 months remaining)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,948 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7951000 4997000 0 0 0 0 12948000 Revenue<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of both March 31, 2025 and December 31, 2024, our deferred revenue balance totaled $0.1 million. During the three months ended March 31, 2025, the Company recognized approximately $18 thousand of revenue that was included in the deferred revenue balance at the beginning of the year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, hPL media, evo ModPaks, and ThawSTAR products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenues are generated from various customer service agreements to provide warranty and other engineering services. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three months ended March 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue from the leasing of our evo cold chain systems to customers pursuant to rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All customers leasing shippers currently do so under rental arrangements for durations of one year or less, with each unit having the option to continue its rental arrangement on a month-to-month basis until returned to the Company beyond the initial rental period. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total bioproduction tools and services revenue for the three months ended March 31, 2025 and 2024 were composed of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except percentages)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell processing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,941 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,433 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period of March 31, 2025. The Company elected not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 100000 100000 18000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total bioproduction tools and services revenue for the three months ended March 31, 2025 and 2024 were composed of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except percentages)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell processing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evo and Thaw</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,941 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,433 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21574000 16186000 725000 557000 60000 25000 1582000 1665000 23941000 18433000 Stock-based compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-based vesting stock options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of service-based vesting stock option activity for the three months ended March 31, 2025, and the status of service-based vesting stock options outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options exercisable as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, there was $2.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2025. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three months ended March 31, 2025. There were no exercises of service vesting-based awards during the three months ended March 31, 2025. There were no service-based vesting options granted during the three months ended March 31, 2025. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of March 31, 2025 is 1.2 years. There were no unrecognized compensation costs for service-based vesting stock options as of March 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-based vesting restricted stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2025, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(171,379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,399,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of the service-based vesting awards granted was $7.4 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2025. The aggregate fair value of the service-based vesting awards that vested was $4.5 million during the three months ended March 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized stock compensation expense related to service-based vesting awards of $2.7 million during the three months ended March 31, 2025. As of March 31, 2025, there was $22.5 million in unrecognized compensation costs related </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to service-based vesting awards. The weighted average remaining recognition period over which these service-based vesting awards will be expensed is approximately 2.8 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based restricted stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2024, the Company granted a performance-based restricted stock award for 109,512 shares to an executive. The shares granted contain performance conditions based on Company metrics related to future performance. The shares will vest as to between 0% and 200% of the number of restricted shares granted to the recipient based on performance conditions during the period beginning on January 1, 2024 through December 31, 2025. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of the year ended December 31, 2024, it was determined the probability of attainment of the performance condition increased to greater than 100% of shares granted. In accordance with ASC 718, we recognized a cumulative catch up in stock compensation expense of $0.4 million to reflect the increased probability the performance-based award would vest in excess of the shares originally granted. The fair value of this award is being expensed on a straight-line basis in accordance with the estimated quantity of shares expected to vest over the requisite service period ending on December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company's Board approved a modification to the metrics underlying the performance-based award to give effect to the adjusted operating results of the Company following the divestitures that occurred during the year ended December 31, 2024. The modification increased the probability that the performance-based award would vest in excess of the shares originally granted to its maximum amount of 200%. In accordance with ASC 718, this modification resulted in an incremental compensation cost of $1.6 million, which will be recognized over the remainder of the service period of the award.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized stock compensation expense of $0.4 million related to performance-based restricted stock awards for the three months ended March 31, 2025. As of March 31, 2025, there was $2.7 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 0.8 years. Non-cash compensation costs are expensed over the period for which performance was measured.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no performance-based restricted stock awards granted or vested during the three months ended March 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based restricted stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2025 and the status of market-based restricted stock outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Grant</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(470,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested as of March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.02 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of key inputs to our market-based restricted stock awards as of March 31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Assumptions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Target Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vesting Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Market Condition Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FV of Award <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Free Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividend Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Attainment %</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vested Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/3/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,738</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2023 - 12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">470,287</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3/8/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239,464</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2024 - 12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 TSR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3/18/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250,252</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2025 - 12/31/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the market-based restricted stock awards outlined above were granted to its executives. The restricted stock awards granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards vest at a range determined by the Compensation Committee of the Board of Directors in comparison to the TSR of a group of the Company's peers. The fair value of these awards are determined using a Monte Carlo simulation with various assumptions. These assumptions include historical volatility, dividend yield, and a risk-free interest rate. The historical volatility is based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the measurement date with a maturity consistent with the 2-year term associated with the market condition of these awards. The fair value of these awards are expensed on a straight-line basis over the grant date to the vesting date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the TSR period for each award has elapsed, the Company determines the TSR attainment percentage to award each recipient based on the targeted amount of shares granted. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized stock compensation expense of $1.0 million and $1.1 million related to market-based restricted stock awards for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, there were $12.0 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. The weighted average remaining recognition period over which these market-based awards will be expensed is approximately 1.5 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of the market-based awards granted was $6.3 million for both the three months ended March 31, 2025 and 2024. The aggregate fair value of the market-based awards that vested was $11.5 million and $5.1 million for the three months ended March 31, 2025 and 2024, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total stock compensation expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three months ended March 31, 2025 and 2024, as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of service-based vesting stock option activity for the three months ended March 31, 2025, and the status of service-based vesting stock options outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options exercisable as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 127000 2.19 0 0 127000 2.19 127000 2.19 2600000 0 0 0 0 P1Y2M12D 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of service-based vesting restricted stock activity for the three months ended March 31, 2025, and the status of unvested service-based vesting restricted stock outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">290,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(171,379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,399,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.53 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of market-based restricted stock activity under our stock option plan for the three months ended March 31, 2025 and the status of market-based restricted stock outstanding as of March 31, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wtd. Avg. Grant</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451,801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(470,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-vested as of March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.02 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1295640 16.00 290333 25.33 171379 19.47 15151 14.17 1399443 17.53 7400000 4500000 2700000 22500000 P2Y9M18D 109512 0 2 17.36 1 400000 2 1600000 400000 2700000 P0Y9M18D 0 495686 25.69 451801 32.91 470287 25.19 477200 33.02 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of key inputs to our market-based restricted stock awards as of March 31, 2025:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Assumptions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Target Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vesting Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Market Condition Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FV of Award <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Free Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividend Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Attainment %</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vested Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/3/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,738</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2023 - 12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">470,287</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 TSR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3/8/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239,464</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2024 - 12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 TSR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3/18/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">250,252</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0% - 200%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1/1/2025 - 12/31/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Of the $6.8 million fair value of the 2023 Total Shareholder Return ("TSR") award being expensed on a straight-line basis over the grant date to the vesting date, $1.6 million of expense was recognized in 2023 to reflect accelerations in the vesting period of certain awards.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Of the $6.3 million fair value of the 2024 TSR award being expensed on a straight-line basis over the grant date to the vesting date, $0.3 million of expense was recognized in 2024 to reflect accelerations in the vesting period of certain awards.</span></div> 268738 0 2 6800000 0.78 0.044 0 1.75 470287 239464 0 2 6300000 0.80 0.046 0 250252 0 2 9800000 0.60 0.041 0 6800000 1600000 6300000 300000 P2Y 0 P2Y 1000000.0 1100000 12000000.0 P1Y6M 6300000 6300000 11500000 5100000 P4Y We recorded total stock compensation expense for the three months ended March 31, 2025 and 2024, as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 292000 308000 2967000 2833000 388000 424000 506000 563000 4153000 4128000 Income taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. Income tax expense of $14.0 thousand for the three months ended March 31, 2025 resulted in an effective income tax rate of negative 3.2%. Included in the $14.0 thousand of tax expense was discrete tax benefit of $0.5 million related to stock compensation, which was offset by a change in the valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s projected effective income tax rate for the year ending December 31, 2025 excluding the impact, if any, of discrete items is negative 5.3%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates all available positive and negative evidence to determine if it is more likely than not that its deferred tax assets are realizable. As of March 31, 2025, the Company continues to provide a full valuation allowance against its deferred tax assets as the realization of such assets is not considered to be more likely than not at this time. If the Company's conclusion about the realizability of its deferred tax assets and therefore the appropriateness of the valuation allowance changes in a future period, the Company could record a substantial tax benefit in its Condensed Consolidated Statements of Operations when that occurs.</span></div> 14000.0 -0.032 14000.0 -500000 -0.053 0.21 Net loss from continuing operations per common share <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income by the weighted average number of shares of common stock during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents computations of basic and diluted earnings per share:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and earnings per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic earnings (loss) per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares issued and outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,134,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,432,426</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss from continuing operations per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span id="i5d0ce85a8d5a484aaa112f6fef441342_9-1-1-7-174301"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,070,693</span></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents computations of basic and diluted earnings per share:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and earnings per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic earnings (loss) per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares issued and outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,134,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,432,426</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss from continuing operations per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span id="i5d0ce85a8d5a484aaa112f6fef441342_9-1-1-7-174301"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232,836</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,070,693</span></td></tr></table></div> -448000 -3199000 47134720 47134720 47134720 47134720 45432426 45432426 45432426 45432426 -0.01 -0.01 -0.07 -0.07 1232836 1070693 Segment, customer, and geographic information<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, Mr. Roderick de Greef, who is the CODM, reviews the Company’s operations on a consolidated basis for purposes of allocating resources and evaluating financial performance. As a single reportable segment entity, the Company’s segment performance measure is consolidated net (loss) income from continuing operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant segment expenses are presented in the Company’s Condensed Consolidated Statements of Operations. Additional significant segment expenses that are not separately presented in the Company’s Condensed Consolidated Statements of Operations include Shared-based compensation and Depreciation expense. These are presented in the Condensed Consolidated Statement of Cash Flows, and Note 14: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Note 7: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets held for rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note 8: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense items not individually significant in net loss from continuing operations are changes in inventory values due to changes in its carrying basis, costs associated with the Company’s acquisitions or divestitures in the period these take place, and gain or loss on disposal of fixed assets. The information provided to the Company’s CODM for purposes of making decisions and assessing segment performance excludes asset information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">less than 10%</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of revenue by major product family representing over 10% of the Company's total revenue:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product revenue concentration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CryoStor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s total revenue by geographic area (based on the location of the customer):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by customers’ geographic locations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe, Middle East, Africa (EMEA)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's long-lived assets, totaling $22.4 million as of March 31, 2025, are located within the United States. Though the Company's evo shippers under rental arrangements may be outside of the United States, all are shipped back to our United States warehouse upon completion of the applicable rental arrangement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2025 and 2024, no suppliers accounted for more than 10% of purchases. </span></div>As of March 31, 2025, three different suppliers accounted for 17%, 16%, and 11% of accounts payable. As of December 31, 2024, no suppliers accounted for more than 10% of accounts payable. 1 1 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span></td></tr></table></div> 0.18 0.18 0.18 0.19 0.21 0.11 0.13 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of revenue by major product family representing over 10% of the Company's total revenue:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product revenue concentration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CryoStor</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.77 0.73 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s total revenue by geographic area (based on the location of the customer):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by customers’ geographic locations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe, Middle East, Africa (EMEA)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.81 0.81 0.14 0.14 0.05 0.05 1 1 22400000 0.17 0.16 0.11 Employee benefit plan<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.2 million in contributions to this plan for both the three months ended March 31, 2025 and 2024.</span></div> 1 200000 200000 Subsequent events<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated events subsequent to March 31, 2025 through the date of this filing to assess the need for potential recognition or disclosure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stock Purchase Agreement for PanTHERA Acquisition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2025, the Company entered into the PanTHERA Purchase Agreement for the purchase by the Company of all of the issued and outstanding shares of common stock of PanTHERA from the Sellers for an aggregate purchase price of $22.7 million, net of cash acquired, which included $10.0 million in cash, subject to any adjustments pursuant to the purchase price adjustment provision in the PanTHERA Purchase Agreement, 213,361 shares of our common stock, and an additional $7.2 million in earnout payments over the next three years contingent on the achievement of certain scientific and revenue milestones (the “PanTHERA Transaction”). Following the execution of the PanTHERA Purchase Agreement, the PanTHERA Transaction was consummated on April 4, 2025 (the “Closing Date”). The PanTHERA Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired PanTHERA's portfolio of molecules and other assets including certain technology under development. Management is in the process of determining the purchase price allocation and accounting treatment. The </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. Acquisition related costs before tax incurred thus far were $0.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Consent and Fourth Amendment to Loan and Security Agreement with Silicon Valley Bank</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2025, the Company entered into a Consent and Fourth Amendment to Loan and Security Agreement (the “Fourth Amendment”), by and among Bank, the Company, SAVSU, SciSafe Parent, and Sexton. Pursuant to the Fourth Amendment and subject to the conditions set forth therein, Bank consented to the PanTHERA Transaction and the SciSafe Dissolution as required pursuant to the Loan Agreement. The Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of the Company, SAVSU, SciSafe Parent, and Sexton and provides for a release of Bank by the Company, SAVSU, SciSafe Parent, and Sexton for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.</span></div> 22700000 10000000.0 213361 7200000 P3Y 200000 false false false false

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